<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
   xmlns:ao="http://www.w3.org/ns/oa#"
   xmlns:dailymed="http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/"
   xmlns:dct="http://purl.org/dc/terms/"
   xmlns:domeo="http://www.w3.org/ns/domeo#"
   xmlns:foafx="http://xmlns.com/foaf/0.1/"
   xmlns:ncit="http://purl.bioontology.org/ontology/NCIT#"
   xmlns:pav="http://purl.org/pav/"
   xmlns:permissions="http://vocab.deri.ie/cpo#"
   xmlns:poc="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns:sio="http://semanticscience.org/resource/"
>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2CCDC094-75F1-4A14-8D04-0867D3AF24F4">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1BEAB346-F7B3-40D8-AE65-17ACEB48A7A4">
    <ao:body rdf:resource="urn:linkedspls:uuid:D6235B22-042E-4C36-A104-B353CF92CEB8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B0DD1950-EC36-4509-9941-3B4DA4A38494"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:1CAED89B-42E4-493D-B92F-8663CD7F580E"/>
    <pav:previousVersion>urn:domeoserver:annotationset:7A99CBE7-D53A-4DB8-9A92-C3D451D28A0B</pav:previousVersion>
    <pav:lastSavedOn>2014-06-30 12:36:12 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:1A3E31C8-D293-4C5F-8F69-0259C4EBE393"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:15924106-592A-47E7-A01C-764A16E257DC"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:8ECC3E70-0C1E-435D-8ADB-82D27204984F"/>
    <pav:createdOn>2014-06-30 12:31:59 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:77B5C0D4-B728-4F8B-B5B3-E3B3BE2E8C85</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:79A46039-020F-4CFF-8F4F-224895ADAB3C">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3746E014-4500-4C39-A007-7B912571A900">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9992ADBC-4BAB-4529-BAC4-9D7AFD34F098">
    <pav:previousVersion>urn:domeoserver:annotationset:F8403FA3-1909-450C-BEF3-1DCE497A37CC</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:C7EAEB14-8213-4EF8-AC67-469D0609826B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5239657F-5948-4803-B690-76D953D60764"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A26C991-50B7-4DDC-BF64-F11EE048F98A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">40</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E04D6C70-2D6F-4D7B-88FD-4E2EF8886CAC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A74A9220-EE01-45C5-B563-AB9F4F6F5D7A"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-06-23 14:36:56 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:597854EB-61EA-471D-A012-21BF85F7B88D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:824575A2-38D4-4EBC-9991-4987B8CABF6E"/>
    <pav:createdOn>2014-04-14 14:28:54 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:37547FE1-0C49-4ACD-8764-330C113732EE"/>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:6DEFAE04-80DB-4944-B89A-89A36B339F01"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:239C53D0-DD62-4205-BB17-26E9C873641F">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA67625B-2AC1-4E15-BC4C-50D4C7BE0F03">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:691E83A1-1BFF-4939-996A-35C56D0CF2DF">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2A3AE56E-9DA3-4575-BD28-FB1BC6BCE6DD">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C427075F-5339-47EB-A313-AA6B94EB8753">
    <ao:suffix> The most common non-functiona</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>It is recommended that consideration be given to either genotype or phenotype patients for TPMT. Phenotyping and genotyping methods are commercially available.</ao:exact>
    <domeo:uuid>C427075F-5339-47EB-A313-AA6B94EB8753</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C427075F-5339-47EB-A313-AA6B94EB8753"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-30 12:04:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A9D2C42-2B60-4261-806F-7AA8AB609B32">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3CB531B1-A267-4A03-A0C5-D852AB638802">
    <ao:body rdf:resource="urn:linkedspls:uuid:1706E63C-45AC-467E-80FD-06108C69A93D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:99FA827B-1348-4AAF-B462-A763B372625B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">14</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
    <pav:createdOn>2014-04-21 12:35:45 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB14F9C6-5EC7-47CC-A258-035BAAD9EFEC"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1D33EB0C-A03D-481F-991D-B71848865C38"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4DE4F207-7D95-47C1-9546-BD8AD1CC8E5B"/>
    <pav:previousVersion>urn:domeoserver:annotationset:1CB9C999-83C8-467A-9A36-6C4187B3ACE3</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:787BD215-4E21-4960-A53D-22791987879E"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:4018FA6B-4CAF-48CF-9B75-2F22B9E2DDF5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:37A6082B-5282-4E60-83ED-F39B3618B569"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:7F4B6BFE-FDCE-4584-B309-F2FE0FFE0892"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:70BE7DEB-6A8B-41E9-9333-F1F47AC7E1A0">
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0330EA2-4FF0-4F48-B85F-51C143A089A8">
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B036858-70F5-4077-8333-F34F19A042EC">
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:7FADB4CA-581F-409D-A9DE-93A2AD35B45F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3A3DC545-AC9E-4758-9E22-3FFE71F505E6"/>
    <pav:previousVersion>urn:domeoserver:annotationset:707083CE-8C52-4512-BE0C-2E165E446635</pav:previousVersion>
    <pav:createdOn>2014-06-02 14:30:33 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">20</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:356045E2-590C-4AD5-BBE5-F7B03197C94A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:123F2BE5-B94B-4FB6-AEA8-29625DCA77E5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E319F066-2C3E-4B8B-904F-5B682C614A92</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:5BA0362C-1EF8-4647-8A30-017F5378F48F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA8116F7-E363-4BB1-9815-7EC432A940C1"/>
    <pav:lastSavedOn>2014-06-30 11:51:37 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0479EB37-CD5B-497D-AB68-C261585B92A1"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0A52235-7692-496A-9DE2-B919FD0C2AC7</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:EF81C005-29F6-4197-A7F0-73DFD8BCE232"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:752AF63F-9AC6-4011-8D37-310DB23CFB68"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4CA8EAB9-51E6-4B97-AFD7-E2D4FCC3DC56"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE3C3FF6-F83D-47D2-8C4F-944687265F2B">
    <ao:body rdf:resource="urn:linkedspls:uuid:549211CB-8AFF-415A-B1BD-09BC38B52755"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:961BA50E-515C-49B1-9E13-9A89032FBDD0"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:55BCCCDC-ED3F-427D-AFFE-0E80E459C63A"/>
    <pav:previousVersion>urn:domeoserver:annotationset:E56B19ED-CC69-40EB-B68A-25F7DB5534A9</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:createdOn>2014-03-31 09:01:41 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F8624524-9CEA-4109-AD60-7041876D4E8C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:15CFACDA-93A0-4CF4-81F6-D807D5C1DDD5"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:16C3120F-E19F-453E-9222-0C4CAA7503EB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4777BC06-68FA-4171-A52D-68668AD25547"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:19F33D58-FE1E-46C1-B076-70725190FF1F"/>
    <pav:lastSavedOn>2014-03-31 09:06:26 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72569EC5-72D5-43F3-9028-CE31C726B1D0">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>72569EC5-72D5-43F3-9028-CE31C726B1D0</domeo:uuid>
    <ao:prefix>At a median follow up of 73 months, a higher incidence of events was seen for letrozole tablets (13.8%) than for tamoxifen (10.5%) regarding fractures. A higher incidence was seen for tamoxifen compared to letrozole tablets regarding thromboembolic events (4.5% vs 2.9%), and endometrial hyperplasia or cancer (2.9% vs 0.4%) (tamoxifen vs letrozole tablets, respectively).   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:72569EC5-72D5-43F3-9028-CE31C726B1D0"/>
    <pav:createdOn>2014-06-30 12:02:17 -0400</pav:createdOn>
    <ao:exact>Bone Study: Results of a phase 3 safety trial in 262 post menopausal women with resected receptor positive early breast cancer in the adjuvant setting comparing the effect on lumbar spine (L2-L4) bone mineral density (BMD) of adjuvant treatment with letrozole to that with tamoxifen showed at 24 months a median decrease in lumbar spine BMD of 4.1% in the letrozole arm compared to a median increase of 0.3% in the tamoxifen arm (difference = 4.4%) (P&lt;0.0001). No patients with a normal BMD at baseline became osteoporotic over the 2 years and only 1 patient with osteopenia at baseline (T score of -1.9) developed osteoporosis during the treatment period (assessment by central review). The results for total hip BMD were similar, although the differences between the two treatments were less pronounced. During the 2 year period, fractures were reported by 4 of 103 patients (4%) in the letrozole arm, and 6 of 97 patients (6%) in the tamoxifen arm.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F8A06DC-D6FE-466C-AF73-CF9E7A8C2707">
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:563CB9E8-A4E7-43EF-9686-1F5B71F4169D"/>
    <pav:previousVersion>urn:domeoserver:annotationset:586BB8D4-86C3-412E-9702-95D59934639E</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A460766E-6EF1-468A-A8D7-D8163DEDE490"/>
    <pav:createdOn>2014-06-30 12:25:51 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-06-30 12:25:52 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7DCCB62D-29A5-40E9-83C7-DFCF58020046"/>
    <pav:lineageUri>urn:domeoserver:annotationset:77B5C0D4-B728-4F8B-B5B3-E3B3BE2E8C85</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:48A1E6BD-969F-4E11-B89E-72FDEF815354"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:8BDBF128-DEE9-4EB2-B39E-0D98C624E68C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:16494570-4624-4B51-96D2-4591C10B64CC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D8EC8863-EC0C-49E2-9824-C74F9C5C5376"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9396C455-7DD2-4BF6-B3E0-EB48C239E903"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Citalopram</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3665D7A9-FCD1-4278-8B7F-5EA5B3CC19D3">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:7F2054BE-903F-4E27-9C7E-A87C0BC010DD</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:1918EE39-EC8D-40CD-88DD-7786F622ADD4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3138E2AE-09EE-42FC-A600-DCCFD1E806E3"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:E319F066-2C3E-4B8B-904F-5B682C614A92</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:F7A1EEE7-4F7B-4D26-A294-05C81FE4F9B8"/>
    <pav:lastSavedOn>2014-06-30 11:52:19 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8A35BACC-77B7-4822-A677-4D72A3B91942"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A2BB972A-BB8A-4A43-9864-7D082638383E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0A52235-7692-496A-9DE2-B919FD0C2AC7</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:677AE6BB-D9DD-44B7-90F8-559967319E56"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:630E5590-A87E-40A8-A3F3-DE3348285B26"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7E666CF4-DD19-4B4B-AE7B-EF4BCEA0181C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA3DC068-1206-46E2-9872-6AA4128F9AA9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A9D2C42-2B60-4261-806F-7AA8AB609B32"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F0C0BB8-3C88-4F5F-888A-993628CE819E"/>
    <pav:createdOn>2014-06-02 14:34:06 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">21</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:76892146-9A3A-463F-9ABF-573CA0067EFA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA5D15E4-F701-4E25-BBA7-93F9828C1D00"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:121C567F-2959-445A-9390-AB1AD1A2C5C3">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34084-4 ADVERSE REACTIONS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34084-4 ADVERSE REACTIONS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC705FE0-7F27-4CD4-B50D-6B7A4AF34DB1">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9098E55C-952E-46DF-904C-2A3E63492B3A">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In CYP2C19 poor metabolizers, citalopram steady state Cmax and AUC was increased by 68% and 107%, respectively.</ao:exact>
    <ao:suffix> Citalopram 20 mg/day is the m</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9098E55C-952E-46DF-904C-2A3E63492B3A"/>
    <domeo:uuid>9098E55C-952E-46DF-904C-2A3E63492B3A</domeo:uuid>
    <pav:createdOn>2014-06-30 11:21:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B7239DA-6BB5-450F-B107-37E66914C66D">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:586BB8D4-86C3-412E-9702-95D59934639E</pav:previousVersion>
    <pav:lastSavedOn>2014-06-30 12:25:52 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E95F30F-36EE-40C4-991B-275A3AB9E17C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:617FB23D-D90B-41A9-B13D-112F0724E0EC"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:D040FB4D-6347-4C25-B523-64D3BCE93BA1"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:375DD3AE-F16E-43E9-BB3E-D521613E10AF"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:507AAF39-F42E-4A74-860F-425386B82BED"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8734D580-771F-422E-B2C2-CD625AC13731"/>
    <pav:createdOn>2014-06-30 12:24:05 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B030FC79-83F8-4FDB-B7CC-7AA176B54243"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:77B5C0D4-B728-4F8B-B5B3-E3B3BE2E8C85</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:CE76789E-AB5D-4F50-AF22-F3C2D4249992"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7DCCB62D-29A5-40E9-83C7-DFCF58020046">
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8525CDF6-1EFA-4AA5-BD43-C9DDE92E0196">
    <pav:lineageUri>urn:domeoserver:annotationset:1CEDA84C-14E2-4D8B-A754-750B7AAD033F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:97694242-B4F8-4F1C-BB40-15F7AA4313B0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E719DBCC-60BF-47C9-A2A6-B5AD564ED472"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:F7D9EE5F-E5C0-4296-9825-534C2F768855"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:00E8CD81-460D-4060-A021-B8D8C71F86A1</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A00084F3-6649-4F9C-BDA5-E261BBC74F3B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:27B383EF-907E-4762-BA6D-DDC5D1CD9B92"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:69C92FEB-FB69-48D0-8F98-B667A717D1A0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A46D79F-0482-4D27-B84A-FADD47B23284"/>
    <pav:lastSavedOn>2014-06-30 12:02:39 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-06-09 15:59:09 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:07A011F7-AA51-4AF6-9F6E-2ADE83EF58E9"/>
    <pav:previousVersion>urn:domeoserver:annotationset:83F084B6-76CA-4613-8AEB-954B635FF24E</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF096FB6-D36E-43DE-9F79-DAD9217A8F6A">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E1AD726-EA80-471B-8E2C-2AE30256BB1E">
    <sio:SIO_000111>34071-1 WARNINGS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34071-1 WARNINGS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E003EB3-2B97-41C7-BD14-5EAF744BB5F2">
    <ao:body rdf:resource="urn:linkedspls:uuid:1BFA2B92-6713-4B9F-90AE-FCFD6ED07058"/>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F35196A-9B27-4982-ACB1-82F6E1AEE305"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A59A0FFF-C40E-445B-A997-9D6C97BF2B3E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F9269665-A463-462D-91AE-C30A34300D28"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">16</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:BC0C42BD-3C98-4864-9F9C-50F72712CEC9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2740FBC5-62E1-4A34-A993-7667E952F771"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1C81595D-9448-4ED4-9731-68138AAA5864"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:599C562C-AF77-481A-9522-37F7FE7D35CE"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:7D90283E-E189-4D7A-B2FE-77B0A097DC40"/>
    <pav:previousVersion>urn:domeoserver:annotationset:81471911-B497-49F7-88B6-ADDEC2ECD6C4</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:BFA2E65F-3DF8-4BF4-80DE-791E469C1461"/>
    <pav:createdOn>2014-04-21 12:43:51 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C6ED6B4D-6C7E-43B5-B650-F126750D08B0">
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B1E2F2DF-BA97-42E8-8BF9-70A85A763011">
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E0CD575E-3B67-4030-A5F3-832FE1AC8395">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:56454B1C-0054-4957-B706-156C1ECA5394">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3A77F5FE-EF65-4FF1-9BCD-E358D4D5BC82">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Azathioprine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1D6D1BB-344E-42AC-B263-7FB84A0034CB">
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D044EC4-5762-411E-A3D7-4BF4908C494F">
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:7CE2D02E-F446-465D-9CBE-27C213ACCC89"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:73360989-B979-493E-8A6F-9D31D67D94D0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9D056A46-E560-4D06-B8BC-6316B8B51BDD"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:F0B5E6C3-0B65-414A-9318-F39AEE9C75E4"/>
    <pav:previousVersion>urn:domeoserver:annotationset:E96AF2CC-CAE9-496C-ADC0-7F57E68F95B6</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:BCD590DE-4767-42DB-A1CC-95099463B7D0"/>
    <pav:createdOn>2014-04-28 15:54:29 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">30</pav:versionNumber>
    <pav:lastSavedOn>2014-06-30 11:42:30 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4EEB4B8C-B4AE-42C6-9E9C-805907F3A548"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5371C4D7-4911-4F64-8D51-0291251C92B6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:17461CFF-684F-4CC1-9811-4C5C13C44A01"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6C42EB4F-92E1-451F-9125-83C72497CDF3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E1788A3-66E3-4952-B193-2C5E9B1AB551">
    <ao:body rdf:resource="urn:linkedspls:uuid:37AA76F4-09C3-447C-B6E9-D71C6F8AF4B0"/>
    <pav:previousVersion>urn:domeoserver:annotationset:184D766F-E8BD-493E-B5CC-469B67C4540C</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-30 13:17:54 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:3728C2D2-73B4-4F3A-A648-FD42247BA4EE"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:9D677F0E-9F2F-436D-A841-1E5038B33935"/>
    <pav:lastSavedOn>2014-06-30 13:18:20 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:07E8EBFA-A60A-44A6-B4FF-E40C91C5BB4C"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:EEA90F54-8E00-4B5E-B685-11848BFBA55A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E44DEE5B-4DE2-4DE7-B9F4-2EF2B8ECDB21"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:217B566B-E501-4A3D-A7B5-BFA5CE66147B">
    <ao:body rdf:resource="urn:linkedspls:uuid:9E1AD726-EA80-471B-8E2C-2AE30256BB1E"/>
    <pav:createdOn>2014-04-21 13:35:09 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E06F2653-44AD-435F-AB2C-133712B039A6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:026B6D2A-8163-421F-B9FD-6DD02C0747FE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8BF0E0C7-09D1-4AC8-A5E5-F4C0074AC435"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:71E2C57F-182F-4316-8B69-739932B3E614"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-30 11:15:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:AEB8FC73-76B8-4192-8D69-3C44E7145E41</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:1C112F5C-A77D-466F-942A-A407FE0CF126"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:94F5EFA2-DEF5-444E-B4C2-7268B36AF650"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:E6148AE9-D3FF-43CD-B26E-1DDB165D61DD</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">13</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:1EE19009-F28A-47FD-8E3D-A8E9B82B8708"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8E97872D-A5EA-4365-A1DA-DD1AFEB4FCE0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:ABF85151-DB4C-4069-9F3D-A22A295FE2B7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FDAA4CB2-811A-4928-8A6A-39B907F9F312"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B495D868-5058-49BA-B2FC-551A76D36CA2">
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A460766E-6EF1-468A-A8D7-D8163DEDE490">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FB8FC7BE-DF14-4ABF-B790-607DABB38F49">
    <ao:body rdf:resource="urn:linkedspls:uuid:8D47DE7C-DABA-41CE-B00C-7DA122057C67"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D0CCA734-2755-4A63-9280-7C7E4FFB5CF7</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdOn>2014-04-14 14:07:33 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:2F3B0124-31A3-451B-BA81-5652303A452C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C5775E84-0546-4E6E-B45D-FFA024B1972E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1158AAB8-3C05-4AED-8029-D6E9BA759355"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4AB5FE0A-C183-4F94-B914-1228DE7E4196"/>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:92FA8990-60EF-4140-9F60-C12E57E3B114"/>
    <pav:lastSavedOn>2014-06-23 14:25:43 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3689FD7C-4B03-41A9-A867-74E8C7C0FC0E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:4048B9B2-554D-4559-93F6-672B118A87D0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1BFD8F59-2C44-4309-B092-DC7D487CF6CB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">35</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC19F85C-8A63-4FF5-AC2E-DB69D0D86182">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42231-1 SPL MEDGUIDE SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>42231-1 SPL MEDGUIDE SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:27B383EF-907E-4762-BA6D-DDC5D1CD9B92">
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:20FD83E0-8F9F-409B-BA60-7D4A2F8A54AF">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>20FD83E0-8F9F-409B-BA60-7D4A2F8A54AF</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:20FD83E0-8F9F-409B-BA60-7D4A2F8A54AF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-30 11:33:56 -0400</pav:createdOn>
    <ao:exact>Poor metabolizers treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Effectiveness of clopidogrel bisulfate depends on activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. (5.1) </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9978D70F-9B7D-4598-8D12-0D71F5BF406F">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:65BD7CC9-2CFA-43C3-A5F0-FBC0221449BF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:976BDFF3-2BFA-4838-B6A0-327B2921E1B7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">25</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:E6F327D5-6DEE-4EFB-8EC4-6E122CA71411"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:87B8F5B0-8381-4CA7-AE0B-30C481D164B4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:91FC426C-470A-4F05-8189-438F1BBADDAA"/>
    <pav:lastSavedOn>2014-06-30 11:34:30 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B86AA3CC-B57F-4BBB-A6C0-F20063F46FFF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B0D6C928-74B2-4DA1-BBF4-124615410D84"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <pav:createdOn>2014-04-28 15:38:40 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:88CE2DCE-C910-4D43-8410-F1CD5C2E0A07"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:42E0A5C2-D6F2-4284-9E56-B11A767DB4D0"/>
    <pav:previousVersion>urn:domeoserver:annotationset:FBC84091-3201-409B-AEED-D0D661E79218</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B52DDA70-3E7C-4358-8558-ADAC22E0B522">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D1472F3-6F6E-4A37-82F5-074CC3DD8C8F">
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2D2BFB3C-0E2A-4B9E-B9CC-2D21C8035D95">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:73CE8E6E-42C1-40ED-83A1-F186FA6F4BCF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55304B24-8DE1-4B6D-9FDA-B01C9B453126">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e143044e90f26014518a19cf70063">
    <foafx:homepage></foafx:homepage>
    <foafx:name>PgxConsensus</foafx:name>
    <foafx:title></foafx:title>
    <foafx:middlename></foafx:middlename>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <foafx:email>codehop.dev@gmail.com</foafx:email>
    <foafx:lastname>Consensus</foafx:lastname>
    <rdfs:label>PgxConsensus</rdfs:label>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:firstname>Pharmgx</foafx:firstname>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5371C4D7-4911-4F64-8D51-0291251C92B6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42231-1 SPL MEDGUIDE SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>42231-1 SPL MEDGUIDE SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E02315A-EB6D-4693-B3E4-4FB4B99D4253">
    <ao:body rdf:resource="urn:linkedspls:uuid:2CF4F791-1000-45A3-93CF-ACF0A6709ACE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3A77F5FE-EF65-4FF1-9BCD-E358D4D5BC82"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:9E84521E-DB93-437E-ABDA-390CB71443FA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F0627866-7207-4CDB-B718-21756549DDC1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C8BA2048-FAC6-4C0F-B145-427A17AD3E63"/>
    <pav:previousVersion>urn:domeoserver:annotationset:7ED58A9B-BC10-45FD-8B62-40696012B47A</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">13</pav:versionNumber>
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C2B100AA-AED8-4D23-A22B-217E6AF13448"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:814CFBFC-9845-4B07-B4DE-628384917722"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A74CD0BB-2B56-45FC-B50D-C7952B9C9AE4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8696D99F-9273-44E6-ABE8-8C347A8CBFE3"/>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:3D8FCA63-D459-479D-B663-B2AB9028C444"/>
    <pav:createdOn>2014-04-21 12:33:30 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16658488-3D7D-401B-A6A7-80EAC49CAFDC">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*1502</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE73DA30-2D2E-4D34-AC2F-B160599E5ADD">
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:00E8CD81-460D-4060-A021-B8D8C71F86A1</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:AB20CF31-054E-4285-B7BA-A25704491DA8"/>
    <pav:lastSavedOn>2014-06-30 11:59:39 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B17B8190-D4C0-47BD-93D4-59EF1FB8A973"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:BCC8E4C0-518C-4CB7-86BA-64CE75086359"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2C91610D-460B-40E8-B924-B09D6465F662"/>
    <pav:createdOn>2014-06-09 15:37:59 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CBEBA97D-4F36-4510-91B7-69B7D35D5F14"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:482A9B43-D4B0-4890-91BF-CD5DEC8C7BA6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5B23BB9C-106E-465B-95E4-A09741FC6B9E"/>
    <pav:previousVersion>urn:domeoserver:annotationset:5AB704EB-C507-4FF7-B9C4-32F8475094DA</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:E6B02E4B-FDE8-473A-A978-02F98D0FE07D"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1CEDA84C-14E2-4D8B-A754-750B7AAD033F</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1112EF7B-9CDC-4021-94DE-68FB499BCCA8">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34084-4 ADVERSE REACTIONS SECTION</poc:productLabelSection>
    <sio:SIO_000111>34084-4 ADVERSE REACTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7A7EDC45-CF4F-4C98-9560-59ED6861B6F1">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9D01B1F5-3775-4CA3-BDFA-97BF6089AE2E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-22 22:22:30 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:prefix>If symptoms consistent with hypersensitivity are not identified, reintroduction can be undertaken with continued monitoring for symptoms of a hypersensitivity reaction. Make patients aware that a hypersensitivity reaction can occur with reintroduction of ZIAGEN or any other abacavir-containing product and that reintroduction of ZIAGEN or any other abacavir-containing product needs to be undertaken only if medical care can be readily accessed by the patient or others. </ao:prefix>
    <ao:exact>Risk Factor: HLA-B*5701 Allele: Studies have shown that carriage of the HLA-B*5701 allele is associated with a significantly increased risk of a hypersensitivity reaction to abacavir.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9D01B1F5-3775-4CA3-BDFA-97BF6089AE2E"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CBE9DA72-F01C-4A8C-AC13-BE4D7ED71784">
    <rdfs:label>Alternative Recommended</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7156E853-F84A-47E5-A713-7433E0C59749">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Use specific</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B1E4FE2-11FA-4FB0-85F2-014750705FED">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:1737F273-42CA-465E-A534-8B9FEAEB263B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F5898051-49D9-42F0-B014-0C533E59B4F5"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8E97872D-A5EA-4365-A1DA-DD1AFEB4FCE0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:653A3DFC-DFC7-42ED-8D6E-BC5AE5F3E730"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E6148AE9-D3FF-43CD-B26E-1DDB165D61DD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:99ADE58D-3F23-4EA1-8830-1F8A6FF82D58"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:4D4A2434-8FDA-47F1-9486-AC19C47BF61E</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:61316A76-662A-471A-A970-BFBF8EBB83E7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE534BB0-3042-44F4-9B63-01291E28FA45"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-04-21 13:29:03 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:2903BD03-170B-40A1-A944-4092D506137E"/>
    <pav:lastSavedOn>2014-06-30 11:11:09 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:79C530FF-637A-43C8-AECE-CA81458FB5EE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:252018F1-DCA7-4F09-8904-5145010C0308">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3419ECAE-A4FF-4BE4-8679-16B52BA748AC">
    <ao:body rdf:resource="urn:linkedspls:uuid:54AD3A78-A7C9-4CD4-B715-3E91C92E64A6"/>
    <pav:createdOn>2014-04-28 15:43:27 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <pav:lastSavedOn>2014-06-30 11:36:17 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E7A45B66-EEE2-4C03-851A-7F6207712150"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:6F4084B6-F1FF-42F7-A9A4-26DB879ABE6D</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:119F933E-FFF4-4D53-BC7B-2727B9BFAACE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7952BD0B-86EF-4547-9479-6887AFB0956B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:161EC61C-3A7E-4CCF-93D6-FA3749DF7BAF"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:0579E19D-BA85-4595-8F37-A456B687BC45"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2BEFD527-0C92-4B61-A2B9-12F931EDC707"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9DB50485-E87B-495A-97A1-CE8F7916E40D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">26</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:EEEC10EA-111A-47B5-A583-70C4B3F28C0D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BE935BB7-5787-43F4-A8B9-B9FEE59E4B1A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B4CA7086-6798-431D-B76B-5ABC77094611"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9">
    <ao:item rdf:resource="urn:domeoclient:uuid:9DDE5A30-59ED-49D7-B9B6-316245562477"/>
    <rdfs:label>New set 1</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:DCF9A15D-3781-426E-B12E-C37A11772BAD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3419ECAE-A4FF-4BE4-8679-16B52BA748AC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9EBC36A6-A85E-4348-8EBC-5B071D8A79FB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">31</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:AAB53C8F-FB14-4216-82D9-D7CD0AB15000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:942AE26F-116C-4165-9118-723E840DFB17"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0D044EC4-5762-411E-A3D7-4BF4908C494F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1042FEEA-5AF3-4E50-B2A1-053451F2236C"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143044e90f26014518a19cf70063"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CDE45635-21AB-4AC7-89FF-C772F3A15A2C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <dct:description></dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:C692DA9C-1ECF-4A5B-867C-ABAF23492F10"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:44BBF444-A1D4-4182-8B05-775BFFCA0DF4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7D37999E-F183-41DD-8FEF-19696FD23D30"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:65BD7CC9-2CFA-43C3-A5F0-FBC0221449BF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:408C86B9-FFBA-4A7F-A6EC-ECD348FD4782"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:90768224-544A-41CF-9969-E08884F1434D"/>
    <permissions:permissions rdf:nodeID="N51b89368f82b49578d5920d8464f68a3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5CCA20AA-4D3C-40F4-BAED-C832E665FA35"/>
    <pav:lastSavedOn>2014-06-30 11:43:28 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-04-28 15:20:04 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:E1E45497-D882-456B-B573-7A640A307AFB"/>
    <pav:previousVersion>urn:domeoserver:annotationset:E5881C94-41AE-4CCF-8284-C6EBB8241173</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EC203AB9-CA2F-419B-BE90-A6A446A9CFDB">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B50CE5B-C2BB-4D97-838E-E1C2600020BC">
    <ao:body rdf:resource="urn:linkedspls:uuid:291E17EF-EB0A-419A-9930-D6B0402634E2"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:04BA939A-F825-4DE6-B7F6-06D7E2C0A463</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:8C44EE5A-5A11-4743-B389-617115FC82BB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3C75F25B-730C-424C-8A4A-C55F0D242716"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-22 22:16:17 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:84C9C2FD-017F-43C7-AD66-35BE4F24C7CC"/>
    <pav:createdOn>2014-03-22 22:15:46 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E69519CE-CDB4-4ADE-9142-E9FF4BAFBE3D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:A0FDB6D8-3B29-4169-B943-7B9136C0BE5F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">14</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:55700EE9-88B8-49B7-BD64-1A87D99DCC15"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:C24DFA02-2096-4634-974B-1866183BFD0B"/>
    <pav:lastSavedOn>2014-06-30 13:25:26 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:6E1788A3-66E3-4952-B193-2C5E9B1AB551"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:5EE59E00-2977-4F09-A933-867C3E165210"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE4F247F-F7CB-4776-A379-05B0401FC08D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3D5B3334-40F5-4B23-8773-AFED2978DC1D"/>
    <pav:createdOn>2014-06-30 12:48:44 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:7D8A9803-9C09-4301-8254-AF8BCE7E83F8"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:F10FC0DB-5D49-46E9-A2C2-3CFFC5FBF692"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:40B2A403-27A7-43FE-A0AC-5D87E3545981"/>
    <pav:previousVersion>urn:domeoserver:annotationset:00635B37-EF64-4BEB-AF52-7270615FC06E</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE2D417D-24B3-4A7E-BE0B-FBF0E34B509B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:75A79304-2BD1-4F33-9391-4BB93929D4E6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:74791FAB-E4B4-4EA3-9557-BD68EDB49B01"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D3CF5A34-A1A9-4AFC-83F2-A5A1DD6DBB7F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BC0A4D53-4B45-488A-8775-B46BF1E9B010"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:232C5C6E-F6FE-44B8-AE5A-7E1BD427D626"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EE521BAD-75B0-418A-A885-F72D473E4567"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7FDE7EC5-68D1-4D11-A164-0B2DA9D73292"/>
    <permissions:permissions rdf:nodeID="N2cdf0219d90a45d089123ff1e5a8bd8c"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7084C584-8C84-42A3-AFAB-F66F243A2817"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CA417E62-D7D9-4F45-8359-10CCF8D13F90"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143044e90f26014518a19cf70063"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:09730EE5-3645-4E22-8362-E17C60539840"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:55ED86AA-B414-4220-94FD-868AFE2D1278"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C90A84F9-5F30-4BC7-9DE4-4220F6C37BF7">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E826D255-0A7E-4F3C-A59F-675E8A9B606E">
    <ao:prefix>ZIAGEN contains abacavir (also contained in EPZICOM ® and TRIZIVIR ® ).  </ao:prefix>
    <ao:exact>Patients taking ZIAGEN may have a serious allergic reaction (hypersensitivity reaction) that can cause death. Your risk of this allergic reaction is much higher if you have a gene variation called HLA-B*5701 than if you do not. Your doctor can determine with a blood test if you have this gene variation.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid>E826D255-0A7E-4F3C-A59F-675E8A9B606E</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E826D255-0A7E-4F3C-A59F-675E8A9B606E"/>
    <pav:createdOn>2014-06-23 14:42:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2CCF84A-A981-4564-8227-DE5688CB1FED">
    <pav:lineageUri>urn:domeoserver:annotation:5C114E05-B901-4854-ADFC-7481FF0A4FDA</pav:lineageUri>
    <pav:createdOn>2014-03-31 09:10:10 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-31 09:10:25 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:1EF0B4A4-3F75-4AB9-8AA1-84A028AD5EE7"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:97A00FDB-1B7E-4BA6-B531-7DA063BAC30B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C751B6F1-6EDE-4C87-A5FE-1A6E0D3D4C92"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:34F7A071-6983-40CD-B22D-108DA2488667"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC44848F-712F-4F1C-BAFD-94EEC65ED24D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7AE1124F-F104-4EB3-9415-257F81B2E3CE"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:A85EF876-AF0D-4316-82E4-390553A6DEBD"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:616A0715-5B79-4DD8-8392-1FDEF99E9911"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4019443F-CB02-40D7-BB18-37DDB00B1548">
    <pav:createdOn>2014-06-23 14:38:57 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:prefix>Risk Factor: HLA-B*5701 Allele: </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4019443F-CB02-40D7-BB18-37DDB00B1548"/>
    <ao:exact>Studies have shown that carriage of the HLA-B*5701 allele is associated with a significantly increased risk of a hypersensitivity reaction to abacavir.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>4019443F-CB02-40D7-BB18-37DDB00B1548</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E8587041-73D9-4727-A9F5-7445BAF204E3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-30 13:24:15 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose. Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose.</ao:exact>
    <domeo:uuid>E8587041-73D9-4727-A9F5-7445BAF204E3</domeo:uuid>
    <ao:prefix>CLINICAL PHARMACOLOGY and PRECAUTIONS ). </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E8587041-73D9-4727-A9F5-7445BAF204E3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0AE4805A-9064-4B43-9C66-7F8E47ECAB77">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D1491BCF-E2DE-4ACD-A786-633BB7136467">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE2D417D-24B3-4A7E-BE0B-FBF0E34B509B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:691E83A1-1BFF-4939-996A-35C56D0CF2DF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:732B9DAF-16BA-4DEF-9F6F-33E30E2CCDA7"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0DA7AAE6-C82C-4935-9D33-40D96FDB2416"/>
    <pav:previousVersion>urn:domeoclient:uuid:766C374E-9B6F-4C27-8738-436CCC152D43</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:FE6B2026-7838-44E7-9A96-E2BBB8C60F79"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-06-30 12:54:58 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C29BB62F-1380-446E-A6CD-5B46DB334A08"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:097ADA1B-6976-4BDE-AFB2-BB3B661FEAA4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:73CE8E6E-42C1-40ED-83A1-F186FA6F4BCF"/>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-06-30 12:51:53 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9BBDBAC7-FADB-4DF5-9066-F29FDFAE5D8A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2EF23CC0-07B7-43BA-8D93-535D7049CF1D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DEA4B73A-145A-4D61-A6E1-ABAE37F63480">
    <ao:body rdf:resource="urn:linkedspls:uuid:75E5EB7F-648F-4EF9-8C33-D00C2D013D0D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:33209444-B2EB-4B87-8865-C0F674C4BA32"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B170901-0396-4A6F-B879-394F3EF91EDB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B28D214B-5512-4B58-A714-CC034E8D06A9"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0F28EBB9-5E26-448C-911F-5DD64A1FA5F7"/>
    <pav:createdOn>2014-04-14 14:36:29 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:CFEF239C-B763-4864-8DD8-A917EFD12673"/>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">41</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-06-23 14:38:28 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:77A5B46A-613C-4652-B182-17CDCF3C7C3D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:74EA2B44-40D9-44F0-90BA-33EFF2D1B5AA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:545DF6CB-5BC9-413E-A0C5-696FCED7CD6E"/>
    <pav:previousVersion>urn:domeoserver:annotationset:8B7C9D72-5DD1-48AE-928D-A78CCDF396C9</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:86565D69-8F9C-4519-9A52-CD2A2980DEE3">
    <ao:body rdf:resource="urn:linkedspls:uuid:9C09D2F8-83BE-446D-A17A-75402666EE4B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:98D18AEE-09C7-40A9-A144-DE02F0A10386"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D56FB9CC-BBC3-4126-B302-EEAE31038A57"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:D181BF33-A971-4C1A-8908-20D2F9B0EA61"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-06-30 12:14:51 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D9543430-9668-4C09-8709-B8D20B095EEA"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdOn>2014-06-30 12:14:50 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:ABC38527-F428-4D89-B349-CF1D993B7031"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:DAAE6973-853E-4988-8DD1-71C285B27E2E"/>
    <pav:lineageUri>urn:domeoserver:annotationset:77B5C0D4-B728-4F8B-B5B3-E3B3BE2E8C85</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E278366-F0F0-440E-9361-64770240555B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9BCAF415-84AF-4907-8BCF-E79F35898B2C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D8EC8863-EC0C-49E2-9824-C74F9C5C5376">
    <rdfs:label>ESR1, PGR</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1737F273-42CA-465E-A534-8B9FEAEB263B">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B6B4A58C-16B0-408F-A838-47FC8649B72D">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-30 13:25:13 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B6B4A58C-16B0-408F-A838-47FC8649B72D"/>
    <ao:exact>VKORC1CYP2C9*Ranges are derived from multiple published clinical studies. Other clinical factors (e.g., age, race, body weight, sex, concomitant medications, and comorbidities) are generally accounted for along with genotype in the ranges expressed in the Table. VKORC11639 G(rs9923231) variant is used in this table. Other co-inherited VKORC1 variants may also be important determinants of warfarin dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3 and *3/*3 may require more prolonged time (&gt;2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen.*1/*1*1/*2*1/*3*2/*2*2/*3*3/*3GG5 to 7 mg5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mgAG5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mgAA3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg</ao:exact>
    <domeo:uuid>B6B4A58C-16B0-408F-A838-47FC8649B72D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:prefix>Table 5Range of Expected Therapeutic Warfarin Doses Based on CYP2C9 and VKORC1 Genotypes * </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6E680A49-5B91-4058-A09E-25A6ED988EFC">
    <rdfs:label>Azathioprine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D336843D-C700-4B81-AAC2-DB786978197E">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AAB53C8F-FB14-4216-82D9-D7CD0AB15000">
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE4DF0AD-E3A1-4585-AD52-A6AA64D0349C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5F4B7893-348F-4B09-866A-BE0644080293"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1CE911D3-8E07-4217-B9EF-F20B81C6B51F"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-30 11:43:28 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:B97B97E4-D927-457C-8BC7-8AF594D5FD9F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:44A37F21-E420-40D5-A9E0-5CEDEFAEF40B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:7DB3B3C8-0C75-4C85-B7C8-1B8D8817810E</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <pav:createdOn>2014-04-28 15:56:23 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:55544593-2536-44D4-B561-50DB89250F52"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3C852929-ADD4-4383-A351-2D9CF492A6E9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:610138BB-C886-433C-A137-D8C9F0AE2C75"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:945EB72E-5C75-41B0-B8FC-637E1EF0AE7D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:93023233-0D8E-497C-BBF0-DE5DD31AF15E"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:lastSavedOn>2014-06-30 11:16:53 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:10D9A112-25CB-425E-899B-C3AAA3CF633A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DBC5988C-D720-43A9-9D01-8713355AB4AB"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:8FA0DE16-92FC-4098-8E9F-7A129E4349D7</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-04-21 13:39:30 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8E97872D-A5EA-4365-A1DA-DD1AFEB4FCE0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:2CD7E6EE-8F43-4B03-92B9-825A2FD231CF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:048C3B36-1BEC-46CD-96A0-C39142C44747"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF0E7639-6AE6-4519-9A14-41BF8AB6A508">
    <ao:context rdf:resource="urn:domeoclient:uuid:D888391C-2CE3-4955-850C-C8FA6291737A"/>
    <pav:previousVersion>urn:domeoserver:annotationset:829A2EF2-2689-4168-802E-A4A43BDE6D69</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-04-28 14:54:20 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:EA11DA11-0A03-469A-97E9-855E1FA24490</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A397B9B2-FD1E-4F7C-AF2A-E574DDFC476A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D3EDFFC9-9EE3-45DD-B147-801DAB72DF3D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C65A90AC-060B-4128-BBC1-2590A86A3560"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0A77E98C-C600-4EC4-B7B0-FBE6DB0E4100"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B5C424F-CAD0-4CE2-BA6C-0AEC6ADA9CAE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:866BF777-5920-4698-B1A9-093E0CE2D75A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:17A2A5F8-6739-40C4-AEA6-7BE0ABBD5908"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-06-30 11:22:45 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7084C584-8C84-42A3-AFAB-F66F243A2817">
    <pav:previousVersion>urn:domeoserver:annotationset:08BC0DF1-CC79-4344-AB59-48A8C4B06849</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:22C583C8-0AC3-4E1C-A595-4E5CCD32A0F9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:08B881EF-DF79-4F2E-8989-15AFC669C759"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:36230084-C9BE-4A01-BF7F-72D2DA64F5FB"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:96D64C07-9E27-46D2-BE64-358670990970"/>
    <pav:createdOn>2014-06-30 13:01:21 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B973C15-149D-4D98-90E2-4A06A2F30ABD"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:8DB42E98-E31C-4559-9876-3E6F208F6AC4"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8E738FB7-477C-4524-B024-29343F2936EA"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-30 13:01:21 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:103A8210-5E84-43A2-AE2C-0BDD939E55BE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9BF54AC2-D58D-4056-A806-0296CD55AF18"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F7A1EEE7-4F7B-4D26-A294-05C81FE4F9B8">
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5949C0ED-ECE8-4C36-B91D-8E58F7A36AAC">
    <pav:lastSavedOn>2014-03-22 22:22:32 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5CA30A28-B75A-4D14-87B5-8F1D73A58AF0"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE6A11BA-9F40-4FCC-AD6B-A61A5202A894"/>
    <pav:lineageUri>urn:domeoserver:annotation:3E74BD7A-0A67-4373-A844-A3EFAC3B28D2</pav:lineageUri>
    <pav:createdOn>2014-03-22 22:22:30 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:4E6A2736-0750-43A7-A6E9-E7C80E5447ED"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:558D142F-DBE9-4EB9-9F46-4244D63F2FAF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:9D01B1F5-3775-4CA3-BDFA-97BF6089AE2E"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:9953D1B9-8B96-4EC4-AEF7-D059402BDC26"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:87F92664-6A48-4816-A909-6D6A23278C95">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Chinese, SJS, TEN, Asian, Caucasians, African-Americans, Hispanics, Native Americans</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3B78E07-8B27-4774-B221-CC47DAC8365E">
    <ao:body rdf:resource="urn:linkedspls:uuid:CD7BE61C-D111-48EB-A232-1241D41AB8BC"/>
    <pav:createdOn>2014-03-22 22:02:44 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A6669B83-B750-4BCE-A012-641844F7058E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:1F1294AA-1E74-402F-9AED-0611A4B739AB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:64BC1D21-CAE1-4F85-A596-73342A9D5388"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:DAEE8F63-75A3-4EBB-9785-D52BCC522BE0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BCD381EE-901B-423A-AB9C-3DE76C7BF9E1"/>
    <pav:lastSavedOn>2014-03-22 22:03:57 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B0E01B93-2846-4002-87EC-2FEE55716F4C">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D46F2D2-56E5-4ABF-9C97-5A11355C4BA0">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106">
    <ao:item rdf:resource="urn:domeoclient:uuid:FB17C9EA-111C-4784-80AC-30417D974CE8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9E02315A-EB6D-4693-B3E4-4FB4B99D4253"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:405A5AAA-08FD-470C-9B50-67E44ED1462F"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:36D17D73-1169-4131-94F5-24AFD369088A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9E003EB3-2B97-41C7-BD14-5EAF744BB5F2"/>
    <rdfs:label>New set 0</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:F777C391-7D5E-4F49-948B-5B9ACB2587FA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6D4DAD4D-1B63-4482-8060-787D97F917D2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0A45211F-B49B-48F5-A9B9-D593DF301DA5"/>
    <pav:createdOn>2014-04-21 12:22:10 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:AC31138E-D96E-46FA-AD16-E8C5C6855989"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143044e90f26014518a19cf70063"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:38655F0E-DB25-4C1E-A99A-7E2B18134930"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:88C2CEB5-469C-451E-8436-788ABE4338F5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:60281E0C-D291-4163-9B6F-E83A4142CB8E"/>
    <permissions:permissions rdf:nodeID="N960164cae5824bc2910206e9a39196f7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:231E14A4-5E1D-443C-B50C-8E3E00BBAF15"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:121CDD92-5195-42C0-A613-F40D095DA06D"/>
    <dct:description></dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:95EEC2FF-D292-48FE-8FD7-FEF64E2F00E4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3CB531B1-A267-4A03-A0C5-D852AB638802"/>
    <pav:previousVersion>urn:domeoserver:annotationset:0A0D5D01-1239-4811-A433-C691D14F71EC</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:9E9B14EC-233F-4ABE-B627-6150C0C5A5A4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">24</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:720C5233-AF5F-4538-891A-259FD3EE6895">
    <ao:body rdf:resource="urn:linkedspls:uuid:2271B33C-B8BE-45D2-BE91-FC49EEC7F4DA"/>
    <pav:lastSavedOn>2014-06-30 11:59:39 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:1698D07A-FEE7-4646-9922-CE7AE1E284C6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:797741A1-950B-4AB4-AACC-91449700A96E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:05DBF40D-ECCF-4BC6-9077-742EBADF41F9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:00E8CD81-460D-4060-A021-B8D8C71F86A1</domeo:belongsToSet>
    <pav:createdOn>2014-06-09 15:35:34 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CBD21A8A-BC49-4B8A-B7A3-E42A5C22F7CB"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:882E9031-328A-4F6D-8C1A-AE163639BAC5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:1CEDA84C-14E2-4D8B-A754-750B7AAD033F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:87D81A76-B588-47D8-B1D5-76A8263D6516"/>
    <pav:previousVersion>urn:domeoserver:annotationset:5AB704EB-C507-4FF7-B9C4-32F8475094DA</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:0A10CE73-592A-4D92-84AF-63395C43C0F9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:63183DC2-AEAB-428C-8EE7-06585D50BA8C">
    <rdfs:label>Variant Frequency</rdfs:label>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:36DE6D64-E2CB-42B6-9D00-570AC3CAD508">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D640727D-6442-4274-B453-64F04BD595E3">
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1474E26E-D19C-4FDC-9AB0-792A82BB0A07"/>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B03578D-7647-4773-8E59-A027B405D6EF"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9982EFEC-057D-47A7-8241-37ACB3F049AA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D46F2D2-56E5-4ABF-9C97-5A11355C4BA0"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:844BE367-B458-4768-AECE-7675D4FBC121"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7B074451-BDA1-480C-9A76-1FB4ABA06C50"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:2277FF0A-7DF0-46CD-A37F-9F346456C2BE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">36</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:0961EB1D-39A9-4A01-9D9B-C2BC3222987E"/>
    <pav:createdOn>2014-04-14 14:08:25 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-06-23 14:26:37 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:25FCDBC8-E43E-4F5F-AE2A-A12D1E6FB7A5"/>
    <pav:previousVersion>urn:domeoserver:annotationset:3408EABF-8DCD-4D09-A830-2B5B6A75B963</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5B4047A9-42A5-46E5-9848-74F5005C2F7D">
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0961EB1D-39A9-4A01-9D9B-C2BC3222987E">
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D5C1D543-12A2-4AD2-973F-CFDA436726C9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>tochrome P450 (CYP) system, principally CYP2C19 [see Warnings and Precautions (5.1)]. Clopidogrel bisulfate at recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers .  </ao:prefix>
    <ao:exact>Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <pav:createdOn>2014-06-30 11:33:37 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D5C1D543-12A2-4AD2-973F-CFDA436726C9"/>
    <domeo:uuid>D5C1D543-12A2-4AD2-973F-CFDA436726C9</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6">
    <ao:item rdf:resource="urn:domeoclient:uuid:99AB6350-6929-4C24-B144-7B97EBF09B3F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:E34142C5-1680-4612-AC76-D96D8F82364F"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:2386BDBC-D4E5-43AD-9B96-93D7943C7169"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7FA5409D-3EA5-4F92-B738-8577DCEB4D97"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:98743D23-3B02-4029-840D-D16A4F390F95"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:83E53A9A-8702-4167-A12D-1370E2D26E06"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3D5D3473-95BD-41AF-81E6-ED19E81798E9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3C70DFC4-2BEA-46AE-A49C-D4BE3E7466B8"/>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:1E6D8BE7-AC23-449A-83E2-9806683F8162"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2EDDDF15-34C4-4321-9EF6-7ACDEBEFD237"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EED39F7C-032A-4628-9022-2253559E7FEE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:98B929B0-EA85-44FF-B8CA-9D5AC804EBBB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:79AEDAF0-0AC0-4A44-9F6D-05B14ECEF74F"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143044e90f26014518a19cf70063"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DEA4B73A-145A-4D61-A6E1-ABAE37F63480"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FB3C226D-314F-473A-AA0D-98DCD192D7AF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B3811262-7FB7-4610-8AF2-DDBEC1F3F734"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0E9FF6AD-98CE-4932-AD5D-E657F3B363B3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">45</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:D2A37D83-399B-45D1-8F43-9EEAED2472F6</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:D640727D-6442-4274-B453-64F04BD595E3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="Nd3d7d7364dd3473bb2176ddc0d0b2c36"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FB8FC7BE-DF14-4ABF-B790-607DABB38F49"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A753145C-8800-49A8-BE99-D558A1390DAE"/>
    <rdfs:label>New set 0</rdfs:label>
    <dct:description></dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:420A3DFE-8247-4E9B-8E6C-368F1A2C415C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2083D2DB-07EF-4969-A4BB-F5823A134875"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AE6AF907-607C-4B15-B108-FAD4D3010CA4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9992ADBC-4BAB-4529-BAC4-9D7AFD34F098"/>
    <pav:createdOn>2014-04-14 13:34:44 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B35B25D3-31CE-48B5-885E-844B46E97203"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:8CD7F86F-C041-47B7-B7D2-F7B48F523F56"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE1DC1EA-085A-4CF9-8165-5A14A411A633"/>
    <pav:lastSavedOn>2014-06-23 14:43:25 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B706DB0A-7C1C-4FBB-A8FD-B044B8D2278F">
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:37AA76F4-09C3-447C-B6E9-D71C6F8AF4B0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42232-9 PRECAUTIONS SECTION</poc:productLabelSection>
    <sio:SIO_000111>42232-9 PRECAUTIONS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9367EFAD-3937-467F-97D9-F2F6C8B119CE">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:8E97872D-A5EA-4365-A1DA-DD1AFEB4FCE0">
    <rdfs:label>New set 1</rdfs:label>
    <pav:createdOn>2014-04-21 13:17:29 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="Nb52f683eb1a644149b9838a5c6972ed8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:46C63D3B-0000-404E-BC76-FB01C42DC7B2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C09E3379-98EF-4D6C-8046-8C000B4A6C99"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:671F2493-9F0B-4BB9-94E6-4B432F418763"/>
    <dct:description></dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:E6148AE9-D3FF-43CD-B26E-1DDB165D61DD</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:0E8391AF-66D2-4522-A2CE-1780560964DD</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:5D7649B4-7723-40DE-B9AD-4926156D8C0A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1B1E4FE2-11FA-4FB0-85F2-014750705FED"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:217B566B-E501-4A3D-A7B5-BFA5CE66147B"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3C852929-ADD4-4383-A351-2D9CF492A6E9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:139D3D04-C6A8-40B1-A6F1-5FBFB1B6B7CE"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143044e90f26014518a19cf70063"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:lastSavedOn>2014-06-30 11:16:53 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:59E6E4F8-DCB3-4875-86B2-D5885FD80EF7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:87B41003-CAA6-4329-8F8E-1B7CE3C8C785">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>42231-1 SPL MEDGUIDE SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42231-1 SPL MEDGUIDE SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E17574BF-3BA6-48DA-B0DA-6E8DF716A03D">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:98B929B0-EA85-44FF-B8CA-9D5AC804EBBB">
    <ao:body rdf:resource="urn:linkedspls:uuid:6C46DA96-FEC2-4B95-8625-1684409FF5E6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">37</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:930446CC-16E7-4398-8215-BD74669EBB25"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:26F33332-4430-4B1C-AEDE-DC532B427FC2"/>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:3F9C95E5-3E51-4181-8B39-0EF6D0D28957"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-04-14 14:18:30 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:38CB7B79-EA55-443D-8F52-A694D541E5E3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4366F716-A9BD-4BB3-A724-CD58B2F64C8C"/>
    <pav:previousVersion>urn:domeoserver:annotationset:53BF920D-B37F-4CA4-BEB1-394C4948438A</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:357D535A-D77A-4C4A-9D40-D98925D3E30B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:25348450-1CCF-4BEC-84EF-0EA92F67DD3A"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E86A2192-2C3E-4D7F-A0BC-6E287398885C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-06-23 14:34:21 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34095CA4-DD11-4155-9F46-72AFCB3BF738">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8BDBF128-DEE9-4EB2-B39E-0D98C624E68C">
    <rdfs:label>Not Important</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is not associated with clinically relevant pharmacodynamic effect</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16494570-4624-4B51-96D2-4591C10B64CC">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EFBCF9E3-E6EB-44EB-9FA9-FA8288501BCA">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A6AED276-0422-482B-8802-87BDABE2C035">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:9B46003C-0670-415D-A0B8-07A2C1200DF4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:BD4A21D3-9E4C-44A5-9D57-BE07399B0E6D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F96C1A6A-B9D9-48CC-8285-213F65E552C0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5662AE7C-04D2-4B36-91D7-EE2DC27AB384"/>
    <pav:lastSavedOn>2014-06-30 12:20:40 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0F470552-D38F-4A4F-9BCF-4088552F5D62"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:745C184B-12B3-435F-99C5-252556EB53B9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:F3FDFBC5-B694-42BC-8B00-F60FE7BE0B9E"/>
    <pav:createdOn>2014-06-30 12:20:40 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:77B5C0D4-B728-4F8B-B5B3-E3B3BE2E8C85</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:24265221-E0B1-4F13-A2EB-0E9D9DC6F5D4"/>
    <pav:previousVersion>urn:domeoserver:annotationset:03040E3F-A84E-4F41-8D00-F9C0CE9B2C5C</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35B89AC4-DAE5-4207-B319-F9479AE77CDE">
    <pav:createdOn>2014-03-22 22:09:39 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5542691E-3FD7-4CD4-B22C-7D237B921E99"/>
    <pav:previousVersion>urn:domeoclient:uuid:9372D3E2-2D34-4B3E-9DEE-0B5D2C57BB6B</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:EB29F991-E821-40B7-BEDC-BCF13D7DBF99"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA4519DC-727B-4A71-AFAE-85DE63C6BE8D"/>
    <pav:lastSavedOn>2014-03-22 22:11:45 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E4B01B1-801C-4C26-86B8-852138AD8BE2"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:4683D5EB-6628-4644-AF10-7D65325E3A8C"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8BEEBA62-C519-4421-9038-113DCDFC9B2C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F6DB437A-60FD-4998-97F4-9BA04097046A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:9692B313-0E4E-4D52-9D7C-456D2EE68F54"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:141D5512-1FE5-4684-BAA6-CA59DA362006">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metabolizer groups, evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg per day and 600 mg followed by 150 mg per day, each for a total of 5 days. Decreased active metabolite exposure and diminished inhibition of platelet aggregation were observed in the poor metabolizers as compared to the other groups. When poor metabolizers received the 600 mg/150 mg regimen, active metabolite exposure and antiplatelet response were greater than with the 300 mg/75 mg regimen (see Table 3). An appropriate dose regimen for this patient population has not been established in clinical outcome trials.</ao:exact>
    <domeo:uuid>141D5512-1FE5-4684-BAA6-CA59DA362006</domeo:uuid>
    <ao:prefix>Tests are available to determine a patient’s CYP2C19 genotype.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:141D5512-1FE5-4684-BAA6-CA59DA362006"/>
    <pav:createdOn>2014-06-30 11:37:10 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F37561CF-3DB7-4C0E-9AAF-1FB64D1D32C7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97CDCA51-103C-4EB7-BA80-9670B117D103">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:F4EE660C-81BD-481C-87C1-B5548B4F1A11"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F24B76FE-400E-4AB5-B120-5A127E5DCE2F"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C8824A36-9C96-4389-B215-2638B48B5437"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:386FFD8A-E0F1-4DB6-8CB3-C72EC135E05D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5AC5462B-2AAA-42B0-BA6D-B0EFB4BC80C9"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-06-30 12:16:47 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:77B5C0D4-B728-4F8B-B5B3-E3B3BE2E8C85</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:34095CA4-DD11-4155-9F46-72AFCB3BF738"/>
    <pav:lastSavedOn>2014-06-30 12:16:48 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8C0132CB-1BA7-4320-8C5F-E55761BC596E"/>
    <pav:previousVersion>urn:domeoclient:uuid:E1BDC5E1-315D-4FAC-9352-DA0D105F9794</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:0E61C616-830C-42EA-A5CA-1C03C20ABEE9"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B00F626B-2496-40FE-8B44-A026746EF9DB">
    <pav:createdOn>2014-06-23 14:47:28 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:hasSource>
    <domeo:uuid>B00F626B-2496-40FE-8B44-A026746EF9DB</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalyzed by CYP3A4. Aripiprazole is the predominant drug moiety in the systemic circulation. At steady-state, dehydro-aripiprazole, the active metabolite, represents about 40% of aripiprazole AUC in plasma. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Approximately 8% of Caucasians lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are extensive metabolizers (EM). PMs have about an 80% increase in aripiprazole exposure and about a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to EMs. Coadministration of ABILIFY with known inhibitors of CYP2D6, such as quinidine or fluoxetine in EMs, approximately doubles aripiprazole plasma exposure, and dose adjustment is needed [see DRUG INTERACTIONS (7.1)]. The mean elimination half-lives are about 75 hours and 146 hours for aripiprazole in EMs and PMs, respectively.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B00F626B-2496-40FE-8B44-A026746EF9DB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1F2D1F90-DA97-42FE-836C-EBF3BAC56349">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS. TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity.</ao:exact>
    <domeo:uuid>1F2D1F90-DA97-42FE-836C-EBF3BAC56349</domeo:uuid>
    <ao:suffix> Patients with low or absent T</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1F2D1F90-DA97-42FE-836C-EBF3BAC56349"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-06-30 12:04:53 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9EBC36A6-A85E-4348-8EBC-5B071D8A79FB">
    <ao:body rdf:resource="urn:linkedspls:uuid:529AD6A6-8E8F-489A-ACB4-7A0F257564D4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">29</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:C149CB6A-CE40-4BB1-914A-78298BDE4A29"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ECF44606-203D-4F28-9A50-FD8FFEEC4CB5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B989DC55-96AA-4A58-B072-99CFCD1CAFEB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:892A695C-E193-428D-AC55-6A2B7CB155C9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:1790EBCC-3CD4-47C0-91AA-F43CF7D8380F"/>
    <pav:previousVersion>urn:domeoserver:annotationset:91F8713E-28D7-41EE-928D-64E365CB5CE4</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:5666EA61-2604-4EA0-923E-C3F3965ED1CA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA731133-82ED-4CB3-BCB9-8BD9BD290A27"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:C6988919-6455-4291-92FF-E4F63DF9F9BF"/>
    <pav:createdOn>2014-04-28 15:49:18 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B90750B7-FB2D-473A-BDC7-2488F5F05E49"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:361D5826-4D47-4DC3-A6FC-C7D8C1594A3A"/>
    <pav:lastSavedOn>2014-06-30 11:41:08 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FCE7C9FB-8A9B-4379-9663-1AAC8E3A180A">
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdfs:label>Variant Frequency</rdfs:label>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6C42EB4F-92E1-451F-9125-83C72497CDF3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>The search magnifying glass does not work to find this one.</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7DEDF8DC-A385-40F7-A245-769DD46D6F05">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:84E1DA52-81E4-4BFA-B539-5B91FB1CCCD7">
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2436FF6C-87D4-4EA7-8571-4021D0FA8E81">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*1502 </ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C2B48AD-A4E0-4C6C-9246-E6FD6CF712C8">
    <domeo:uuid>9C2B48AD-A4E0-4C6C-9246-E6FD6CF712C8</domeo:uuid>
    <ao:prefix>.</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-30 13:03:17 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9C2B48AD-A4E0-4C6C-9246-E6FD6CF712C8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact> For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:41CC62A5-5C3A-449F-B7A3-675F76FA4085">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:61549475-56A3-499A-8BDC-5B228AB88444"/>
    <pav:lastSavedOn>2014-04-28 15:07:15 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:35C5BE0D-1E7D-4AB9-85A8-DE7D27EDC887"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-04-28 15:07:12 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3F04058D-E19C-45A2-8FED-97E877DAD6A9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B39F957-E88F-427C-AC41-F1B9DC711A02"/>
    <pav:lineageUri>urn:domeoserver:annotation:532BAB76-345C-46B8-BEDC-2F17BA48D7CB</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:99C027B2-936F-4C6B-AF41-38394AEC4210"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A66A7AB1-C314-421A-9CD3-AF23ABF28E51"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9CA1FBF8-5D9F-4C89-9F89-2BC4E3DB1BF5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B5C424F-CAD0-4CE2-BA6C-0AEC6ADA9CAE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:4AE1B6C1-9402-47D5-8CFA-FED3CA8293DC"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:33209444-B2EB-4B87-8865-C0F674C4BA32">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BBD1EA14-A142-47FF-A3B5-D848FFAED44F">
    <ao:prefix>SERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS (TEN) AND STEVENS-JOHNSON SYNDROME (SJS), HAVE BEEN REPORTED DURING TREATMENT WITH CARBAMAZEPINE. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BBD1EA14-A142-47FF-A3B5-D848FFAED44F"/>
    <domeo:uuid>BBD1EA14-A142-47FF-A3B5-D848FFAED44F</domeo:uuid>
    <pav:createdOn>2014-06-30 11:03:00 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:44BBF444-A1D4-4182-8B05-775BFFCA0DF4">
    <ao:body rdf:resource="urn:linkedspls:uuid:B0E01B93-2846-4002-87EC-2FEE55716F4C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:CB74EF29-97D6-47E2-9621-FAF1E3947B17"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6B4C9D47-E3BF-4D75-A661-0D5A649108C6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4E001AB1-2305-4837-8AF8-180376395180</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <pav:createdOn>2014-04-28 15:21:52 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC47136B-865E-48AE-AD43-B4C2E038387D"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F1F72593-1500-4B06-AE14-AE29B3EAE9B1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5FCDB62A-A30F-44C0-8195-0C47BECA767B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">24</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:3A97A9BB-5FAA-48E8-960E-08933020FF0F"/>
    <pav:lastSavedOn>2014-06-30 11:33:55 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:96C7AAF0-4163-4CE9-A1C9-9C9DA05E8866"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ABA7A2B9-17AA-424E-850E-21298BD2BEBC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6118FDF6-9FBD-4FBB-BC8E-583BED7322E8">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F023FCCC-7096-430B-8BB2-66379ADF411E">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13">
    <pav:createdOn>2014-06-30 12:13:28 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:90E4AF52-01F4-4371-B3ED-D400FF8B1C1E"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A6AED276-0422-482B-8802-87BDABE2C035"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143044e90f26014518a19cf70063"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1BEAB346-F7B3-40D8-AE65-17ACEB48A7A4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F498E725-B59B-4357-806F-4F316B1EAB6C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4BED623F-9685-4D95-8EAD-FDE3617D193B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CF35511B-7BED-446A-B970-33FEE5C13C88"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:97CDCA51-103C-4EB7-BA80-9670B117D103"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0F8A06DC-D6FE-466C-AF73-CF9E7A8C2707"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5229A912-1F9A-40AD-9994-79886D701F6C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:69B50E0E-4BB4-49DC-AE8B-4326D0F0A959"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <permissions:permissions rdf:nodeID="Nefc4c1b5764f402ea31b179b328b7394"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:43CE071E-85A3-4BC0-AEAC-4FC4DCBB3D02"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:annotatesResource>
    <pav:lastSavedOn>2014-06-30 12:41:34 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:56ECCD1C-D5DA-4A5F-A470-A96F404E1CB8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5B7239DA-6BB5-450F-B107-37E66914C66D"/>
    <pav:lineageUri>urn:domeoserver:annotationset:77B5C0D4-B728-4F8B-B5B3-E3B3BE2E8C85</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:FE154A72-C1D3-4027-8C73-C71A948D0F52"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:86565D69-8F9C-4519-9A52-CD2A2980DEE3"/>
    <pav:previousVersion>urn:domeoserver:annotationset:FC944D7E-3092-4D9E-BC75-2C68BA283BDD</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:8B4BE2A8-5AB2-47D3-A46D-2D1D5E7AC42F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74791FAB-E4B4-4EA3-9557-BD68EDB49B01">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:396CB021-3C85-4E20-B020-3714CE558E2D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B3F5BE7C-7508-4D94-B8EE-CF1506541167"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0E2849C6-750A-4F3F-8F6E-81977414BC10"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:52F46F4F-994A-471F-88EF-A2701E9008A7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-06-30 12:54:57 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:766C374E-9B6F-4C27-8738-436CCC152D43</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:6D20A91A-BAD7-4E87-930B-A5394D2732C8"/>
    <pav:lastSavedOn>2014-06-30 12:54:58 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:00B62E1D-9BFE-498E-82E3-A23E5F356480"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF3EE487-6CDE-46E4-9A82-94DBA07862ED"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:016B445E-4C36-4A69-A68F-8C8A0A19611C"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F30A3592-1EDA-414B-8C7B-2B931B766619"/>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:420A3DFE-8247-4E9B-8E6C-368F1A2C415C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:80EF1495-53DE-404E-89C4-746A487232BF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:37614B56-7E7C-420A-959A-82B4155B865F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9DE5C0EE-8425-41E9-90F5-C6819D71FBF1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:306BB501-1412-442C-97E0-18E5341107D5"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:EADEE32B-28EE-4C9C-B22D-1B2A9202C5F3</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-23 14:35:57 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:81525CE9-0714-4D48-9149-6C8B8671E117"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E18535D1-97BE-45EA-89C5-7DFF12A67C62"/>
    <pav:createdOn>2014-04-14 14:25:51 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">39</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:283D346E-70C4-4BA5-A324-BF69F44C2CDA"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:903F27DB-914A-44A2-B01F-A36164AAC4DB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F50056E6-0B34-41B6-A646-9D522C97885A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:391E5A08-84AA-4F04-BF93-C7505FEF9363">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ED352AE7-8ADB-4333-9B07-4FF6A08E047A">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BD4A21D3-9E4C-44A5-9D57-BE07399B0E6D">
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D61EF3CA-BC6E-4D40-9A14-5EF6B2C2E6EF">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:88C2CEB5-469C-451E-8436-788ABE4338F5">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">21</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:A3C1B92C-CBE0-4BA8-A41C-D3C3CD26FA51"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:7E8BE7BD-6706-41DA-8A1D-0B7370BBB62B"/>
    <pav:previousVersion>urn:domeoserver:annotationset:7E551245-CDB2-473E-9C9F-6F78F83685D1</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:7F3229B1-9DC9-47C2-BAA8-1B7679F38B10"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9B2F43E4-7567-4CE3-A607-E0FC62A2C865"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1F2D1F90-DA97-42FE-836C-EBF3BAC56349"/>
    <pav:createdOn>2014-04-21 13:04:12 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:D8B0CCC0-6E93-4175-9490-3B07D43C176E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DDC6A971-06AB-44BC-B5DD-01B41956F9CA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A2BBBDE3-D2ED-4260-A2C1-CD5432736CE7"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A9263118-2AF9-4363-A044-80F842A46F75"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:563CB9E8-A4E7-43EF-9686-1F5B71F4169D">
    <ao:exact>In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estrogen- and progesterone-receptor levels less than 10 fmol. In women aged 60 to 70 years, there was a trend toward a beneficial effect of tamoxifen without any clear relationship to estrogen- or progesterone-receptor status.</ao:exact>
    <pav:createdOn>2014-06-30 12:25:51 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:563CB9E8-A4E7-43EF-9686-1F5B71F4169D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>In the Hubay study, patients with a positive (more than 3 fmol) estrogen receptor were more likely to benefit.  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>563CB9E8-A4E7-43EF-9686-1F5B71F4169D</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:94DE53A7-7CD1-44E7-AF38-A58BCF1EE14B">
    <rdfs:label>Recommend</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:719A5C02-D66E-489E-89AA-07BB27CD191F">
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9F23E4DD-C825-4CCC-BD6E-1514188AFFA7">
    <ao:body rdf:resource="urn:linkedspls:uuid:C808949D-5BD1-408B-BF95-40D480E14DDE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ED434685-C34B-43FB-AA23-F008E3AF787A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5AB14F2B-DF42-42DD-A33F-63DB4F3769D1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D1D85749-709E-4FD8-A464-C8E7CD8158BB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7780497E-7FA1-4043-A85C-7AD8535B86EB"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:5A997B78-0557-4495-BDBD-42F5B4B30412"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E759252F-F886-4AB1-9DDB-9C5EC3A84DCE"/>
    <pav:lineageUri>urn:domeoserver:annotationset:EA11DA11-0A03-469A-97E9-855E1FA24490</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B5C424F-CAD0-4CE2-BA6C-0AEC6ADA9CAE</domeo:belongsToSet>
    <pav:createdOn>2014-04-28 14:50:56 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:D2F53974-B796-40CB-96DB-17B918867DA6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:9A0675C5-A6BA-4582-A77B-1E90DB7B1E3A"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-30 11:21:57 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:74383823-4D42-47C6-B39E-4DDBA1FB0880"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D012DD29-40AB-4FD2-9E0A-EEC5604FC242</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9A15D029-5B02-4107-A829-E2BD1B1219FE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DBBF90A0-6468-4792-B1CC-02DDD21B4A08">
    <ao:body rdf:resource="urn:linkedspls:uuid:7302A873-FD71-484E-8E7A-C3C5EE43F4ED"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:72569EC5-72D5-43F3-9028-CE31C726B1D0"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1CEDA84C-14E2-4D8B-A754-750B7AAD033F</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:5D167F57-525D-4D90-815E-8DE7F9F474CC</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-06-09 16:02:14 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-06-30 12:02:39 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DC523344-070F-4A21-93A7-EA5583F3D921"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:09071EE6-03DB-49CA-BA67-1589B0E2FDBD"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:00E8CD81-460D-4060-A021-B8D8C71F86A1</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:07F4F9C7-1286-482C-9AD5-B17158B8DE17"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F6A08C2D-396E-49CC-B12F-1CE908524D8C"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1790EBCC-3CD4-47C0-91AA-F43CF7D8380F">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#intermediate-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>intermediate-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE483709-CD8C-4493-A2B7-8E589B98BF31">
    <ao:context rdf:resource="urn:domeoclient:uuid:E03CFE71-0FEF-4840-A587-1D360CBF035C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EBB55D0F-81EB-491D-87E0-80476C5A79F6"/>
    <pav:createdOn>2014-06-02 14:43:54 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3AD8ABEC-70ED-4E2B-AB0C-6F8F35433F49"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:31432C21-1CC7-4786-94EE-581440200D4B"/>
    <pav:lastSavedOn>2014-06-30 11:55:13 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:67FDD5CA-F0B9-408A-BF01-D48590C5451A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AB290A68-3247-40C6-9972-295B29412E87"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:371E9234-A9B7-442E-859C-76A157371805"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8AE2E772-5C7A-49D5-AD43-70DA1C97F946"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CCE70AC9-D0A9-404D-A9AB-347491143696"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB08B748-CC53-4FAE-92CF-D91CBEB2C83B"/>
    <pav:lineageUri>urn:domeoserver:annotation:6FC733CA-DD2A-4C8C-A26E-0DA80E613520</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:864E5B2D-ED7F-4A2C-8736-D569472536C2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0A52235-7692-496A-9DE2-B919FD0C2AC7</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:9CE888B2-376C-4C40-BC8C-90A37F6C59F4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3CF5A34-A1A9-4AFC-83F2-A5A1DD6DBB7F">
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:D4240442-246A-4779-9FAE-DD8D26B1CEFA</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:2B18C74E-C402-4DA6-A980-C0CD8AB6866C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:7011CFB2-61E8-47F2-9EB6-733E1486BBD3"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-06-30 13:16:49 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-06-30 13:16:49 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:55F59962-81BB-4F69-B3DD-6B65B3526228"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA0F2FE0-000F-4D17-9DBE-D18CEFAF648E"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:5AA1F3D7-DA5F-4139-AD64-27615B483059"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:00E93A49-55CE-4990-8FAD-F248D724AC04"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:56D95EC4-D0D7-4BD6-B13C-E145F6A4E568"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6D228B36-7EE7-4E73-A125-2D77761283AF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE4F247F-F7CB-4776-A379-05B0401FC08D">
    <ao:body rdf:resource="urn:linkedspls:uuid:FBEDA24D-50C7-407C-9337-9A08D9456999"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-30 13:25:26 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7156E853-F84A-47E5-A713-7433E0C59749"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0F7495B8-0992-476A-98CC-CD6EF2EC377D"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C1908624-6F0B-47BD-8D70-8EACD877F4A9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:27ECD580-6FBD-4860-AF7C-6D918CCAA65F"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-06-30 13:24:52 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:68018327-94E5-4F2E-A765-82FA2F698F99</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF74DA0E-580E-47E3-831F-DB38FFA1DAF4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AAE4FFBF-9026-445A-8595-1E7CFB03644D">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:74BB3F3E-AD24-438C-9250-4357E959069E">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Clopidogrel</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E02C5AB-C35D-4ACA-8EF0-DF0F481E6A00">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Carbamazepine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D66A54D7-BD47-4E22-B2F3-09A5D190955A">
    <ao:exact>For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D66A54D7-BD47-4E22-B2F3-09A5D190955A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-03-22 22:11:34 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:69F2525A-EF9A-4F04-A361-B7633D964121">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B4FA5D29-61B8-4A79-A14C-BDBBE573E4FB">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>VKORC1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DAEE8F63-75A3-4EBB-9785-D52BCC522BE0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3846BD3B-067C-4D62-AAA4-6A53131A2A2B">
    <domeo:uuid>3846BD3B-067C-4D62-AAA4-6A53131A2A2B</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3846BD3B-067C-4D62-AAA4-6A53131A2A2B"/>
    <ao:prefix>Hypersensitivity to abacavir is a multi-organ clinical syndrome. (5.1) </ao:prefix>
    <ao:exact>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-23 14:22:58 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B7B25E99-EE57-41AC-BDE2-45DCC1447471">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DAD6A4A1-3C31-49E3-8C6D-C1CA02D6FDC5">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <rdfs:label>Do not start</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6D07FA7D-BE83-49F6-9169-78027B43EEA3">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>tissue necrosis</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0E9FF6AD-98CE-4932-AD5D-E657F3B363B3">
    <ao:body rdf:resource="urn:linkedspls:uuid:8112D95B-8CA4-42C2-8097-E42E759FEF68"/>
    <pav:previousVersion>urn:domeoserver:annotationset:9CD1FA68-606B-432D-868F-5FA9882274FA</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:399D443C-D2F6-4970-824D-D31A4503C94A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:E95F8BA7-9F3C-4C75-B657-5BDDDE255E17"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:138F9317-E2D6-4CCC-B563-10CCEEA17309"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-04-14 14:51:08 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-06-23 14:40:12 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:FBE1CF41-A5EC-4665-B2D5-A9DBD4B43608"/>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:45B95464-0287-435F-86B4-0253D73E6DA8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DD65D0CA-5F1F-4015-B5EA-5786A91B7E0A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE162B39-590D-488C-9A77-88A953329FE5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C90A84F9-5F30-4BC7-9DE4-4220F6C37BF7"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">43</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:9739D8D8-F16D-4FF9-BD63-1945B116EEC4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:357D535A-D77A-4C4A-9D40-D98925D3E30B">
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76AEC8EC-841B-4618-8A97-4D6655CE39F4">
    <ao:prefix> </ao:prefix>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <pav:createdOn>2014-03-31 14:04:21 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:76AEC8EC-841B-4618-8A97-4D6655CE39F4"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9C09D2F8-83BE-446D-A17A-75402666EE4B">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23FACDDB-003E-40B5-AB79-B52F5FD124B3">
    <pav:createdOn>2014-06-09 15:55:39 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:00E8CD81-460D-4060-A021-B8D8C71F86A1</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:8FD74D14-41E4-4A55-AAC7-3B207B0782D6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F01C02F-0F0D-49BE-8BFD-675A75F2FC42"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:1CEDA84C-14E2-4D8B-A754-750B7AAD033F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:D1D7D169-0E2B-45E3-A952-C352826FE500"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F4A1F36B-587E-4CAB-89F7-D0D9C1FF9786"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:746B1DCC-2D97-4F85-9CB7-22A8D2279302"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AE8364C5-84D3-4210-94AB-392D28082812"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EF919E4C-C0B0-4D8B-A273-2F4A806A828D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:lastSavedOn>2014-06-30 12:00:37 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8431F83B-801B-499C-A34F-25B983A4B198"/>
    <pav:previousVersion>urn:domeoserver:annotationset:369EA3AC-DABB-4AA3-9442-5ABC2DB50C13</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:476620C9-1693-43B1-9388-D0A05A007BB0">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:224ACECA-832C-4CE1-B586-4BB3E2AC8018">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:224ACECA-832C-4CE1-B586-4BB3E2AC8018"/>
    <ao:suffix>.Prior to initiating Carbamaze</ao:suffix>
    <ao:exact>Retrospective case-control studies have found that in patients of Chinese ancestry there is a strong association between the risk of developing SJS/TEN with carbamazepine treatment and the presence of an inherited variant of the HLA-B gene, HLA-B*1502. The occurrence of higher rates of these reactions in countries with higher frequencies of this allele suggests that the risk may be increased in allele-positive individuals of any ethnicity.\nAcross Asian populations, notable variation exists in the prevalence of HLA-B*1502. Greater than 15% of the population is reported positive in Hong Kong, Thailand, Malaysia, and parts of the Philippines, compared to about 10% in Taiwan and 4% in North China. South Asians, including Indians, appear to have intermediate prevalence of HLA-B*1502, averaging 2 to 4%, but higher in some groups. HLA-B*1502 is present in &lt;1% of the population in Japan and Korea.\nHLA-B*1502 is largely absent in individuals not of Asian origin (e.g., Caucasians, African-Americans, Hispanics, and Native Americans)</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>224ACECA-832C-4CE1-B586-4BB3E2AC8018</domeo:uuid>
    <pav:createdOn>2014-06-30 11:04:07 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFEF239C-B763-4864-8DD8-A917EFD12673">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-23 14:38:27 -0400</pav:createdOn>
    <domeo:uuid>CFEF239C-B763-4864-8DD8-A917EFD12673</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CFEF239C-B763-4864-8DD8-A917EFD12673"/>
    <ao:prefix>If hypersensitivity cannot be ruled out, DO NOT reintroduce ZIAGEN or any other abacavir-containing product.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:232C5C6E-F6FE-44B8-AE5A-7E1BD427D626">
    <ao:body rdf:resource="urn:linkedspls:uuid:B510E06B-24AA-42F4-885F-7A183BFBB2EB"/>
    <pav:createdOn>2014-06-30 13:06:13 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:0A43F475-9E2C-483D-B6D9-13930E867A59"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:89CFECFF-FA62-4DDF-8491-A92805B332EC"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-30 13:06:14 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:DAF687CB-C150-4457-815A-875B9BBE8525"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:52CEE330-B545-46E1-9B57-54C7396F53EF"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B3E23EF-1696-4FF7-BEEB-8158BDA84294"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:06D82CA6-0CF7-4FF8-AAFC-BBA8D9EB0083</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:D41F355D-F8FE-4A71-87B6-FCA587AFAA6A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:DB8F110F-7415-4B13-AB5B-23F1D7A1C6BF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A95A5108-B963-46F5-8C52-A24452946316"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:69AED5D9-7A39-4908-932C-7553B3E13B24">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1EF0B4A4-3F75-4AB9-8AA1-84A028AD5EE7">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:13F3B206-EA87-463E-9DA8-93AA056A9117">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ACFB40D4-2EF4-455C-A6CF-EF07C399FC84">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1924E2D5-9E52-46A8-925D-043869F8F777">
    <ao:body rdf:resource="urn:linkedspls:uuid:6535077F-E961-482C-8B57-F786CEC0E8B6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A572B29E-DA06-4D69-9DBD-1D5AA92BBB2C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D742086D-FBE4-4E5E-8129-F5C607743253"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1523E385-B7C2-4B6B-B365-918336BC31D4"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-22 22:01:09 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:75C4424E-2C9D-40D9-82CF-7E02CFDCA301"/>
    <pav:lastSavedOn>2014-03-22 22:03:57 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:14099187-A7EA-4F77-905D-B1B942FF80D7"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B0497B5-2A21-46A2-983F-7992EF169EE9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E33403E1-9E18-4800-B583-B5ECE131DDBB"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B730B18-8380-46F1-B12C-A7D99D832F96">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4AE1B6C1-9402-47D5-8CFA-FED3CA8293DC">
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52CB1ACE-5349-4E7A-A0E1-84BC726E8B27">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B230E58-95D9-46A9-A29D-9E6B4FC1F375">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>VKORC1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DF1A2A13-1CD9-47EC-A75C-192353959653">
    <domeo:uuid>DF1A2A13-1CD9-47EC-A75C-192353959653</domeo:uuid>
    <ao:suffix> Codeine is contraindicated in children who undergo tonsillectomy and/or adenoidectomy. Advise caregivers of children receiving codeine for other reasons to monitor for signs of respiratory depression.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DF1A2A13-1CD9-47EC-A75C-192353959653"/>
    <ao:exact>Advise patients that some people have a genetic variation that results in codeine changing into morphine more rapidly and completely than other people. Most people are unaware of whether they are an ultra-rapid codeine metabolizer or not. These higher-than-normal levels of morphine in the blood may lead to life-threatening or fatal respiratory depression or signs of overdose such as extreme sleepiness, confusion, or shallow breathing. Children with this genetic variation who were prescribed codeine after tonsillectomy and/or adenoidectomy for obstructive sleep apnea may be at greatest risk based on reports of several deaths in this population due to respiratory depression.</ao:exact>
    <pav:createdOn>2014-06-30 11:55:11 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:38655F0E-DB25-4C1E-A99A-7E2B18134930">
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F9A68240-FAD6-4604-8DEE-1B0E4AF9BD21"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9816DE92-75B8-4F98-BAC5-A337C56E26C8"/>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:09AF0419-C474-466C-9CFA-513366CFB1B2"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:4826D0A7-3478-419F-BF7D-07A505A34470</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">18</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:5C01B11A-0A96-4782-8474-7B0B0F7074FD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA262512-E130-4C45-941A-8173486F6F26"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F0EA10D1-D8AA-4606-8CBC-23FA4F5245B5"/>
    <pav:createdOn>2014-04-21 12:54:12 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:8175988B-12BF-411F-A136-BAFE3294C9B0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BAF9B034-78F8-482A-9158-845E6B793A4E"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F3C6E27C-CBBA-4B36-810C-D42C3FA4AB93"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9978D70F-9B7D-4598-8D12-0D71F5BF406F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9A074D82-152F-415F-84A1-93EDCC8179B1">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <pav:createdOn>2014-06-30 11:33:32 -0400</pav:createdOn>
    <ao:prefix>Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function.  </ao:prefix>
    <ao:exact>Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>9A074D82-152F-415F-84A1-93EDCC8179B1</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9A074D82-152F-415F-84A1-93EDCC8179B1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55544593-2536-44D4-B561-50DB89250F52">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-30 11:42:55 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:55544593-2536-44D4-B561-50DB89250F52"/>
    <ao:exact>Your doctor may do genetic tests to make sure clopidogrel tablets are right for you.</ao:exact>
    <domeo:uuid>55544593-2536-44D4-B561-50DB89250F52</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CF18371E-94C7-4F05-99A0-E7703B3AF94B">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B8FAA54-48A6-4B88-A9A5-5D1373EB3B83">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69B50E0E-4BB4-49DC-AE8B-4326D0F0A959">
    <ao:body rdf:resource="urn:linkedspls:uuid:62E969AE-74E5-408D-9A40-653A02F406B1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A0C444A-69BB-4499-A9B4-71AB565DFA0F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:027C2589-BFC8-4644-BDD7-59E1118E9A50"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:9E603461-7970-417A-9A5B-9F64572BB0D3</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:44D99766-DFE5-4574-AF0D-48B1878395B0"/>
    <pav:lineageUri>urn:domeoserver:annotationset:77B5C0D4-B728-4F8B-B5B3-E3B3BE2E8C85</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:65CEA66D-37F6-4803-B0EA-C4E278013D5D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:362F640C-AB81-40B0-8D31-9BB314901AFB"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-30 12:22:01 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:D26DCABA-C665-4147-A57B-F26195C0188E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8F43AB1F-C086-4AF5-AC19-E87F1E304346"/>
    <pav:lastSavedOn>2014-06-30 12:22:01 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:AF427FC6-54B8-4CA4-9C51-233E64726500"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:29B0BAC9-227E-4C4D-96D2-143CC457E50C">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:3958ACA5-AE43-4D05-8DDA-C14850163ED9"/>
    <pav:previousVersion>urn:domeoserver:annotationset:29D3C9B3-4442-4AC2-AA09-4E58BE74858A</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D939C426-7E0B-4A32-80F1-7344D702AA97"/>
    <pav:lastSavedOn>2014-06-30 11:21:27 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B5C424F-CAD0-4CE2-BA6C-0AEC6ADA9CAE</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:F9A528AF-AAD1-4EF0-A22A-22A6A4B9650C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0BD5D97A-48FE-4639-AFFA-348BA4F27E1E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:558B5390-D54F-492E-8261-0744746B91C7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC3133B3-AD9F-4CEC-ABCF-7B9CA3E793EA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F2185B16-8B27-4708-8E81-3BB0550B3A35"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9098E55C-952E-46DF-904C-2A3E63492B3A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:71B4E351-9545-4BDB-AC93-670DEC3E5644"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-04-28 14:49:07 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:EA11DA11-0A03-469A-97E9-855E1FA24490</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:448D0EAF-27BF-49D5-8111-6984A1BB5502">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:86218E9C-9C50-4CF1-BDF5-7480485335DE">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:94569D13-A994-40FA-BDCF-C0391FE365FD"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:lastSavedOn>2014-03-22 22:18:31 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C4B5F9D6-6190-4D39-A50E-B39CD7193832"/>
    <pav:createdOn>2014-03-22 22:18:30 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3AFDF697-A5A4-42EF-BE12-893415E6A1D6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:79ABCEB5-E291-4F30-AC29-AC52FD7620B8</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:52601F35-C2AB-4602-BD13-6B9999A0266A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4F7F0EB3-F9C8-4AAE-BCD4-4A03CA215C14"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:037A2873-CACE-474F-B3EB-1EF6E0A58FCF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B4BFDF8-85C4-40F2-A42F-23B4B1176095"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:40AC27D0-6D44-444E-A3B8-CE5689AD915D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8BCA690B-96B0-4C8D-98E0-7BCECE8ACB28">
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:12A88496-C15E-4555-B3A9-C7977BBC3923">
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:68DCA25B-DD2E-4D5B-95F4-195A31DA252C">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F19D3DA9-E091-415D-A43E-483BEC7B68FB">
    <ao:body rdf:resource="urn:linkedspls:uuid:3773AECF-F557-44FF-8952-7E065FDEE47F"/>
    <pav:lastSavedOn>2014-06-30 12:02:39 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:A1D6D1BB-344E-42AC-B263-7FB84A0034CB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:00E8CD81-460D-4060-A021-B8D8C71F86A1</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:1112EF7B-9CDC-4021-94DE-68FB499BCCA8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3A01499B-5164-40C0-A088-804F0AEC5A43"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:1CEDA84C-14E2-4D8B-A754-750B7AAD033F</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:398416DB-3813-458C-AEAD-1E703244DEC7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:65192B6B-F432-4495-9208-AADAAF9CEFD3"/>
    <pav:previousVersion>urn:domeoserver:annotationset:5D167F57-525D-4D90-815E-8DE7F9F474CC</pav:previousVersion>
    <pav:createdOn>2014-06-09 16:03:11 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:53864EAA-1CCE-403A-8033-F40243F0BB66"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9BD38C7E-B2D9-4C83-903C-F86556F46EF2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5B0C74E7-D5E1-4750-A159-40BCA7DDA80D">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2740FBC5-62E1-4A34-A993-7667E952F771">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:4B5C424F-CAD0-4CE2-BA6C-0AEC6ADA9CAE">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:41CC62A5-5C3A-449F-B7A3-675F76FA4085"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CA5A93F5-5D2A-44BF-8951-9EF6DFE12F1B"/>
    <pav:lineageUri>urn:domeoserver:annotationset:EA11DA11-0A03-469A-97E9-855E1FA24490</pav:lineageUri>
    <rdfs:label>New set 0</rdfs:label>
    <pav:lastSavedOn>2014-06-30 11:22:45 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:annotatesResource>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:110488CA-F3AF-470D-8866-0D6851A9B4A2</pav:previousVersion>
    <pav:createdOn>2014-04-28 14:49:08 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143044e90f26014518a19cf70063"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:29B0BAC9-227E-4C4D-96D2-143CC457E50C"/>
    <permissions:permissions rdf:nodeID="N1564200f8e48460a8d0a85c3c1c411b6"/>
    <dct:description></dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:9F23E4DD-C825-4CCC-BD6E-1514188AFFA7"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:CF0E7639-6AE6-4519-9A14-41BF8AB6A508"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ED2F98CA-60F0-4D49-9803-FED968AA3114"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B03578D-7647-4773-8E59-A027B405D6EF">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3773AECF-F557-44FF-8952-7E065FDEE47F">
    <dct:description>Referred to clinical trial</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6D4DAD4D-1B63-4482-8060-787D97F917D2">
    <ao:body rdf:resource="urn:linkedspls:uuid:F422F587-45DC-4DC7-A282-356062E94D7C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:61CB1288-5910-49B6-BD6B-6D9969B20C6B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:4CB3EFD1-0AC6-4124-967C-F5439301F1C1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:56C616E5-80D0-4A03-8C0B-348E4596BF51"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:734B20E0-4BAF-4E5F-A4EE-CABD0B5E152C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:5DBD6868-2A73-4E0E-944E-4DCB9B33336C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:49F3189A-5919-4644-A23D-E7DDE2686F73"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">19</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdOn>2014-04-21 12:57:37 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8CC7CC7E-B852-4CC8-8722-89DA67CDACC1"/>
    <pav:previousVersion>urn:domeoserver:annotationset:16692C75-8E29-45F7-9628-009820E70749</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:48E004DE-D237-4356-9685-3F49A3503C25"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CBE9DA72-F01C-4A8C-AC13-BE4D7ED71784"/>
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:33D89E0F-4370-431E-8DB5-094F3AF78C75"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CE130BB6-55F9-4A0A-BDB0-FFD4D080CBD6">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE1DC1EA-085A-4CF9-8165-5A14A411A633">
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:E7A7C80F-C900-4A84-AB0D-3F983C8ED120"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE2B43A2-F01E-499B-B632-58EB54437102"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:30201CA6-94D8-4A83-9451-AF1497A97E75"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DFBABE58-5163-486D-9C9E-3EABDEDFE17C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F3B6A4B9-0416-414A-8BF4-C9ACD4D497C3"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:42FA1C17-B780-423F-B993-EAF8D8DF0329"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D65CE270-4D80-4B9B-824A-BD5403AE0B20"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6DC3D6BC-081A-4B0D-B1DE-234266603363"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">39</pav:versionNumber>
    <pav:lastSavedOn>2014-06-23 14:35:57 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:EADEE32B-28EE-4C9C-B22D-1B2A9202C5F3</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF342E5A-6B19-4100-B8EB-12EB7496C6EB"/>
    <pav:createdOn>2014-04-14 14:27:46 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5D7649B4-7723-40DE-B9AD-4926156D8C0A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8E97872D-A5EA-4365-A1DA-DD1AFEB4FCE0</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:224ACECA-832C-4CE1-B586-4BB3E2AC8018"/>
    <pav:previousVersion>urn:domeoserver:annotationset:94669385-318C-4E58-97B1-033AF9C48990</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:256E17DA-EE2D-43DC-B2E0-D1323508DB8D"/>
    <pav:lastSavedOn>2014-06-30 11:09:18 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:E6148AE9-D3FF-43CD-B26E-1DDB165D61DD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdOn>2014-04-21 13:23:42 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:87F92664-6A48-4816-A909-6D6A23278C95"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:17583134-0072-4B0F-AE5B-F068E67A4CF1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:70BE7DEB-6A8B-41E9-9333-F1F47AC7E1A0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:863F2BBA-B74C-425F-B4F3-D4BEF5E1873C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:16658488-3D7D-401B-A6A7-80EAC49CAFDC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C22FFE05-E6B2-4D81-81D7-BFA7F760B4E4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C940F77D-EACF-4BC4-BF01-761762EDF0C0"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F02E7ED-3C9D-4E0E-9FA2-85D054927729">
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E06F2653-44AD-435F-AB2C-133712B039A6">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Carbamazepine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A9E04695-935E-489D-B1CC-1339AC7774C6">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>UGT1A1</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017048</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:43CE071E-85A3-4BC0-AEAC-4FC4DCBB3D02">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:6CE555C3-7C30-4D10-B475-4043F081E7B3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BAF3588C-CD18-4C25-B486-8956069332AC"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-30 12:18:59 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:AB653C40-C16E-4E15-AF0A-01467E32868A"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:14BA7077-8D33-42DD-A380-DD27F50087AD"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:9BAF37F0-7AB9-4B5F-A357-A9C5B0E979FD</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:9D58177E-4634-4343-9151-CCD4668C812B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:93494806-AB88-48E2-9119-48F2F284F99F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:26120AB9-1EF9-4541-82FA-D6061CD6EB77"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A4A66EEF-B4F6-4130-AF77-2C59D3213AA5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:77B5C0D4-B728-4F8B-B5B3-E3B3BE2E8C85</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:8C4CA7C1-4757-4722-A8E7-A90189672AF3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:31115D88-2436-4D8C-B5E2-A7636A9DA498"/>
    <pav:createdOn>2014-06-30 12:18:51 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:307BDD85-8198-47F7-A1D4-290758EE20B5">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E7A45B66-EEE2-4C03-851A-7F6207712150">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D5CF7A64-E07F-419A-8900-15F969F2D51F">
    <ao:body rdf:resource="urn:linkedspls:uuid:289239D5-3976-472F-9914-D5F5369EE441"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:78A1719D-0994-4541-ACAD-575FC841174F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0BEDE64D-11D3-4746-9532-E747F6A427E0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdOn>2014-03-31 09:05:56 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:D07A471E-9AE7-4A93-BF39-B8A753C23859"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:33C9F7CE-B041-40EE-8E53-5C94B51B626C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:E56B19ED-CC69-40EB-B68A-25F7DB5534A9</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:8B74A738-1124-4DAC-BE25-F15C78CFBA15"/>
    <pav:lastSavedOn>2014-03-31 09:06:26 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FF1F10F0-D061-4FDE-925A-1B1B7243A890"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5464F1B8-CF3D-4DA9-99F4-5F156C14CE70">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:231FB605-C0BA-4076-A03F-F60FA03C8005"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6EB23E7A-2869-485D-965A-820F1D704C25"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EA4D8CB8-B8F8-4FBB-B8A9-1F499DD7A9C8"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:F10DDB11-A5F0-4B5E-B3CE-47B1F2145E34"/>
    <pav:createdOn>2014-03-31 09:02:38 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA67625B-2AC1-4E15-BC4C-50D4C7BE0F03"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:1D9B7794-EB80-4C0A-A5B6-F9B8661691D2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2F9CF447-9D4F-4E5C-9689-2FDCB70C37A1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BDEED6AF-6C6D-44F0-8470-40D3A54778C5"/>
    <pav:previousVersion>urn:domeoserver:annotationset:E56B19ED-CC69-40EB-B68A-25F7DB5534A9</pav:previousVersion>
    <pav:lastSavedOn>2014-03-31 09:06:26 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D9543430-9668-4C09-8709-B8D20B095EEA">
    <pav:createdOn>2014-06-30 12:14:50 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> Among these patients, 54% had node-positive disease and 46% had node-negative disease.Among women with ER positive o</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D9543430-9668-4C09-8709-B8D20B095EEA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) conducted worldwide overviews of systemic adjuvant therapy for early breast cancer in 1985, 1990, and again in 1995. In 1998, 10 year outcome data were reported for 36,689 women in 55 randomized trials of adjuvant tamoxifen using doses of 20 to 40 mg/day for 1 to 5+ years. Twenty-five percent of patients received one year or less of trial treatment, 52% received 2 years, and 23% received about 5 years. Forty-eight percent of tumors were estrogen receptor (ER) positive (&gt; 10 fmol/mg), 21% were ER poor (&lt; 10 fmol/l), and 31% were ER unknown. Among 29,441 patients with ER positive or unknown breast cancer, 58% were entered into trials comparing tamoxifen to no adjuvant therapy and 42% were entered into trials comparing tamoxifen in combination with chemotherapy vs. the same chemotherapy alone.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D9543430-9668-4C09-8709-B8D20B095EEA</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91E145AE-4A66-4F7C-885F-39E651D5592A">
    <sio:SIO_000111>34071-1 WARNINGS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34071-1 WARNINGS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:45844BA9-29ED-4EC6-94C0-81C9883F880F">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0DA7AAE6-C82C-4935-9D33-40D96FDB2416">
    <ao:exact> The variant alleles CYP2C9*2 and CYP2C9*3 result in decreased in vitro CYP2C9 enzymatic 7-hydroxylation of S-warfarin. The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9*2 and CYP2C9*3, respectively1. Patients with one or more of these variant CYP2C9 alleles have decreased S-warfarin clearance (Table 1).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0DA7AAE6-C82C-4935-9D33-40D96FDB2416"/>
    <domeo:uuid>0DA7AAE6-C82C-4935-9D33-40D96FDB2416</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>The S-enantiomer of warfarin is mainly metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>2</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <pav:createdOn>2014-06-30 12:51:53 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F24B76FE-400E-4AB5-B120-5A127E5DCE2F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34092-7 CLINICAL STUDIES SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34092-7 CLINICAL STUDIES SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:073BA57C-2916-4E35-9AF3-AA99E504958C">
    <rdfs:label>Do not restart</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:96B9ECF9-7144-4F27-A420-DB0B6C289CA9">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:231E14A4-5E1D-443C-B50C-8E3E00BBAF15">
    <ao:body rdf:resource="urn:linkedspls:uuid:DCAE5D15-64ED-4B98-9356-0513BD12B1E0"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:BD33E8D1-8AEF-4E43-9C57-35AB0263305D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E11F0D6C-95F3-42B2-811F-05032EFF6897"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:592CCB10-6744-415A-9E3D-BA1CA292DC87"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2293D62E-8DFE-4093-89D0-CE5AFE62A5D7"/>
    <pav:createdOn>2014-04-21 12:30:56 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:32F674E2-70DC-4D21-87DA-B2FC17FC2EF5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:45EDCED8-9B43-464F-AC7F-898A9009649D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:6E4DC2F2-83E8-4160-B6D5-B1C311A3EB1E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:91815DE5-C358-4A60-8E59-4C8D7FAE5784"/>
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3919A0FC-9B55-4ED7-9514-90C32737E519"/>
    <pav:previousVersion>urn:domeoserver:annotationset:3746A507-CE58-4588-B931-C336B1314742</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5C3FAD25-158A-40FD-BB28-96D11E1A9866">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B3811262-7FB7-4610-8AF2-DDBEC1F3F734">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">36</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:53154C36-3543-4DB8-9FA2-B2B42F144C1F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5946A3F9-5969-4A42-95D2-AFE3E8251A48"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:87A687A4-9001-4015-86E8-43D83AC97EC6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:93F6979E-271D-482A-A141-5F0AD6C66E22"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1AD9A29D-96AB-4840-AF6E-CB07A28360A4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4EBD3E7B-F7AA-4839-9764-73A89D5C987F"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdOn>2014-04-14 14:12:22 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:33DF4147-AF32-4C0A-BC7E-F80CCCE6834F"/>
    <pav:lastSavedOn>2014-06-23 14:26:37 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:3408EABF-8DCD-4D09-A830-2B5B6A75B963</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:7BFF4A61-D45D-4C1F-9599-BD435EF039B8"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:905B00B5-CD9F-4F5A-BDCD-2E0771AC9B73"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A45211F-B49B-48F5-A9B9-D593DF301DA5">
    <pav:previousVersion>urn:domeoserver:annotationset:FA37F879-8CBC-4ABA-B812-53CC76964CFF</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:CBFF7BA1-E3EB-4A35-A0F4-FEA5E336D101"/>
    <pav:createdOn>2014-04-21 12:22:10 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:63183DC2-AEAB-428C-8EE7-06585D50BA8C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D64C9075-1FB5-47EA-9312-70A065865D71"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3BB6B488-00C3-4740-9F20-8C6AB5C8FCD5"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:29951346-424F-4492-B79A-EF5022CB7F05"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:86052180-6BE9-4913-AEF5-69CD8CDFBDBD"/>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:76924EA6-1981-4B77-ADA6-C632565C6480"/>
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:00AD9037-A37E-4477-9CCF-AF769A47482B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C6BE7951-1E6B-4301-BC65-53D6F750C89B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FAB88EF9-1AA0-47F8-A9F7-12B52C2724BA">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Decrease from baseline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:73528957-0BB4-4A36-9188-2651756AFFD5">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E33403E1-9E18-4800-B583-B5ECE131DDBB">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>abacavir naiive</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C97CADE4-3861-4CB6-A21E-09BF0AEB1F88">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:43B85AB2-533A-4A3B-932F-7CD7177449ED"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A66F219-499B-4560-AA94-F96598D0B126"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:E56B19ED-CC69-40EB-B68A-25F7DB5534A9</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:D43D74B1-E88C-4FBE-8716-B5F76BDE8FF1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:99B84487-54C4-4044-B319-C00A3689F0FA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lastSavedOn>2014-03-31 09:06:26 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-31 08:59:45 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:240C39EC-A129-42D3-8602-5C743EC412D2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0EF2A15B-07C7-4714-B698-FA75EA02612F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E03CFE71-0FEF-4840-A587-1D360CBF035C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E03CFE71-0FEF-4840-A587-1D360CBF035C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:exact>Advise patients that nursing mothers taking codeine can have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. These higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies. Advise nursing mothers to watch for signs of morphine toxicity in their infants which includes increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness.</ao:exact>
    <ao:suffix> Instruct nursing mothers to talk to the baby’s doctor immediately if they notice these signs and, if they cannot reach the doctor right away, to take the baby to an emergency room or call 911 (or local emergency services).</ao:suffix>
    <domeo:uuid>E03CFE71-0FEF-4840-A587-1D360CBF035C</domeo:uuid>
    <pav:createdOn>2014-06-30 11:55:08 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C770CC01-B9C9-4A7E-9F26-0E9C5E977617">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>42232-9 PRECAUTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42232-9 PRECAUTIONS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B83FE4F6-90A7-4140-A2C5-F71A9351F2D0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>We chose 1 annotation here.

How do we code for dose adjustment is needed? (does this mean time or a catch-all term)</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:408C86B9-FFBA-4A7F-A6EC-ECD348FD4782">
    <ao:body rdf:resource="urn:linkedspls:uuid:7F02E7ED-3C9D-4E0E-9FA2-85D054927729"/>
    <pav:lastSavedOn>2014-06-30 11:33:55 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:9A15D029-5B02-4107-A829-E2BD1B1219FE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:37985B75-E006-4646-954C-8237811DD0CA"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:4E001AB1-2305-4837-8AF8-180376395180</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:F0BBC254-D123-49BE-A254-67148370DC96"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CF3C9EDB-86A3-43C4-8D5B-0E221AA24650"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:95001B32-BCDE-46A6-A31C-19D445F40585"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:04B8D3B4-3A5C-4768-8DA3-C8C5D6222987"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:931F0B8F-C8A6-44A1-8713-51ECF3BB19BB"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">24</pav:versionNumber>
    <pav:createdOn>2014-04-28 15:31:28 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CF18371E-94C7-4F05-99A0-E7703B3AF94B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B35B25D3-31CE-48B5-885E-844B46E97203">
    <ao:body rdf:resource="urn:linkedspls:uuid:2DE7C82E-87D5-4A30-8DC1-75927DA0FF1E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D777A328-AEC0-4B48-8600-F84337D718D1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:961381E3-666C-448A-8F5E-E67933E35872"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8E902352-92DC-4687-80A3-2CE0B7F85201"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <pav:createdOn>2014-04-14 15:04:17 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-06-23 14:43:25 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:21696431-95DF-4AEB-A7A1-D4F7E7AE1525"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:15D4F66A-672C-4C20-AA7F-E7EBA0A7045B</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:55709DA6-0396-4327-B704-FE38E5F01C43"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FBD3A076-17BF-416E-9EEC-89C39FD558A3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:84B3F194-B698-4B0A-A280-2EE501615FA4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">29</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:91050818-2692-4B82-B3D8-A52A364F00D7">
    <ao:context rdf:resource="urn:domeoclient:uuid:DF1A2A13-1CD9-47EC-A75C-192353959653"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F349B074-7921-49F7-81EB-C8633E266F1E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:60E169BB-ADA3-4069-A5AD-09029A8F4F19"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">22</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E8E29A4A-3D14-4F45-BCE2-FE6490057A38"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:139701B4-343D-4042-94C9-2491CED57B47"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CD75F884-0A53-4582-AC31-492E9137F76E"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-06-02 14:39:24 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0A52235-7692-496A-9DE2-B919FD0C2AC7</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-30 11:55:13 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:07FDA150-3B31-4537-8993-9483B01FEF84"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:11AF6CFE-E78B-456E-BE42-3A1661B7118A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D1F73A7B-87F7-4F2B-93BA-E28FF40C75AD"/>
    <pav:previousVersion>urn:domeoserver:annotationset:E11D6466-9711-4830-9833-3DBFE683955D</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:307BDD85-8198-47F7-A1D4-290758EE20B5"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:E319F066-2C3E-4B8B-904F-5B682C614A92</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:25781413-3765-4C00-AB09-CF920462A870"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DCF9A15D-3781-426E-B12E-C37A11772BAD">
    <ao:body rdf:resource="urn:linkedspls:uuid:599459E0-8D98-4627-BC38-BA5B6BEC6B33"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BD5374B4-F192-4BDB-9CFF-EDFB1BF312E5"/>
    <pav:createdOn>2014-04-28 15:21:03 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:403ED560-E6D3-4B1C-BAF1-DD0E0D87AA3F"/>
    <pav:lastSavedOn>2014-06-30 11:33:55 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9C6627CE-F5DF-4F72-AA63-7AC2438EFB56"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4E001AB1-2305-4837-8AF8-180376395180</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:04422703-DCDE-4204-A942-3FEC91CA56D0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">24</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:E5FBDB9C-E8A2-41BA-AB64-639E73F1343C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:9367EFAD-3937-467F-97D9-F2F6C8B119CE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0E2849C6-750A-4F3F-8F6E-81977414BC10">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34479C82-F0F0-471A-A6BF-F84F48068921">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:158713E6-223A-4BE2-8C4A-663906E57A2A">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>HLA-B*5701 positive on abacavir</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:07A011F7-AA51-4AF6-9F6E-2ADE83EF58E9">
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:32A9DB60-B29A-4DDE-9C14-7F018F0728CA">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:139D3D04-C6A8-40B1-A6F1-5FBFB1B6B7CE">
    <ao:body rdf:resource="urn:linkedspls:uuid:D9566645-2367-4127-97ED-FEFEB81B1860"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C7E5E18B-7DAC-440F-A4AE-4F3F0BE85F12"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ED9FC62F-6F5A-4AEC-B2EB-900F4C21E312"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E6148AE9-D3FF-43CD-B26E-1DDB165D61DD</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-04-21 13:25:55 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:05A8BCC3-6277-4F17-A060-416AD1F106CE"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:98226070-C5AF-407A-B6D1-D521CD001163"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:02541206-0D89-4418-A8FF-FA3E161C64DD"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:94669385-318C-4E58-97B1-033AF9C48990</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E9858AE-79C0-437B-A7EA-AD326494395F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6E4FAE9A-BCAB-43D2-99CA-20C3101D8DD0"/>
    <pav:lastSavedOn>2014-06-30 11:09:18 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8E97872D-A5EA-4365-A1DA-DD1AFEB4FCE0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B7F3E46-D643-4624-87F8-2CA5BF6054AA">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B6D3900-DB2F-43B3-910E-08797EA1F227">
    <sio:SIO_000111>34090-1 CLINICAL PHARMACOLOGY SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34090-1 CLINICAL PHARMACOLOGY SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BD5374B4-F192-4BDB-9CFF-EDFB1BF312E5">
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95EEC2FF-D292-48FE-8FD7-FEF64E2F00E4">
    <pav:previousVersion>urn:domeoserver:annotationset:B6ECB9A2-9EC8-4604-8083-31DFE65BDF4C</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:9843AD8C-F6A5-4324-81DE-9E7505C0CCAF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:42129E3A-F6BF-4351-B780-2CCB2B2CA39E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:855697DF-EBFA-4343-B2F2-023B6F284D48"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:94DE53A7-7CD1-44E7-AF38-A58BCF1EE14B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:55304B24-8DE1-4B6D-9FDA-B01C9B453126"/>
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:C427075F-5339-47EB-A313-AA6B94EB8753"/>
    <pav:createdOn>2014-04-21 12:38:07 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:80BBDCC8-E953-421D-91E4-F8FB47321D0B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E2A31DB2-6CF9-4A0C-9708-109CC7FFA7B5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>FIX TABLE</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C09E3379-98EF-4D6C-8046-8C000B4A6C99">
    <pav:lastSavedOn>2014-06-30 11:12:54 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F8216E2F-0352-4586-95B0-0AD50C30869C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:07F347BB-54A7-4EBD-96D0-3FEE77788DE0"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8E97872D-A5EA-4365-A1DA-DD1AFEB4FCE0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E6EA4868-B541-4A53-9D34-1E6CAD274D8C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E6148AE9-D3FF-43CD-B26E-1DDB165D61DD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:4C6F6544-9DB6-404F-BD19-22E1463B3B1D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2EF12CE2-C7B6-43E9-8273-1A86AC282CD6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E02C5AB-C35D-4ACA-8EF0-DF0F481E6A00"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:9F0CE910-4782-4E6D-B7E2-C7C784B10B90"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E88FDC54-C499-48EE-BE43-B919760B2AB6"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:0C1275CE-E02A-4CA5-9EC8-0B105F3598C6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2436FF6C-87D4-4EA7-8571-4021D0FA8E81"/>
    <pav:previousVersion>urn:domeoserver:annotationset:E808A218-4A46-4A7A-8864-3700BE8E6D11</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdOn>2014-04-21 13:32:07 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8C0132CB-1BA7-4320-8C5F-E55761BC596E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7952BD0B-86EF-4547-9479-6887AFB0956B">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0299EF23-53A3-465D-BBC0-D798C9EC6E18">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity </poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:745C184B-12B3-435F-99C5-252556EB53B9">
    <ao:suffix> The effects of about 5 years of tamoxifen on recurrence and mortality were similar regardless of age and concurrent chemotherapy. There was no indication that doses greater than 20 mg per day were more effective.</ao:suffix>
    <domeo:uuid>745C184B-12B3-435F-99C5-252556EB53B9</domeo:uuid>
    <ao:exact>Benefit is less clear for women with ER poor breast cancer in whom the proportional reduction in recurrence was 10% (2p = 0.007) for all durations taken together, or 9% (2p = 0.02) if contralateral breast cancers are excluded. The corresponding reduction in mortality was 6% (NS).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:745C184B-12B3-435F-99C5-252556EB53B9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <pav:createdOn>2014-06-30 12:20:40 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:53B64B1F-739B-46F0-99EE-89EF4131A8D2">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Codeine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6EB23E7A-2869-485D-965A-820F1D704C25">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:09730EE5-3645-4E22-8362-E17C60539840">
    <ao:body rdf:resource="urn:linkedspls:uuid:D0869B07-1155-430B-8AD6-B3D91EA533C0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">13</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A837016-62F3-4B6D-9730-CDAD010A98DE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2A3AE56E-9DA3-4575-BD28-FB1BC6BCE6DD"/>
    <pav:lastSavedOn>2014-06-30 13:24:20 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0F7B1E31-9D8A-45AA-8F34-A942EE6FBB80"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E8587041-73D9-4727-A9F5-7445BAF204E3"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <pav:createdOn>2014-06-30 13:24:15 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:2D77D03D-7AFC-443D-B2A4-AD57E38946EE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:97C0B757-E6B8-4479-A84D-2083D8FB6CB5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A59A0FFF-C40E-445B-A997-9D6C97BF2B3E">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34075-2 LABORATORY TESTS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34075-2 LABORATORY TESTS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AC31138E-D96E-46FA-AD16-E8C5C6855989">
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <pav:createdOn>2014-04-21 13:06:35 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:17F4FC04-A894-4AE5-B819-04A114687F45"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7B1D893F-6D49-4E8E-84CD-1AF31A949F9D"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:87228117-6F6A-41A0-9709-5D0977E83A06"/>
    <pav:previousVersion>urn:domeoserver:annotationset:38C868F5-0561-4B99-A7E7-0D5DF1B6A047</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:AD99D105-745D-4452-A054-674F93273D57"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FF5E88F5-B94D-48ED-B889-7EEE5AAC13C6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A65FF93C-5572-4A51-A9E0-77CA1FE21DE2"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:17111230-1211-460A-B383-3D65082506CF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4DA6E07F-7E36-48E4-A071-62F94AA47FB9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7837AD3A-635E-44DB-94FD-C81623976C01"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:942BE2E4-F2DF-4734-B53E-6B0DCCD0A545"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">22</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B3109958-C49A-4EC9-AC70-C869B50D7E19"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7011CFB2-61E8-47F2-9EB6-733E1486BBD3">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:9179</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>POLG</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2446A882-2020-42F8-AD24-FE3B4F839958">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9D58177E-4634-4343-9151-CCD4668C812B">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:990A861C-8128-4BEB-B3B9-1F189E42FDD0">
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Recommend</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:94B53E9F-5329-43D3-AD42-03C430F6E877">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:49473EAE-FFE9-49C4-8E8F-674168905020">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87228117-6F6A-41A0-9709-5D0977E83A06">
    <pav:createdOn>2014-06-30 12:04:57 -0400</pav:createdOn>
    <domeo:uuid>87228117-6F6A-41A0-9709-5D0977E83A06</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:87228117-6F6A-41A0-9709-5D0977E83A06"/>
    <ao:exact>Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity from azathioprine tablets if conventional doses are given. Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for non-functional alleles).</ao:exact>
    <ao:prefix>TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity.  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:461FDA58-8FAB-4951-B04A-F969D73C634D">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:61BA8ACB-D63A-46FF-8B5D-79E9326A61A3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact> In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been reported in Asian patients.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:61BA8ACB-D63A-46FF-8B5D-79E9326A61A3"/>
    <pav:createdOn>2014-06-30 13:11:19 -0400</pav:createdOn>
    <domeo:uuid>61BA8ACB-D63A-46FF-8B5D-79E9326A61A3</domeo:uuid>
    <ao:prefix>Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G&gt;A allele) have been associated with lower dose requirements for warfarin.</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A10CE73-592A-4D92-84AF-63395C43C0F9">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <domeo:uuid>0A10CE73-592A-4D92-84AF-63395C43C0F9</domeo:uuid>
    <pav:createdOn>2014-06-30 11:58:10 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0A10CE73-592A-4D92-84AF-63395C43C0F9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52F5A13C-EFE7-4849-8CA0-A0C9CDBADB82">
    <rdfs:label>ESR1, PGR</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BCCF3F22-38AE-4F01-87D0-22C1B07EC947">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77A5B46A-613C-4652-B182-17CDCF3C7C3D">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F54825B6-3CF9-4465-A4BE-7C6747734A6E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-23 14:25:12 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F54825B6-3CF9-4465-A4BE-7C6747734A6E"/>
    <ao:prefix>ea, vomiting, diarrhea, or abdominal pain), (4) constitutional (including generalized malaise, fatigue, or achiness), and (5) respiratory (including dyspnea, cough, or pharyngitis). Discontinue ZIAGEN as soon as a hypersensitivity reaction is suspected. </ao:prefix>
    <domeo:uuid>F54825B6-3CF9-4465-A4BE-7C6747734A6E</domeo:uuid>
    <ao:exact>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:201331AB-54CD-4BE2-81C9-806CCB6E5915">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:201331AB-54CD-4BE2-81C9-806CCB6E5915"/>
    <pav:createdOn>2014-06-30 13:18:20 -0400</pav:createdOn>
    <ao:exact> Numerous factors, alone or in combination, including changes in diet, medications, botanicals and genetic variations in the CYP2C9 and VKORC1 enzymes (seeCLINICAL PHARMACOLOGY,Pharmacogenomics) may influence the response of the patient to warfarin.</ao:exact>
    <ao:prefix>DOSAGE AND ADMINISTRATION : Laboratory control ). </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>201331AB-54CD-4BE2-81C9-806CCB6E5915</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:976BDFF3-2BFA-4838-B6A0-327B2921E1B7">
    <domeo:uuid>976BDFF3-2BFA-4838-B6A0-327B2921E1B7</domeo:uuid>
    <pav:createdOn>2014-06-30 11:34:29 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:976BDFF3-2BFA-4838-B6A0-327B2921E1B7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel’s active metabolite.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:438281C3-C647-40A0-876E-C7D2D5069693">
    <dct:description>Referred to Prodrug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C29BB62F-1380-446E-A6CD-5B46DB334A08">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E9B14EC-233F-4ABE-B627-6150C0C5A5A4">
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:7A7EDC45-CF4F-4C98-9560-59ED6861B6F1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:121C567F-2959-445A-9390-AB1AD1A2C5C3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4C6A2A40-EB7B-43F7-8E2F-DA2AEAFB7030"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">20</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F"/>
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <pav:createdOn>2014-04-21 13:01:24 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:3A476905-474C-4143-843A-E6C5FE613246</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:74693C6A-93CE-494A-B1A2-F02599BCD449"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2A54DC85-4F68-4509-A879-96F2E86AECFE"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:878D746A-3252-462C-AA1E-A857E2FC63AF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9261BA20-6306-4EC3-BE27-7705499B11D4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E9EC87B4-979D-4E8D-B84A-ECD61AE573EC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4DA93D3D-14FD-4739-A7EC-F5ADCEDB5CB0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F8166271-C1E5-46A1-9876-DA65BA73DCD9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1D9B7794-EB80-4C0A-A5B6-F9B8661691D2">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Reinitiating abacavir</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86366FDE-6665-48F6-BFB3-E95DBF8A1B2A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4D2E94C8-8F4A-4F8D-8CC1-2800C6BA22F1">
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Prodrug</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55ED86AA-B414-4220-94FD-868AFE2D1278">
    <pav:previousVersion>urn:domeoserver:annotationset:BF375829-3538-4BFD-A5B6-4A2CE209BD07</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:28F5248D-2360-4A65-9C87-F31FB5E058FC"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA191114-E5D7-495A-9C11-23DD267847E1"/>
    <pav:createdOn>2014-06-30 13:03:17 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:2F4146E2-F264-4965-8410-02C26DF7C9B4"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9C2B48AD-A4E0-4C6C-9246-E6FD6CF712C8"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:lastSavedOn>2014-06-30 13:03:17 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:461FDA58-8FAB-4951-B04A-F969D73C634D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:51EA4BF7-D3D9-48AC-8608-E62CCAE8CF75"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2F4C97C8-3FB9-401C-B323-6300518C3198"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FAB88EF9-1AA0-47F8-A9F7-12B52C2724BA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:6C85B913-2858-4D1D-9AAF-E971C083B56E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:73360989-B979-493E-8A6F-9D31D67D94D0">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C7EAEB14-8213-4EF8-AC67-469D0609826B">
    <domeo:uuid>C7EAEB14-8213-4EF8-AC67-469D0609826B</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C7EAEB14-8213-4EF8-AC67-469D0609826B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:prefix>HLA-B*5701-negative patients may develop a hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.  </ao:prefix>
    <pav:createdOn>2014-06-23 14:36:33 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:882E9031-328A-4F6D-8C1A-AE163639BAC5">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>postmenopausal, early breast cancer</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0A77E98C-C600-4EC4-B7B0-FBE6DB0E4100">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FBA8BE44-2409-4673-8D2F-0E2947538FCE">
    <pav:createdOn>2014-06-30 12:30:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen citrate tablets are an alternative to oophorectomy or ovarian irradiation. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <domeo:uuid>FBA8BE44-2409-4673-8D2F-0E2947538FCE</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FBA8BE44-2409-4673-8D2F-0E2947538FCE"/>
    <ao:exact>Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablet therapy.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:405A5AAA-08FD-470C-9B50-67E44ED1462F">
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:D336843D-C700-4B81-AAC2-DB786978197E"/>
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:A6D763A6-26BF-4BA0-B4EB-60A2EDE685F6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F2190B2B-E2DC-45AB-AB25-CB7DD9192C64"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:04E39F17-24C2-48B2-87A1-2648282F8A03"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:74DD167E-84A5-4F2E-9B72-BEF1FCA1F812"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:BF8C1810-3B2F-446D-95FB-F6382AEE1DC0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6B9F2EDD-8EC9-441C-9B9C-6DE4ED079F50"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B70DD975-4D1D-4F7B-A6D2-55287EFC95A9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:5975F77C-3B5B-409B-9619-3ABC2AD31A28</pav:previousVersion>
    <pav:createdOn>2014-04-21 12:27:23 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:ACECDF46-D28E-49E8-B2DF-97FC16B093EA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:21DAABB4-71ED-4547-9902-CAEFBC1D07BB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6CE555C3-7C30-4D10-B475-4043F081E7B3">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34092-7 CLINICAL STUDIES SECTION</poc:productLabelSection>
    <sio:SIO_000111>34092-7 CLINICAL STUDIES SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:00E8CD81-460D-4060-A021-B8D8C71F86A1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:F19D3DA9-E091-415D-A43E-483BEC7B68FB"/>
    <permissions:permissions rdf:nodeID="N1dda9f31d4cb49e087349463088824e9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:58D07047-AF21-4623-8E4E-4CB2945F5986"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>urn:domeoserver:annotationset:5E48A15C-00B4-4A17-A4DF-2642EBF7D771</pav:previousVersion>
    <pav:createdOn>2014-06-09 15:15:26 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:23FACDDB-003E-40B5-AB79-B52F5FD124B3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:720C5233-AF5F-4538-891A-259FD3EE6895"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143044e90f26014518a19cf70063"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:FE73DA30-2D2E-4D34-AC2F-B160599E5ADD"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:DBBF90A0-6468-4792-B1CC-02DDD21B4A08"/>
    <pav:lastSavedOn>2014-06-30 12:02:38 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1CEDA84C-14E2-4D8B-A754-750B7AAD033F</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:B8BA0ADB-2437-4F14-9102-2EC16B13EE4C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8525CDF6-1EFA-4AA5-BD43-C9DDE92E0196"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">13</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F50056E6-0B34-41B6-A646-9D522C97885A">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE154A72-C1D3-4027-8C73-C71A948D0F52">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1769615F-FAC0-4900-9DC6-5021630F8524"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B4D69718-1E39-448F-9056-D5C7E8C902E3"/>
    <pav:previousVersion>urn:domeoserver:annotationset:586BB8D4-86C3-412E-9702-95D59934639E</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:90982EDF-B4D4-45BA-A707-BC09270B9519"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ABC34EDB-BF59-4E20-8274-F896596AEA01"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:lastSavedOn>2014-06-30 12:25:52 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:FA0C425E-2A1E-4059-BAC2-34BD4239836F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:40C626E6-884D-4EA1-A1CA-C16B5F06A3F0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:77B5C0D4-B728-4F8B-B5B3-E3B3BE2E8C85</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:AC3CA09A-7F4D-4251-92E9-089254257BF3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9ADC7DB1-8D79-4494-96BB-4A7FA41490E8"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-06-30 12:25:05 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9FEAD25C-8497-4E5F-AC0F-D9B37282619E">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#66106-6 PHARMACOGENOMICS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>66106-6 PHARMACOGENOMICS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:136CA05A-B32D-4CAF-B985-0FB9EF4F0455">
    <ao:exact>Tamoxifen citrate tablets are a prescription medicine that is like estrogen (female hormone) in some ways and different in other ways. In the breast, tamoxifen can block estrogen's effects. Because it does this, tamoxifen may block the growth of breast cancers that need estrogen to grow (cancers that are estrogen- or progesterone-receptor positive).</ao:exact>
    <ao:prefix>What is the most important information I should know about using tamoxifen citrate tablets to reduce the chance of getting breast cancer? </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-30 12:41:32 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:136CA05A-B32D-4CAF-B985-0FB9EF4F0455"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>136CA05A-B32D-4CAF-B985-0FB9EF4F0455</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:84B3F194-B698-4B0A-A280-2EE501615FA4">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2A54DC85-4F68-4509-A879-96F2E86AECFE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:942AE26F-116C-4165-9118-723E840DFB17">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA3B0B94-7858-4E6B-B828-AB6A8867E1D3"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D92166A3-0B32-4545-B4CA-719FEDAF410D"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:8EE67176-9F55-46AB-91C9-4F10951C11A4"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">27</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:05220B0B-E773-4262-8FFB-37C20132138B"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC705FE0-7F27-4CD4-B50D-6B7A4AF34DB1"/>
    <pav:previousVersion>urn:domeoserver:annotationset:956639A9-2989-412C-8ECD-8055491DC522</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:F45F585A-05C5-49B5-BABB-73BFBE9E9753"/>
    <pav:lastSavedOn>2014-06-30 11:37:28 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:58563954-332F-464C-8460-68E5B2018068"/>
    <pav:createdOn>2014-04-28 15:43:59 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64BC1D21-CAE1-4F85-A596-73342A9D5388">
    <pav:createdOn>2014-03-22 22:02:44 -0400</pav:createdOn>
    <ao:exact>HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:64BC1D21-CAE1-4F85-A596-73342A9D5388"/>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4018FA6B-4CAF-48CF-9B75-2F22B9E2DDF5">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
    <rdfs:label>TPMT</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF3EE487-6CDE-46E4-9A82-94DBA07862ED">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>CYP2C9*1/*1, CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3, CYP2C9*3/*3, CYP2C9*5, CYP2C9*6, CYP2C9*11, CYP2C9*9</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D8A9803-9C09-4301-8254-AF8BCE7E83F8">
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <pav:createdOn>2014-06-30 13:23:21 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-06-30 13:24:20 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:0AB99582-A22B-403F-9604-C35A9897CE91"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F48C3C33-678B-486C-B677-C6FFA206E24A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1532F8ED-1CF3-45D5-8A36-00FA8FD6060D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">13</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA00EA65-56B8-400A-BD7B-CBC28C8835D4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7EA5841C-261F-43DD-BE19-7566B1DCC787"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2D77D03D-7AFC-443D-B2A4-AD57E38946EE</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:F7684C08-2D03-4CFE-B6ED-3598D9C30C18"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0579E19D-BA85-4595-8F37-A456B687BC45">
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA262512-E130-4C45-941A-8173486F6F26">
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF35511B-7BED-446A-B970-33FEE5C13C88">
    <ao:body rdf:resource="urn:linkedspls:uuid:77594AF7-4C1F-4FAA-8FC3-84489C84CB17"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:77B5C0D4-B728-4F8B-B5B3-E3B3BE2E8C85</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13</domeo:belongsToSet>
    <pav:createdOn>2014-06-30 12:29:04 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:B7C74F66-7541-40DE-86DE-F53FC1962E66</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:39F4E826-731D-452F-BFE9-052B1EC82FC7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9C843591-806D-42E0-88A9-58DC59076B3D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1CF08EE8-3F2A-4FE9-A883-E2FB099710F3"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:74B97B42-8CF1-41BB-84AD-CF0995E7508C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A8F70682-D5CB-4276-AB4B-8856ECC0EE29"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:657DCC6E-580E-4775-A090-F145328680B3"/>
    <pav:lastSavedOn>2014-06-30 12:29:05 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C89E80EC-0820-406B-99C8-D495EC5F054E">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:83CA0C0D-6F7B-4FD7-94F8-FAB3FE827447"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E568EFC-3592-49B7-A800-3C6E0D51E918"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E319F066-2C3E-4B8B-904F-5B682C614A92</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:39A685C2-1AA3-415F-8F2F-3F82C6914A2D"/>
    <pav:previousVersion>urn:domeoserver:annotationset:AF4D26A8-1226-474B-84F9-E6B3F8D83ABA</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0A52235-7692-496A-9DE2-B919FD0C2AC7</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E525054-D8AA-41ED-B402-1724F218F644"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B18AC1F-0336-4DE3-AE4A-C9C0CE29BE6B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D2DE610F-DC5B-42B2-8C18-D03E18FE3264"/>
    <pav:createdOn>2014-06-02 14:03:56 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:4D2E94C8-8F4A-4F8D-8CC1-2800C6BA22F1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:12A88496-C15E-4555-B3A9-C7977BBC3923"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7705072C-9052-4674-921A-6BE7E5A1BAFD"/>
    <pav:lastSavedOn>2014-06-30 11:47:15 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:480F809C-0DAD-4297-969A-E832E3A5A336"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E9EC87B4-979D-4E8D-B84A-ECD61AE573EC">
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A65FF93C-5572-4A51-A9E0-77CA1FE21DE2">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B3E23EF-1696-4FF7-BEEB-8158BDA84294">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:813B467D-E573-4F02-B5FD-95E3A0050ADC">
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:39A685C2-1AA3-415F-8F2F-3F82C6914A2D">
    <domeo:uuid>39A685C2-1AA3-415F-8F2F-3F82C6914A2D</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:39A685C2-1AA3-415F-8F2F-3F82C6914A2D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>WARNING: DEATH RELATED TO ULTRA-RAPID METABOLISM OF CODEINE TO MORPHINE\nRespiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <pav:createdOn>2014-06-30 11:47:14 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D5B3334-40F5-4B23-8773-AFED2978DC1D">
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:D6B65EB6-3BF7-43C0-BEF9-77B5DC9D2601"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdOn>2014-06-30 13:18:20 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:86480047-DD43-4A54-B258-3772C18237F7"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:B4FA5D29-61B8-4A79-A14C-BDBBE573E4FB"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:34479C82-F0F0-471A-A6BF-F84F48068921"/>
    <pav:lastSavedOn>2014-06-30 13:18:20 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:184D766F-E8BD-493E-B5CC-469B67C4540C</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:201331AB-54CD-4BE2-81C9-806CCB6E5915"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C770CC01-B9C9-4A7E-9F26-0E9C5E977617"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D33EB0C-A03D-481F-991D-B71848865C38">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1D33EB0C-A03D-481F-991D-B71848865C38"/>
    <ao:prefix>Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>TPMT genotyping or phenotyping can help identify patients who are at an increased risk for developing azathioprine toxicity.</ao:exact>
    <domeo:uuid>1D33EB0C-A03D-481F-991D-B71848865C38</domeo:uuid>
    <pav:createdOn>2014-06-30 12:04:19 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E32A745-A354-4E89-B502-25D8192C980B">
    <rdfs:label>biomarker-level-low</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1A9E2879-AD9B-48F5-B672-AB5C06A28080">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Letrozole</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8CD7F86F-C041-47B7-B7D2-F7B48F523F56">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:2C6B9A5A-8AF2-42AD-BBC3-F6BD0F24F710"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A4C02E85-B069-4AF9-BE5D-3C781D0C2CC1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D87AC20-773F-4241-AA52-57BF86A4A93A"/>
    <pav:createdOn>2014-04-14 13:34:44 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:FDF4DC15-174B-44D2-8BB3-1ED10ED1ED83"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1F9B8CBD-BC64-4EF6-A7CE-5ED4242D4C3C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D4F7410C-1DFB-4286-B219-984A8005A9DA"/>
    <pav:lastSavedOn>2014-06-23 14:23:27 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5BF25FD8-2729-4DCC-801E-315EEA82F89B"/>
    <pav:previousVersion>urn:domeoserver:annotationset:C81648BE-BB1C-4670-B054-AE1D1A22A750</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:AFE902B5-9F02-47A7-B23B-3F49A78A50C8"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:3846BD3B-067C-4D62-AAA4-6A53131A2A2B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">33</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:630E5590-A87E-40A8-A3F3-DE3348285B26">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34081-0 PEDIATRIC USE SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34081-0 PEDIATRIC USE SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BE588D93-C0EC-4E98-AC83-D151CAD07967">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>Hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A997B78-0557-4495-BDBD-42F5B4B30412">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>and AUC was increased by 68% and 107%, respectively.  </ao:prefix>
    <pav:createdOn>2014-06-30 11:21:56 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5A997B78-0557-4495-BDBD-42F5B4B30412"/>
    <ao:exact>Citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <domeo:uuid>5A997B78-0557-4495-BDBD-42F5B4B30412</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17A2A5F8-6739-40C4-AEA6-7BE0ABBD5908">
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:58EFF7E3-78B6-4587-A089-7F58793F2EBF">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ABA7A2B9-17AA-424E-850E-21298BD2BEBC">
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46C63D3B-0000-404E-BC76-FB01C42DC7B2">
    <pav:lineageUri>urn:domeoserver:annotationset:E6148AE9-D3FF-43CD-B26E-1DDB165D61DD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8E97872D-A5EA-4365-A1DA-DD1AFEB4FCE0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:2C7D68CA-AF82-4CD6-94A2-A51D70D09712"/>
    <pav:previousVersion>urn:domeoserver:annotationset:0CE00703-0D12-4B44-8EC9-540C86C15C6D</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:58A5256A-166D-4E36-9513-8392BC71360E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0D634683-D28C-42DC-9911-DFD0C9EB289D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FCE7C9FB-8A9B-4379-9663-1AAC8E3A180A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:36DE6D64-E2CB-42B6-9D00-570AC3CAD508"/>
    <pav:createdOn>2014-04-21 13:17:29 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3FF3DEC0-759E-46A4-AB19-7748B16272DC"/>
    <pav:lastSavedOn>2014-06-30 11:03:00 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:BBD1EA14-A142-47FF-A3B5-D848FFAED44F"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:D1491BCF-E2DE-4ACD-A786-633BB7136467"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:81FC4ABF-FFA6-4A93-A74E-A025DFD17C00"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1035F78D-B81D-4CA7-9A11-4648026B2B7A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8063FB58-0C19-4F4D-87DC-7AFA705FCE00">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6A7BDA4E-7AB8-4FE1-9B04-B1133604AD33">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:74EA2B44-40D9-44F0-90BA-33EFF2D1B5AA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6A08C2D-396E-49CC-B12F-1CE908524D8C">
    <dct:description>Referred to clinical trial</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7EA5841C-261F-43DD-BE19-7566B1DCC787">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3B713685-9EC6-4CDC-A319-C8182DAF4210">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E014618E-3373-4F61-BAF6-4ABD45885081">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>E014618E-3373-4F61-BAF6-4ABD45885081</domeo:uuid>
    <pav:createdOn>2014-06-23 14:40:11 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E014618E-3373-4F61-BAF6-4ABD45885081"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Screening for carriage of the HLA -B*5701 allele is recommended prior to initiating treatment with abacavir. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.</ao:exact>
    <ao:prefix>Based on this study, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected hypersensitivity reaction during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8BA5860F-EC3D-4A39-A59F-2C87A9414AC5">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BC59C368-6171-459A-BA88-9B57AAC67FD8">
    <ao:suffix> HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</ao:suffix>
    <ao:exact>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BC59C368-6171-459A-BA88-9B57AAC67FD8"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-03-22 22:01:43 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86480047-DD43-4A54-B258-3772C18237F7">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF7AF633-8B36-41BF-AC4F-0BA548A0DB2F">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D6C5A56-8085-48FE-B0EA-E439AEC8B746">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E4B01B1-801C-4C26-86B8-852138AD8BE2">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:147B38AF-9E51-4D8A-B5CF-D7FAE7375257">
    <ao:prefix>). Women should understand that tamoxifen reduces the incidence of breast cancer, but may not eliminate risk.</ao:prefix>
    <domeo:uuid>147B38AF-9E51-4D8A-B5CF-D7FAE7375257</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <pav:createdOn>2014-06-30 12:38:14 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:147B38AF-9E51-4D8A-B5CF-D7FAE7375257"/>
    <ao:suffix> In women with breast cancer who are at high risk of developing a second breast cancer, treatment with about 5 years of tamoxifen reduced the annual incidence rate of a second breast cancer by approximately 50%.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> Tamoxifen decreased the incidence of small estrogen receptor positive tumors, but did not alter the incidence of estrogen receptor negative tumors or larger tumors.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9F0CE910-4782-4E6D-B7E2-C7C784B10B90">
    <ao:exact>Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN. Consideration should be given to avoiding use of other drugs associated with SJS/TEN in HLA-B* 1502 positive patients, when alternative therapies are otherwise equally acceptable.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>The HLA-B*1502 allele has not been found to predict risk of less severe adverse cutaneous reactions from carbamazepine, such as anticonvulsant hypersensitivity syndrome or non-serious rash (maculopapular eruption [MPE]) . </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9F0CE910-4782-4E6D-B7E2-C7C784B10B90"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>9F0CE910-4782-4E6D-B7E2-C7C784B10B90</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-30 11:12:53 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:76892146-9A3A-463F-9ABF-573CA0067EFA">
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B4CA7086-6798-431D-B76B-5ABC77094611">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#66106-6 PHARMACOGENOMICS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>66106-6 PHARMACOGENOMICS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6347DAEC-6E58-45D7-9A9D-16BE602F4930">
    <ao:exact>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Serious and sometimes fatal hypersensitivity reactions have been associated with ZIAGEN and other abacavir-containing products. </ao:prefix>
    <domeo:uuid>6347DAEC-6E58-45D7-9A9D-16BE602F4930</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6347DAEC-6E58-45D7-9A9D-16BE602F4930"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-06-23 14:35:00 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:65192B6B-F432-4495-9208-AADAAF9CEFD3">
    <rdfs:label>ESR1, PGR</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5630014D-C820-4E31-A061-529A1A06548B">
    <ao:context rdf:resource="urn:domeoclient:uuid:1DB91157-FBA4-4FE0-BAB1-68BB8A5A145E"/>
    <pav:createdOn>2014-03-22 22:10:26 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:512081E4-B6CF-4E36-B991-10F09074D3A4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6477100F-B124-46B7-94A1-A46956E0A307"/>
    <pav:lastSavedOn>2014-03-22 22:11:45 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:E2118E19-85E9-439B-A2BE-5001150AB7C2"/>
    <pav:previousVersion>urn:domeoclient:uuid:9372D3E2-2D34-4B3E-9DEE-0B5D2C57BB6B</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:D66FA8C3-8BAB-4A6F-8234-6DD134876578"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3F354582-DE01-47DD-929D-B501E8EB5B46"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:D4DBC7AE-A1A8-401A-9345-BB0D2918876C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2F20CE66-F8C3-45F5-997D-6DA3618A2E36"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8FD74D14-41E4-4A55-AAC7-3B207B0782D6">
    <poc:MedicalCondition>postmenopausal, breast cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DDC6A971-06AB-44BC-B5DD-01B41956F9CA">
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33D89E0F-4370-431E-8DB5-094F3AF78C75">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Patients receiving azathioprine tablets and allopurinol concomitantly should have a dose reduction of azathioprine tablets, to approximately ⅓ to ¼ the usual dose. It is recommended that a further dose reduction or alternative therapies be considered for patients with low or absent TPMT activity receiving azathioprine tablets and allopurinol because both TPMT and XO inactivation pathways are affected</ao:exact>
    <domeo:uuid>33D89E0F-4370-431E-8DB5-094F3AF78C75</domeo:uuid>
    <ao:prefix>One of the pathways for inactivation of azathioprine is inhibited by allopurinol. </ao:prefix>
    <pav:createdOn>2014-06-30 12:04:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:33D89E0F-4370-431E-8DB5-094F3AF78C75"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:50BC8289-8484-45F5-AF7C-591A9AC3A328">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8BA0ADB-2437-4F14-9102-2EC16B13EE4C">
    <ao:context rdf:resource="urn:domeoclient:uuid:10B1EB06-38FD-41C2-A3B7-625B2825B889"/>
    <pav:createdOn>2014-06-09 15:40:26 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1CEDA84C-14E2-4D8B-A754-750B7AAD033F</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:1A9E2879-AD9B-48F5-B672-AB5C06A28080"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C736103C-9AA0-48C1-8314-B13D1585FA1C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:5AB704EB-C507-4FF7-B9C4-32F8475094DA</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:57DEF5AD-FC2E-4EB0-AED9-CA33AAAF117D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8B9A8142-A3D9-411C-BFE7-DD2A2C9E4588"/>
    <pav:lastSavedOn>2014-06-30 11:59:39 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:77D310FC-B5EB-4AEB-AE29-1746D651FEB3"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:52F5A13C-EFE7-4849-8CA0-A0C9CDBADB82"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:00E8CD81-460D-4060-A021-B8D8C71F86A1</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E91F8D63-309E-4A05-9F9A-6C42F2D86071"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5D85FB52-BA95-409A-8974-2E14C9527722">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <ao:prefix>HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5D85FB52-BA95-409A-8974-2E14C9527722"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-03-22 22:03:47 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E86AE4A1-3150-4C61-A54E-57E3099D70B7">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F30A3592-1EDA-414B-8C7B-2B931B766619">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>F30A3592-1EDA-414B-8C7B-2B931B766619</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>CYP2C9 GenotypeNS-Warfarin Clearance/Lean Body Weight(mL/min/kg)Mean (SD)**SD=standard deviation.p&lt;0.001. Pairwise comparisons indicated significant differences among all 3 genotypes.*1/*11180.065 (0.025)*1/*2 or*1/*3590.041 (0.021)*2/*2, *2/*3or *3/*3110.020 (0.011)Total188Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9 and *11 alleles in Caucasians.</ao:exact>
    <ao:prefix>Table 1 Relationship between S-Warfarin Clearance and CYP2C9 Genotype in Caucasian Patients </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F30A3592-1EDA-414B-8C7B-2B931B766619"/>
    <pav:createdOn>2014-06-30 12:54:57 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4DE4F207-7D95-47C1-9546-BD8AD1CC8E5B">
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:75D456DC-1DB0-4F96-A11F-551CC8425889">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74EB8F8A-FCEA-41C8-BAB2-B4DFA1190D34">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>. For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact> Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:74EB8F8A-FCEA-41C8-BAB2-B4DFA1190D34"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-06-30 13:02:40 -0400</pav:createdOn>
    <domeo:uuid>74EB8F8A-FCEA-41C8-BAB2-B4DFA1190D34</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0BBC254-D123-49BE-A254-67148370DC96">
    <domeo:uuid>F0BBC254-D123-49BE-A254-67148370DC96</domeo:uuid>
    <pav:createdOn>2014-06-30 11:33:15 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>CYP2C19 poor metabolizer status is associated with diminished antiplatelet response to clopidogrel. Although a higher dose regimen in poor metabolizers increases antiplatelet response [see Clinical Pharmacology (12.5)], an appropriate dose regimen for this patient population has not been established.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F0BBC254-D123-49BE-A254-67148370DC96"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:41D2E64F-6C03-4744-A4FC-79ED77085E81">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>intermediate-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#intermediate-activity</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:80BBDCC8-E953-421D-91E4-F8FB47321D0B">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:07FDA150-3B31-4537-8993-9483B01FEF84">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:386FFD8A-E0F1-4DB6-8CB3-C72EC135E05D">
    <rdfs:label>Increased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1908624-6F0B-47BD-8D70-8EACD877F4A9">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>VKORC1CYP2C9*Ranges are derived from multiple published clinical studies. Other clinical factors (e.g., age, race, body weight, sex, concomitant medications, and comorbidities) are generally accounted for along with genotype in the ranges expressed in the Table. VKORC11639 G(rs9923231) variant is used in this table. Other co-inherited VKORC1 variants may also be important determinants of warfarin dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3 and *3/*3 may require more prolonged time (&gt;2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen.*1/*1*1/*2*1/*3*2/*2*2/*3*3/*3GG5 to 7 mg5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mgAG5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mgAA3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg</ao:exact>
    <ao:prefix>Table 5Range of Expected Therapeutic Warfarin Doses Based on CYP2C9 and VKORC1 Genotypes * </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C1908624-6F0B-47BD-8D70-8EACD877F4A9"/>
    <pav:createdOn>2014-06-30 13:24:52 -0400</pav:createdOn>
    <domeo:uuid>C1908624-6F0B-47BD-8D70-8EACD877F4A9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C692DA9C-1ECF-4A5B-867C-ABAF23492F10">
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:D4015F92-6E92-4747-8C53-576B05F5F8DD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-06-30 11:37:28 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:956639A9-2989-412C-8ECD-8055491DC522</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:E1359351-C74E-4A28-8C9F-2C60202AC39E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8648AFA6-90E3-4694-9036-FA71297EDFF7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:564FEFB4-6F3C-4EC5-83C4-F2B923D57CFC"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:141D5512-1FE5-4684-BAA6-CA59DA362006"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:438281C3-C647-40A0-876E-C7D2D5069693"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:720BFDB8-45DA-4138-A91C-A97DEA535F6A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:66084BA8-1CB4-456E-817A-27E19B84E73C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">27</pav:versionNumber>
    <pav:createdOn>2014-04-28 15:45:35 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:AC5F1BAD-8B6A-49DB-8147-AB1394EC169F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A32573A9-E320-478C-B4C9-72AD9BFC6D60"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:54722E3B-3E2D-4588-9273-0CAEB7A40EDB"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2CF4F791-1000-45A3-93CF-ACF0A6709ACE">
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdfs:label>Prodrug</rdfs:label>
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F44C82D4-AD38-4E0B-8A24-64DCDDEF9BBF">
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6A8CCA59-FFB8-48B8-8E0F-797519671DF1">
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdfs:label>Recommended</rdfs:label>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C22C69B4-13C5-4AEB-AC17-A4EC837664A0">
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:36FDCB4E-5E54-4CBA-BC44-04B836C019F0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D1D7D169-0E2B-45E3-A952-C352826FE500">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9261BA20-6306-4EC3-BE27-7705499B11D4">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8026784E-DC9A-4F18-963D-495E0532BB97">
    <rdfs:label>Clopidogrel</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AB20CF31-054E-4285-B7BA-A25704491DA8">
    <rdfs:label>ESR1, PGR</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:53864EAA-1CCE-403A-8033-F40243F0BB66">
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0B13BA6D-FAED-4224-BF7E-64E31E595AD6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>             </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>0B13BA6D-FAED-4224-BF7E-64E31E595AD6</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by:\n●\n     Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\n●\n     Genetic factors (CYP2C9 and VKORC1 genotypes).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0B13BA6D-FAED-4224-BF7E-64E31E595AD6"/>
    <pav:createdOn>2014-06-30 13:22:05 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7FADB4CA-581F-409D-A9DE-93A2AD35B45F">
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CD2860A2-9F69-4238-8D11-9B4606D54691">
    <poc:Comment>mixing terminology... positive and high/low for biomarker test results</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5F727C30-AB90-4303-A365-864EDED053D8">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1118944-CD8D-492D-A34A-6893C7DD7CF4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7681A333-BC11-48FC-823D-621F24823764">
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC44848F-712F-4F1C-BAFD-94EEC65ED24D">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:371CCDDE-6701-46A5-B84D-5ECAE73E3523">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.1alpha-050">
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <foafx:build>050</foafx:build>
    <foafx:version>2.1alpha</foafx:version>
    <foafx:homepage></foafx:homepage>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC3133B3-AD9F-4CEC-ABCF-7B9CA3E793EA">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F8216E2F-0352-4586-95B0-0AD50C30869C">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:10D9A112-25CB-425E-899B-C3AAA3CF633A">
    <ao:exact>If you are of Asian descent you may need a genetic blood test before you take Carbamazepine Extended-Release Capsules to see if you are at a higher risk for serious skin reactions with this medicine.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <domeo:uuid>10D9A112-25CB-425E-899B-C3AAA3CF633A</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-30 11:16:53 -0400</pav:createdOn>
    <ao:suffix> </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:10D9A112-25CB-425E-899B-C3AAA3CF633A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1FCB6C74-C406-41C1-8A44-C9D033D5834C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1FCB6C74-C406-41C1-8A44-C9D033D5834C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-23 14:36:55 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid>1FCB6C74-C406-41C1-8A44-C9D033D5834C</domeo:uuid>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <ao:prefix>HLA-B*5701-negative patients may develop a hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BDEED6AF-6C6D-44F0-8470-40D3A54778C5">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BC0C42BD-3C98-4864-9F9C-50F72712CEC9">
    <domeo:uuid>BC0C42BD-3C98-4864-9F9C-50F72712CEC9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BC0C42BD-3C98-4864-9F9C-50F72712CEC9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Phenotyping and genotyping methods are commercially available.  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <pav:createdOn>2014-06-30 12:04:35 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>The most common non-functional alleles associated with reduced levels of TPMT activity are TPMT*2, TPMT*3A and TPMT*3C. Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:913C60A2-43CE-4C57-A674-6B283C08A75E">
    <dct:description>The pharmacogenomic biomarker is not associated any clinically relevant pharmacokinetic with respect to the drug.</dct:description>
    <rdfs:label>Not Important</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:616A0715-5B79-4DD8-8392-1FDEF99E9911">
    <ao:exact>Patients taking ZIAGEN may have a serious allergic reaction (hypersensitivity reaction) that can cause death. Your risk of this allergic reaction is much higher if you have a gene variation called HLA-B*5701 than if you do not. Your doctor can determine with a blood test if you have this gene variation. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:616A0715-5B79-4DD8-8392-1FDEF99E9911"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:suffix> If you get a symptom from 2 or more of the following groups while taking ZIAGEN, call your doctor right away to determine if you should stop taking this medicine</ao:suffix>
    <pav:createdOn>2014-03-31 09:10:10 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:57C31E76-2CAB-44D8-BF63-BD3A403D8090">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1FAA2AB1-96D9-4225-A9E1-763F045EE2CD">
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4A5BB36A-D20C-4306-8958-609D3F9A13D0">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-03-22 22:06:02 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4A5BB36A-D20C-4306-8958-609D3F9A13D0"/>
    <ao:exact> NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>ZIAGEN is contraindicated in patients with previously demonstrated hypersensitivity to abacavir or any other component of the products.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8E5C0517-FC5F-4811-91F1-B52AE5D14B4F">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A4A66EEF-B4F6-4130-AF77-2C59D3213AA5">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:671F2493-9F0B-4BB9-94E6-4B432F418763">
    <ao:body rdf:resource="urn:linkedspls:uuid:98E9963D-2C0C-454B-A9DC-070814A6B531"/>
    <pav:previousVersion>urn:domeoserver:annotationset:1B4D7885-2831-422A-A480-44589A3632F7</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8E97872D-A5EA-4365-A1DA-DD1AFEB4FCE0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:ABB77F0A-DE6D-4F3D-87F3-CFA59807AA63"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E6148AE9-D3FF-43CD-B26E-1DDB165D61DD</pav:lineageUri>
    <pav:createdOn>2014-04-21 13:36:34 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:FC766D1F-0C5B-4C57-8386-30CC6B3408B5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">14</pav:versionNumber>
    <pav:lastSavedOn>2014-06-30 11:16:17 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF30CBA1-E27E-45AF-BF4D-A00797B55052"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:571A40A9-6C8A-4451-8D48-850DB2D15DDD"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:60208860-79EE-4EFA-BB03-9218CBD7E12F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6C8A8806-064F-4761-952B-0C28E16C7E92"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1694EBD6-F324-4F34-BF46-96811165F624">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55700EE9-88B8-49B7-BD64-1A87D99DCC15">
    <pav:lastSavedOn>2014-06-30 13:11:19 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:27FF0571-815C-48EE-8217-44C7CA977578"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:3A46F417-9109-42AC-B7E5-BB66778BB733</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:61BA8ACB-D63A-46FF-8B5D-79E9326A61A3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C0C19A25-A7A1-4DB0-AC0B-733F13D447FC"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-06-30 13:11:19 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:151DFA13-B2DF-4857-AAE9-51CADEC9A12F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:51D383C3-FE6E-4B78-9094-946EA250AE63"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1F456E39-8BAF-49DF-A9BC-B27C097C28A7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ABEE5CB7-ED0D-41AF-9E83-A2013E029601">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58D07047-AF21-4623-8E4E-4CB2945F5986">
    <domeo:belongsToSet>urn:domeoserver:annotationset:00E8CD81-460D-4060-A021-B8D8C71F86A1</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:4835A301-3D76-4808-B690-1E812E56166C"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:7FD03E69-B442-41B6-B8EB-38BD572E8F45"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:AAE4FFBF-9026-445A-8595-1E7CFB03644D"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1CEDA84C-14E2-4D8B-A754-750B7AAD033F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:208EC5EB-DF9F-4549-835B-D22F46813813"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:A696E3C2-ABF6-4D74-8862-D11D03E8A317"/>
    <pav:previousVersion>urn:domeoserver:annotationset:0245B556-8F27-41F6-93E5-E438E1E2BEC6</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:763ABA1D-A316-42DE-AA02-A7123411CD6C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:327B5301-12DD-4333-AF75-3141D1F104B9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-06-30 12:00:02 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:EF8CD2C6-A0E1-4347-BE88-A674C977C78D"/>
    <pav:createdOn>2014-06-09 15:47:23 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75A79304-2BD1-4F33-9391-4BB93929D4E6">
    <ao:body rdf:resource="urn:linkedspls:uuid:958C79FD-EC3C-4B05-84AC-164A4BF11722"/>
    <pav:lastSavedOn>2014-06-30 13:22:32 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-30 13:22:05 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:0B13BA6D-FAED-4224-BF7E-64E31E595AD6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D6C5A56-8085-48FE-B0EA-E439AEC8B746"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:4BCBEECE-3BEC-4460-9E86-B8C4CFA6608F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7DB7DA55-3D41-44AC-9585-F841B07B2CBD"/>
    <pav:previousVersion>urn:domeoserver:annotationset:A3776D92-8930-4618-9CD5-65A783FA0E71</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:C9CADF5C-CD94-4A8C-B6CF-12220ED65397"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:96ECABED-2877-4D78-8B9B-5349CE5119C0">
    <rdfs:label>Recommended</rdfs:label>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:08308CA2-E50D-41DB-873B-E57372B5FBDB">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Citalopram</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B209F2D-47BE-4267-B895-92D67A47AE61">
    <ao:body rdf:resource="urn:linkedspls:uuid:67993F55-3C23-4878-B0E4-0EF16AB56657"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2578ED0F-1456-4115-ABD2-3303381991FB"/>
    <pav:createdOn>2014-06-02 14:14:35 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">17</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:B50257B8-7562-4205-8805-682752312AB4</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7FD85CE9-994B-4E84-9DA8-1C07BDEC44AF"/>
    <pav:lastSavedOn>2014-06-30 11:50:02 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:E319F066-2C3E-4B8B-904F-5B682C614A92</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:6B1BA68C-A21B-49F1-8D31-5B808D766739"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:817AD388-46C0-4445-8DB6-0F338A24872D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4DD12842-1372-434A-AAAC-CF806F82DBB8"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0A52235-7692-496A-9DE2-B919FD0C2AC7</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:C5DDB9F7-C202-4F11-830A-22AC8C32D972"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:DEE1B9FD-09F4-4AD6-9BEB-55CF10F2FDDB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FCF99C56-B841-47D0-8AC5-0B5E9904C1C6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FF6CBD3F-A19F-4BC9-93F5-AC24A293075D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4F233EAC-B92F-417C-9A99-AE8B63C98A45"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:567C114E-1526-43CA-A424-9D04FDD6BFAB">
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:824575A2-38D4-4EBC-9991-4987B8CABF6E">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A46D79F-0482-4D27-B84A-FADD47B23284">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:855BF4FE-7082-466C-AEC2-BA37C5A2F93C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A1A364D-4605-4907-84D6-773AB8094C55">
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Prodrug</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F5C1D0C-9AFC-4B3A-83EC-AC9CB72FB0C9">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:9600B75E-4610-4889-BDFC-ECAB5CB72410"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5B91F78A-EEB0-41A3-8995-90B920D09520"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-06-30 11:50:02 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B706DB0A-7C1C-4FBB-A8FD-B044B8D2278F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:643D5630-A314-4EB0-86E3-0C32AA09CD16"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0A52235-7692-496A-9DE2-B919FD0C2AC7</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:37D8A15F-B81C-4D02-ACB8-420691E1AE81"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9C3F4619-C266-4C03-ACF8-B5180BDF384C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0DA8F1F1-00FB-4612-86F5-7F3B3E521995"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A640EA70-3185-419A-8CAB-67E0D6F126F2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B7F3E46-D643-4624-87F8-2CA5BF6054AA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">17</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:E319F066-2C3E-4B8B-904F-5B682C614A92</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:B50257B8-7562-4205-8805-682752312AB4</pav:previousVersion>
    <pav:createdOn>2014-06-02 14:16:25 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:EA1EC7B8-7DC1-4F77-8A25-9D3549FA41E4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:597854EB-61EA-471D-A012-21BF85F7B88D">
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DEE1B9FD-09F4-4AD6-9BEB-55CF10F2FDDB">
    <domeo:uuid>DEE1B9FD-09F4-4AD6-9BEB-55CF10F2FDDB</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Respiratory depression and death have occurred in children who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 [CYP2D6] or high morphine concentrations)</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DEE1B9FD-09F4-4AD6-9BEB-55CF10F2FDDB"/>
    <ao:suffix>. Deaths have also occurred in nursing infants who were exposed to high levels of morphine in breast milk because their mothers were ultra-rapid metabolizers of codeine </ao:suffix>
    <pav:createdOn>2014-06-30 11:49:40 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF5E88F5-B94D-48ED-B889-7EEE5AAC13C6">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4BED623F-9685-4D95-8EAD-FDE3617D193B">
    <ao:body rdf:resource="urn:linkedspls:uuid:A4216A9D-F032-421F-A904-D698F0AFF3D1"/>
    <pav:lineageUri>urn:domeoserver:annotation:E174DBD5-DF2F-4BC1-B3EC-756B3E8DD148</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-06-30 12:41:32 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:87B41003-CAA6-4329-8F8E-1B7CE3C8C785"/>
    <pav:lastSavedOn>2014-06-30 12:41:34 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:413F51D3-4F13-471E-85D1-A227CEDBF377"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0FDD7BA5-D168-490F-94C1-35D9C071D955"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:136CA05A-B32D-4CAF-B985-0FB9EF4F0455"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1DA28968-6C74-475E-AB4F-5E6E22DFF8BD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:8D30CB12-D87B-444B-A8CC-EE3BA6929B2D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FB3C226D-314F-473A-AA0D-98DCD192D7AF">
    <ao:body rdf:resource="urn:linkedspls:uuid:448D0EAF-27BF-49D5-8111-6984A1BB5502"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:239D0F43-DA9B-4ED8-A683-6BF29DB82241"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:25A77C80-E001-4AFE-9AB5-73749FB780F9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D7C73AD-5779-4EBD-A3A2-517775A82AEB"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:13F3B206-EA87-463E-9DA8-93AA056A9117"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:53BF920D-B37F-4CA4-BEB1-394C4948438A</pav:previousVersion>
    <pav:lastSavedOn>2014-06-23 14:34:21 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0299EF23-53A3-465D-BBC0-D798C9EC6E18"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6D6458DB-4B7A-4047-9A4E-854DB95439BF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C6B564A1-ECD5-4228-8E37-B298AE35DE9A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">37</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:4F3A0EB6-D824-48B6-9824-5CFC954EB8B7"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <pav:createdOn>2014-06-23 14:34:14 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B44F6619-C144-4D12-B575-BA96FED0BC7B">
    <poc:MedicalCondition>Hypersensitivity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE">
    <ao:item rdf:resource="urn:domeoclient:uuid:D62A1217-AE83-41D2-B678-FDCD04344D8B"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:E6578AA5-3295-46D7-B3F2-55CD3CFB5B0F"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:35B89AC4-DAE5-4207-B319-F9479AE77CDE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D3B78E07-8B27-4774-B221-CC47DAC8365E"/>
    <pav:lastSavedOn>2014-04-14 14:04:17 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <permissions:permissions rdf:nodeID="Na713f4159fa74743bdad29a749ba7fee"/>
    <pav:createdOn>2014-03-22 21:59:50 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:1924E2D5-9E52-46A8-925D-043869F8F777"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:47718F61-F7FA-4A83-BB17-C13189D5E884"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143044e90f26014518a19cf70063"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DF92C1E1-A223-4737-8028-06DD03B558D2"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:C37B19E6-A2FE-4CF4-9914-61A4EF8E7827"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FC7D109F-F404-4287-BE4A-D7C5AA057401"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5464F1B8-CF3D-4DA9-99F4-5F156C14CE70"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D5CF7A64-E07F-419A-8900-15F969F2D51F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B2CCF84A-A981-4564-8227-DE5688CB1FED"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE5D6919-6972-4689-B658-C5432A02F905"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5630014D-C820-4E31-A061-529A1A06548B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B752346E-6167-497D-B585-83983FA71DA2"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4BD531B7-C313-4175-81A7-D9BCA0951071</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:F5C240E5-0680-4CDA-ACC9-4DB8C5A0984B"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:C97CADE4-3861-4CB6-A21E-09BF0AEB1F88"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:5949C0ED-ECE8-4C36-B91D-8E58F7A36AAC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:51CDF79D-8F09-44DB-AE3B-91C93D13095C"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:86218E9C-9C50-4CF1-BDF5-7480485335DE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:89320F5F-262D-4657-8A52-4432EC0101F8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8B50CE5B-C2BB-4D97-838E-E1C2600020BC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE3C3FF6-F83D-47D2-8C4F-944687265F2B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4364906C-8414-403A-BB1D-1DDCC5F6A4DA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C1BF7FF6-707B-4750-BA47-274111148F96"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EE8AF84A-98F2-4EED-8B54-4312A50FBA31"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:524C3AB2-2955-4538-A46C-63CDD0BC11D2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EEA90F54-8E00-4B5E-B685-11848BFBA55A">
    <domeo:uuid>EEA90F54-8E00-4B5E-B685-11848BFBA55A</domeo:uuid>
    <ao:prefix>).</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EEA90F54-8E00-4B5E-B685-11848BFBA55A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> Numerous factors, alone or in combination, including changes in diet, medications, botanicals and genetic variations in the CYP2C9 and VKORC1 enzymes (seeCLINICAL PHARMACOLOGY,Pharmacogenomics) may influence the response of the patient to warfarin.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-30 13:17:54 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C808949D-5BD1-408B-BF95-40D480E14DDE">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CDE45635-21AB-4AC7-89FF-C772F3A15A2C">
    <pav:createdOn>2014-04-28 15:28:34 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:D79C039C-CEA6-4F1E-BD39-551E5EC30D17"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:47C06731-44B6-43B1-A393-9B723D8C46B5"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B58710C3-10FA-4324-B774-6BB2FF164982"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA9DB972-7500-4AC1-B7DF-126C0429537A"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:2185EE39-FD81-4C83-ABDF-E5D59B789F96"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A9EE2F08-2514-469A-87EC-1BEBC7BA954B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:FF67FF75-E560-4D2F-BDE0-15789AF13759"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">24</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:2D0B9A22-6129-4786-B0A4-7384B3324DF0"/>
    <pav:lastSavedOn>2014-06-30 11:33:55 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8E5C0517-FC5F-4811-91F1-B52AE5D14B4F"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4E001AB1-2305-4837-8AF8-180376395180</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F1F0B2C7-CD6B-47A1-8A2E-0C58AFF1C1AA">
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A6D763A6-26BF-4BA0-B4EB-60A2EDE685F6">
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:40B2A403-27A7-43FE-A0AC-5D87E3545981">
    <ao:context rdf:resource="urn:domeoclient:uuid:A1F7627F-2636-46AA-A344-F9978C2AA71C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF096FB6-D36E-43DE-9F79-DAD9217A8F6A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:58DF4FFA-C471-49E6-B1E7-F9AD44FF292D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:186E793B-79FA-44FB-8629-C2A8C0087C7C"/>
    <pav:createdOn>2014-06-30 13:15:04 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C9D34B80-736E-4124-B99A-5ADD357C4F8B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6D07FA7D-BE83-49F6-9169-78027B43EEA3"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E32A745-A354-4E89-B502-25D8192C980B"/>
    <pav:previousVersion>urn:domeoserver:annotationset:11D71C7C-D649-4A67-AA24-D0979BC16C5F</pav:previousVersion>
    <pav:lastSavedOn>2014-06-30 13:15:04 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:4C36F11A-E282-4BFB-849D-B93A233A50FB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2C7D68CA-AF82-4CD6-94A2-A51D70D09712">
    <ncit:Alleles>HLA-B*1502</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:98226070-C5AF-407A-B6D1-D521CD001163">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Prior to initiating Carbamazepine Extended-Release Capsule therapy, testing for HLA-B*1502 should be performed in patients with ancestry in populations in which HLA-B*1502 may be present. In deciding which patients to screen, the rates provided above for the prevalence of HLA-B*1502 may offer a rough guide, keeping in mind the limitations of these figures due to wide variability in rates even within ethnic groups, the difficulty in ascertaining ethnic ancestry, and the likelihood of mixed ancestry.</ao:exact>
    <ao:prefix>HLA-B*1502 is largely absent in individuals not of Asian origin (e.g., Caucasians, African-Americans, Hispanics, and Native Americans) . </ao:prefix>
    <domeo:uuid>98226070-C5AF-407A-B6D1-D521CD001163</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-30 11:09:18 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:98226070-C5AF-407A-B6D1-D521CD001163"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AE6AF907-607C-4B15-B108-FAD4D3010CA4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:977E5F5B-8852-45BE-A6FC-8DEB91191DED"/>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <pav:lastSavedOn>2014-06-23 14:40:56 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:ED198F67-8FAC-4F01-B6A5-79EF37E40269"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:567C114E-1526-43CA-A424-9D04FDD6BFAB"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-04-14 14:55:16 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F023FCCC-7096-430B-8BB2-66379ADF411E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5ED3EB82-A209-453F-8EBC-3338CD4BE633"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">44</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:81A89FD0-328F-42B9-9E97-F2ECC3D4D0E9</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:E76B18A1-DB9E-4F80-9F85-F68457DA227D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:410722E1-1877-490D-944A-22265E55A048"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:20E1A485-18B3-4C4F-82DA-B81AB694ED2D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:75D456DC-1DB0-4F96-A11F-551CC8425889"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:524C3AB2-2955-4538-A46C-63CDD0BC11D2">
    <ao:body rdf:resource="urn:linkedspls:uuid:1564A1CD-1DE3-44A9-B41C-23910512D5FC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4079A418-64B5-4D13-BEAA-79C2F16D8E58"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B8FB07F0-0211-45FC-B75C-FC0ED5802AAD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-03-22 22:03:47 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-22 22:03:57 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9EE83BC1-292A-4DC6-92A2-6BDA81A04501"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:4CFDD438-5250-4D24-9933-43397A6F2E0F"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:FB1D64ED-6852-4F82-BF48-6711B335904D"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5D85FB52-BA95-409A-8974-2E14C9527722"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A9EE2F08-2514-469A-87EC-1BEBC7BA954B">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2083D2DB-07EF-4969-A4BB-F5823A134875">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">28</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:445C56FC-3F37-4EDE-AD86-0E5B03A0BAF8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2AC31440-393B-42C4-BEF9-164B6631EF5B"/>
    <pav:lastSavedOn>2014-06-23 14:43:25 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9A365B9B-3FE9-4C17-AFDC-838F7A683714"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5B264A8F-827F-4546-BEC0-334B51ED1056"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:514D9B63-92BC-45AD-B61F-062FD65D8BF2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:50BC8289-8484-45F5-AF7C-591A9AC3A328"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:2BB0E9F3-52F1-4631-B37B-DBFB53B3B0C9"/>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:6EA97CB8-2121-4B3F-947B-32720F5EF6CB</pav:previousVersion>
    <pav:createdOn>2014-04-14 15:03:24 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:4D27D69B-2F63-4940-AD74-710454AA1E6A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B4BE2A8-5AB2-47D3-A46D-2D1D5E7AC42F">
    <ao:body rdf:resource="urn:linkedspls:uuid:D7469020-1B15-4E1B-884C-C23AB75DB446"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:990602A6-FB67-4288-B32D-B85635AF420D"/>
    <pav:lineageUri>urn:domeoserver:annotationset:77B5C0D4-B728-4F8B-B5B3-E3B3BE2E8C85</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:D0072C9A-B3D9-4846-8E25-33DCAD62CC03"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:87D0F0C2-6038-41AA-B84E-85497D292836"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:80201FA1-C475-48D5-9DD6-975B4F8DD33A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D1DA67AC-9434-4681-B83E-62E189DF97CF"/>
    <pav:previousVersion>urn:domeoserver:annotationset:058D76DA-65A8-4712-97E2-21D819BA162D</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-30 12:27:38 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:63302B4D-3943-432F-9962-94FC88216BF3"/>
    <pav:lastSavedOn>2014-06-30 12:27:40 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:4983978B-E3A3-4BE0-AB51-21C8B49B0EDA"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:CD2860A2-9F69-4238-8D11-9B4606D54691"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:29A5252E-79CA-41F6-BF34-26789C947F8D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:00E93A49-55CE-4990-8FAD-F248D724AC04">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>No gene symbol for protein S. Add a not there for the future.  Should we just remove this annotation</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:11AF6CFE-E78B-456E-BE42-3A1661B7118A">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:610138BB-C886-433C-A137-D8C9F0AE2C75">
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:98743D23-3B02-4029-840D-D16A4F390F95">
    <ao:body rdf:resource="urn:linkedspls:uuid:54942D51-2FE7-4151-873B-B7D21EF96C08"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:96B9ECF9-7144-4F27-A420-DB0B6C289CA9"/>
    <pav:createdOn>2014-04-14 14:45:02 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">42</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:6F2EA2D8-F158-41C8-A138-52E47C92AF0B"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:A578E5C2-C979-4E31-8142-42465213430D</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:54804CDF-87E3-4C5C-9C13-A18143DF3B86"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:C22C69B4-13C5-4AEB-AC17-A4EC837664A0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:45844BA9-29ED-4EC6-94C0-81C9883F880F"/>
    <pav:lastSavedOn>2014-06-23 14:38:58 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:54464D81-BD6C-480A-ACC6-9010609166A5"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:4019443F-CB02-40D7-BB18-37DDB00B1548"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:83AE278F-105A-4DE5-A541-EDB41878FEE9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0BEDE64D-11D3-4746-9532-E747F6A427E0">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0FDD8CC-36F0-4CD7-8BED-ACDCE33BE83C">
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdfs:label>Variant Frequency</rdfs:label>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E278366-F0F0-440E-9361-64770240555B">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8BF0E0C7-09D1-4AC8-A5E5-F4C0074AC435">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8E64225F-F6B0-40B1-B4DB-69CB3ADCCA82">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BC0A4D53-4B45-488A-8775-B46BF1E9B010">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:7681A333-BC11-48FC-823D-621F24823764"/>
    <pav:previousVersion>urn:domeoserver:annotationset:62355131-B3CD-4D53-A9E0-B1F52DABD85D</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:B88B8114-00C9-4EE1-B39D-A1B4B806C203"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:68DCA25B-DD2E-4D5B-95F4-195A31DA252C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <pav:lastSavedOn>2014-06-30 13:20:01 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-06-30 13:19:32 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D32E2B19-3891-4F8B-98F3-B65344B0F6A8"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:407F8565-3B9C-4CF8-B785-C8286BCD86A2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF6CAECE-87B0-44D5-8E9B-5D977FD17B16"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:CE130BB6-55F9-4A0A-BDB0-FFD4D080CBD6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FD392B67-F560-4A57-AD9C-4EA55954D3A1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D513D738-4472-4743-A187-3200479661B2">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e14304488c4b70144896f4a03000b">
    <foafx:name>Solomon</foafx:name>
    <foafx:homepage></foafx:homepage>
    <foafx:middlename></foafx:middlename>
    <foafx:title></foafx:title>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <foafx:firstname>Solomon</foafx:firstname>
    <foafx:lastname>Adams</foafx:lastname>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:email>soa18@pitt.edu</foafx:email>
    <rdfs:label>Solomon</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4F7F0EB3-F9C8-4AAE-BCD4-4A03CA215C14">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AB290A68-3247-40C6-9972-295B29412E87">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>toxicity, nursing, sleepiness, difficulty breastfeeding, breathing difficulties, limpness</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D76FC3C7-7CFD-4970-AA16-E0B4142CEA6A">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2F9CF447-9D4F-4E5C-9689-2FDCB70C37A1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9982EFEC-057D-47A7-8241-37ACB3F049AA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-23 14:26:18 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible</ao:exact>
    <domeo:uuid>9982EFEC-057D-47A7-8241-37ACB3F049AA</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9982EFEC-057D-47A7-8241-37ACB3F049AA"/>
    <ao:suffix>.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ABB77F0A-DE6D-4F3D-87F3-CFA59807AA63">
    <pav:createdOn>2014-06-30 11:16:17 -0400</pav:createdOn>
    <ao:suffix> Complete pretreatment blood c</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>For genetically at-risk patients [See WARNINGS], high-resolution 'HLA-B*1502 typing' is recommended. The test is positive if either one or two HLA-B*1502 alleles are detected and negative if no HLA-B*1502 alleles are detected.</ao:exact>
    <domeo:uuid>ABB77F0A-DE6D-4F3D-87F3-CFA59807AA63</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ABB77F0A-DE6D-4F3D-87F3-CFA59807AA63"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3A97A9BB-5FAA-48E8-960E-08933020FF0F">
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1BFD8F59-2C44-4309-B092-DC7D487CF6CB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4CFDD438-5250-4D24-9933-43397A6F2E0F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF342E5A-6B19-4100-B8EB-12EB7496C6EB">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FE6B2026-7838-44E7-9A96-E2BBB8C60F79">
    <rdfs:label>Variant Frequency</rdfs:label>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:961BA50E-515C-49B1-9E13-9A89032FBDD0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <rdfs:label>Recommend</rdfs:label>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E1359351-C74E-4A28-8C9F-2C60202AC39E">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Decreased Efficacy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DDD39BF8-E1D2-4288-BEDB-099F391E4009">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>add intermediate to dropdown</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EA4D8CB8-B8F8-4FBB-B8A9-1F499DD7A9C8">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C0C19A25-A7A1-4DB0-AC0B-733F13D447FC">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3AE8BFD1-C5F0-405A-AA64-8DF1B1E22071">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:38B0D49A-8B7C-4D71-B2CE-0388425D3B66">
    <pav:createdOn>2014-06-30 11:03:18 -0400</pav:createdOn>
    <ao:prefix>PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES.  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>38B0D49A-8B7C-4D71-B2CE-0388425D3B66</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:38B0D49A-8B7C-4D71-B2CE-0388425D3B66"/>
    <ao:exact>PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES UNLESS THE BENEFIT CLEARLY OUTWEIGHS THE RISK</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:403ED560-E6D3-4B1C-BAF1-DD0E0D87AA3F">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>403ED560-E6D3-4B1C-BAF1-DD0E0D87AA3F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-30 11:33:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:403ED560-E6D3-4B1C-BAF1-DD0E0D87AA3F"/>
    <ao:prefix>Poor metabolizers treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function.  (12.5) </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:exact>Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:121CDD92-5195-42C0-A613-F40D095DA06D">
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-04-21 12:45:02 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0FD58238-87B6-456F-8854-AE23F15B6EF1"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:DDD39BF8-E1D2-4288-BEDB-099F391E4009"/>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:74BDDF82-70E1-44A8-B130-17D04DE86798"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:875F6756-255E-43CC-8CA5-19D63561F59A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:69AED5D9-7A39-4908-932C-7553B3E13B24"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">17</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:FD773F35-854D-4F87-A80F-4F4782F991EC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1A38012F-D964-4164-A1A4-4A764255C6EE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F0FDD8CC-36F0-4CD7-8BED-ACDCE33BE83C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:867AB118-200E-4AFC-9BFB-E39692D1406F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:B53C3C52-0181-47FF-B094-122556B6B9D8</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:85E2D258-637C-4BA3-8639-3A9449CB6A79"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1077B919-51EA-47FD-823A-B432EA4D1829"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7EA25A65-2DD3-4F50-9FBC-7CAEB8962648">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52CEE330-B545-46E1-9B57-54C7396F53EF">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E779EFBF-EC27-464D-8896-1987AD0C64DB">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#66106-6 PHARMACOGENOMICS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>66106-6 PHARMACOGENOMICS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6C8A8806-064F-4761-952B-0C28E16C7E92">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:942BE2E4-F2DF-4734-B53E-6B0DCCD0A545">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>severe life-threatening myelotoxicity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E95F8BA7-9F3C-4C75-B657-5BDDDE255E17">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:169DB9DD-C966-431C-85FE-C3AC1F8E31D3">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60281E0C-D291-4163-9B6F-E83A4142CB8E">
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:6133C378-02D8-4301-B20A-9D2595AF1A04"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:72D8F9E8-4B4D-4FC2-81A2-A19C5BF05098"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:651C23D1-8C94-475A-999B-C44BD04331B9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:D727CBF5-9DC7-4B41-88A3-A9F0C7943BAF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA13F366-ED95-4FE2-95FF-E471EA29F211"/>
    <pav:previousVersion>urn:domeoserver:annotationset:5975F77C-3B5B-409B-9619-3ABC2AD31A28</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:B1E2F2DF-BA97-42E8-8BF9-70A85A763011"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2A14FC31-E82E-4B10-A2F4-D8F098563B2A"/>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:75D988CE-7527-421D-AAA6-0C9C0D4B30DF"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-04-21 12:25:24 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:D5483BE2-25AD-4265-9A40-3155983DEB22"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:82545F4A-39F9-48B3-A816-0B653AEF77CA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC17395A-7D36-45CC-BFB3-4271FD68383B">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D888391C-2CE3-4955-850C-C8FA6291737A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Citalopram steady state levels were not significantly different in poor metabolizers and extensive metabolizers of CYP2D6.</ao:exact>
    <domeo:uuid>D888391C-2CE3-4955-850C-C8FA6291737A</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D888391C-2CE3-4955-850C-C8FA6291737A"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-30 11:22:44 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1783DA94-68FD-4EE8-A616-0C6EFC8BF4AB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>VKORC1</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2C91610D-460B-40E8-B924-B09D6465F662">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:48E004DE-D237-4356-9685-3F49A3503C25">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:61B14255-647D-4AA2-83E5-B81256BF7A50">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9DDE5A30-59ED-49D7-B9B6-316245562477">
    <ao:body rdf:resource="urn:linkedspls:uuid:F37561CF-3DB7-4C0E-9AAF-1FB64D1D32C7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D70BC1ED-3697-423C-8725-02DBC445E312"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-04-28 15:20:04 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:20FD83E0-8F9F-409B-BA60-7D4A2F8A54AF"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:4E001AB1-2305-4837-8AF8-180376395180</pav:previousVersion>
    <pav:lastSavedOn>2014-06-30 11:33:55 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F6F47A9-4B77-44DC-9EC2-E73867EC5231"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:28576E2D-4BF3-4504-9083-578A2CB1EB0A"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B7B25E99-EE57-41AC-BDE2-45DCC1447471"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">24</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:302DE593-A3EE-4718-A421-A02E84C0A956"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:ED185C6D-0EC4-46D9-9192-DC5925A5D18B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BDDA7498-9665-4B25-9958-F37E05C7F491"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8BCA690B-96B0-4C8D-98E0-7BCECE8ACB28"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1DA28968-6C74-475E-AB4F-5E6E22DFF8BD">
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6C33C97-9A50-4F20-ADA2-11BED29A4BA6">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E6F327D5-6DEE-4EFB-8EC4-6E122CA71411">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#66106-6 PHARMACOGENOMICS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>66106-6 PHARMACOGENOMICS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8F43AB1F-C086-4AF5-AC19-E87F1E304346">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34092-7 CLINICAL STUDIES SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34092-7 CLINICAL STUDIES SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A32573A9-E320-478C-B4C9-72AD9BFC6D60">
    <dct:description>Referred to clinical trial</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:79C530FF-637A-43C8-AECE-CA81458FB5EE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The HLA-B*1502 allele has not been found to predict risk of less severe adverse cutaneous reactions from carbamazepine, such as anticonvulsant hypersensitivity syndrome or non-serious rash (maculopapular eruption [MPE])</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:79C530FF-637A-43C8-AECE-CA81458FB5EE"/>
    <ao:suffix>.</ao:suffix>
    <pav:createdOn>2014-06-30 11:11:07 -0400</pav:createdOn>
    <domeo:uuid>79C530FF-637A-43C8-AECE-CA81458FB5EE</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E7B4486A-24AB-4642-ADB0-B78FF5AF0E42">
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:78AFE987-8397-4F6B-BFB1-A215075C2797"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C6ED6B4D-6C7E-43B5-B650-F126750D08B0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:E8B220AF-2EA7-4429-BC11-4C7ECC9BFBE4"/>
    <pav:lastSavedOn>2014-06-30 11:47:15 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F997305F-4F06-4D67-9354-EE0AE3BED65C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3CFAD10E-67D2-46B9-9730-9136B4ADF59A"/>
    <pav:previousVersion>urn:domeoserver:annotationset:AF4D26A8-1226-474B-84F9-E6B3F8D83ABA</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:E319F066-2C3E-4B8B-904F-5B682C614A92</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1A89E704-ECDB-4495-8848-DB89566FFC2E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0A52235-7692-496A-9DE2-B919FD0C2AC7</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:16882C5F-4C53-4466-A9CC-FC6BCF5EEE08"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:305F92E4-6574-40E6-BDF9-5915C8679BEC"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:7C3837BB-DAF7-4544-9D2C-A63E2F406BAC"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A54E0819-D1CA-4418-838F-FA1698E5AB14"/>
    <pav:createdOn>2014-06-02 14:00:00 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F880CCED-A2A0-4330-B02F-070F7BF5AF00">
    <ao:body rdf:resource="urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:90D83A05-A7E7-4005-976B-C4210F7CA28D"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0A52235-7692-496A-9DE2-B919FD0C2AC7</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:A6637A8D-7411-4CF0-B3EC-0626D0565866</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:F2C1F1F7-17ED-4AE1-91F9-3A2EE9802A65"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E319F066-2C3E-4B8B-904F-5B682C614A92</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:4BCB8722-D18D-4573-863A-0106417F0E4B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7144B0C9-3D2F-4940-885E-C5510A56AB67"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0195CB09-02AC-47BF-A708-470D85342CEE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:9202A289-75A4-4A41-ADFA-9449DA718D24"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">16</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:22D57AAC-94C2-4570-A368-E1EA9EB21860"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A34F9A47-B7C3-4092-A86D-EE6977A46776"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EEF1E888-1159-48A3-9DAF-879DB61D6326"/>
    <pav:createdOn>2014-06-02 14:05:25 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E62D1169-48C0-4111-A664-6E935B2BE813"/>
    <pav:lastSavedOn>2014-06-30 11:48:13 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:1A0A0DFA-90BF-45A5-941C-4C791EE30F18"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5BA0362C-1EF8-4647-8A30-017F5378F48F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:prefix>ng codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. </ao:prefix>
    <pav:createdOn>2014-06-30 11:51:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> </ao:suffix>
    <domeo:uuid>5BA0362C-1EF8-4647-8A30-017F5378F48F</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5BA0362C-1EF8-4647-8A30-017F5378F48F"/>
    <ao:exact>Nursing mothers who are ultra-rapid metabolizers may also experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E95CB72B-266C-4522-BB11-260AD99D20A1">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:74693C6A-93CE-494A-B1A2-F02599BCD449">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>add drop down choice to tests</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2386BDBC-D4E5-43AD-9B96-93D7943C7169">
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:F15A9795-D0CF-4C37-B555-738D3D9E8913</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:08EFF9B8-EA16-426F-A773-9FEFAFB0A603"/>
    <pav:createdOn>2014-04-14 13:50:32 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:F54825B6-3CF9-4465-A4BE-7C6747734A6E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D90D2F8E-34C7-4183-919B-C6541F45FF51"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">34</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:B0DB01D5-CBF4-4F69-ACE4-596319DE386B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4E47853C-E984-40EF-88E5-116C7DE0A76D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F7349E9A-62A7-4DAD-838A-D499FB22C6F7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:86C39220-E4FB-4181-9F12-D824F141371B"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:B24A699D-7127-47C1-BFAE-C1ABB6819E2F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0A551B4E-FB8F-4083-BD23-A1C1B7F4ABCA"/>
    <pav:lastSavedOn>2014-06-23 14:25:28 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EB29F991-E821-40B7-BEDC-BCF13D7DBF99">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E5FBDB9C-E8A2-41BA-AB64-639E73F1343C">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:90E4AF52-01F4-4371-B3ED-D400FF8B1C1E">
    <pav:createdOn>2014-06-30 12:36:03 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:FE1B382B-9F39-4CAA-8A59-17376ED6F061"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:913560DA-801B-448D-BE32-CE773ADDBC84"/>
    <pav:previousVersion>urn:domeoserver:annotationset:7A99CBE7-D53A-4DB8-9A92-C3D451D28A0B</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:CF0F356A-4BD3-4AB3-80E4-DF7EF3CD5F00"/>
    <pav:lineageUri>urn:domeoserver:annotationset:77B5C0D4-B728-4F8B-B5B3-E3B3BE2E8C85</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:9E063046-0F94-45F2-80FD-A860D5215EB0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:FBE92D3D-0364-42A8-82BB-F97A84F672A1"/>
    <pav:lastSavedOn>2014-06-30 12:36:12 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:67993F55-3C23-4878-B0E4-0EF16AB56657">
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3551AA94-D2DA-4524-BEF2-972A5666C00A">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>VKORC1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:855697DF-EBFA-4343-B2F2-023B6F284D48">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5AA1F3D7-DA5F-4139-AD64-27615B483059">
    <sio:SIO_000111>34071-1 WARNINGS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34071-1 WARNINGS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E62019E-3BAC-4750-881C-C4BCBD5FAB71">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:913560DA-801B-448D-BE32-CE773ADDBC84">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Not necessary</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-necessary</poc:TestRecommendation>
    <dct:description>Testing related to the pharmacogenomic biomarker is not necessary.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CBFF7BA1-E3EB-4A35-A0F4-FEA5E336D101">
    <rdfs:label>intermediate-activity</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#intermediate-activity</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:388DE174-1DEA-4AC5-9B06-83813521DCB6">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F4ED235-6F4A-4BDD-A23F-6F2D9FC7A396">
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E335D7C-51C5-4E67-AC27-CE657E471F60"/>
    <pav:lastSavedOn>2014-06-30 11:51:20 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:252018F1-DCA7-4F09-8904-5145010C0308"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FDC6F95B-339C-4DB3-AD3D-ED2779DF97AC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E319F066-2C3E-4B8B-904F-5B682C614A92</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:6FC50BDC-78A6-4D50-8D6E-7FEB6DAFF0E2"/>
    <pav:previousVersion>urn:domeoserver:annotationset:A8A0399E-FEFC-4AFE-AE32-4D1FD846E003</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">19</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:19CB40E5-55B0-4DB4-96AF-609585C45AB3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:99D32DEA-1DC0-471A-B15D-40992DFDA3E1"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0A52235-7692-496A-9DE2-B919FD0C2AC7</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F60046CD-7564-4322-876C-5299CB62C633"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC492FDD-E07F-4334-BB62-1224B3D73215"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3EB27716-2423-4BFA-B0F0-C5B6D824F956"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7418F8FB-E11B-4F6A-946C-8B25C6E6F9DB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:772D1C25-7E9B-4E85-ADB4-BF14E6BF7323"/>
    <pav:createdOn>2014-06-02 14:28:28 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B204F8D-D877-4A83-AC45-1321ACDCBBFF">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:207BA609-3844-44A9-98B4-E6695EA86595">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DAAE6973-853E-4988-8DD1-71C285B27E2E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:54464D81-BD6C-480A-ACC6-9010609166A5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A9F54207-3103-439F-9F37-B7A36B3C8C5F">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A903F38F-38D4-4052-A673-7FF19407E3DB">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02">
    <rdfs:label>Aripiprazole</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01238</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:71B4E351-9545-4BDB-AC93-670DEC3E5644">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74B97B42-8CF1-41BB-84AD-CF0995E7508C">
    <ao:exact>One additional randomized study (NATO) demonstrated improved disease-free survival for tamoxifen compared to no adjuvant therapy following total mastectomy and axillary dissection in postmenopausal women with axillary node-negative breast cancer. In this study, the benefits of tamoxifen appeared to be independent of estrogen receptor status.</ao:exact>
    <pav:createdOn>2014-06-30 12:29:04 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:74B97B42-8CF1-41BB-84AD-CF0995E7508C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>on, axillary dissection, and breast radiation). After 5 years of treatment, there was a significant improvement in disease-free survival in women receiving tamoxifen. This benefit was apparent both in women under age 50 and in women at or beyond age 50. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <domeo:uuid>74B97B42-8CF1-41BB-84AD-CF0995E7508C</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BCC8E4C0-518C-4CB7-86BA-64CE75086359">
    <pav:createdOn>2014-06-30 11:59:06 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BCC8E4C0-518C-4CB7-86BA-64CE75086359"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:exact>Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy </ao:suffix>
    <domeo:uuid>BCC8E4C0-518C-4CB7-86BA-64CE75086359</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FD392B67-F560-4A57-AD9C-4EA55954D3A1">
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-monitoring-strategy</poc:MonitoringRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Change monitoring strategy</rdfs:label>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <dct:description>A strategy changed monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:97C0B757-E6B8-4479-A84D-2083D8FB6CB5">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>VKORC1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B91F78A-EEB0-41A3-8995-90B920D09520">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5B91F78A-EEB0-41A3-8995-90B920D09520"/>
    <ao:prefix>. </ao:prefix>
    <ao:exact>Deaths have also occurred in nursing infants who were exposed to high levels of morphine in breast milk because their mothers were ultra-rapid metabolizers of codeine </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>5B91F78A-EEB0-41A3-8995-90B920D09520</domeo:uuid>
    <pav:createdOn>2014-06-30 11:50:03 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:09071EE6-03DB-49CA-BA67-1589B0E2FDBD">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Letrozole</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1dda9f31d4cb49e087349463088824e9">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:151DFA13-B2DF-4857-AAE9-51CADEC9A12F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7CE2D02E-F446-465D-9CBE-27C213ACCC89">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clopidogrel</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A2121F35-BD9F-4B1B-84CA-327F0300B590">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D2F53974-B796-40CB-96DB-17B918867DA6">
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B4D69718-1E39-448F-9056-D5C7E8C902E3">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34092-7 CLINICAL STUDIES SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34092-7 CLINICAL STUDIES SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:84C9C2FD-017F-43C7-AD66-35BE4F24C7CC">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Do not restart</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2D7FD036-EB64-4C5A-B838-B9A9C1CF132B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF30CBA1-E27E-45AF-BF4D-A00797B55052">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Recommend</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:306BB501-1412-442C-97E0-18E5341107D5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:88CE2DCE-C910-4D43-8410-F1CD5C2E0A07">
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>CYP2C19*1 </ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FCF99C56-B841-47D0-8AC5-0B5E9904C1C6">
    <poc:Comment>multiple copies of gene in allele section?</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:67AF0D11-13BE-4E8C-A78E-337527148480">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2F4146E2-F264-4965-8410-02C26DF7C9B4">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EBA440A2-4EF9-40CD-89BF-56AB858385E6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-30 13:09:12 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EBA440A2-4EF9-40CD-89BF-56AB858385E6"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G&gt;A allele) have been associated with lower dose requirements for warfarin. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been reported in Asian patients.</ao:exact>
    <domeo:uuid>EBA440A2-4EF9-40CD-89BF-56AB858385E6</domeo:uuid>
    <ao:prefix>Warfarin reduces the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle, through inhibition of vitamin K epoxide reductase (VKOR), a multiprotein enzyme complex. </ao:prefix>
    <ao:suffix>6,7</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EA1EC7B8-7DC1-4F77-8A25-9D3549FA41E4">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:863F2BBA-B74C-425F-B4F3-D4BEF5E1873C">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34071-1 WARNINGS SECTION</poc:productLabelSection>
    <sio:SIO_000111>34071-1 WARNINGS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DD2106EC-5F5D-4D09-997E-D0A744AA1320">
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B74A738-1124-4DAC-BE25-F15C78CFBA15">
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:exact> Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.</ao:exact>
    <ao:prefix>In any patient treated with abacavir, the clinical diagnosis of hypersensitivity reaction must remain the basis of clinical decision-making.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-31 09:05:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8B74A738-1124-4DAC-BE25-F15C78CFBA15"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9BD38C7E-B2D9-4C83-903C-F86556F46EF2">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Letrozole</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC7D109F-F404-4287-BE4A-D7C5AA057401">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:237CBF43-3113-4746-AC7C-0EEE2CD7D926"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2D2BFB3C-0E2A-4B9E-B9CC-2D21C8035D95"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9949892E-EB19-49D8-A737-FAF19F57740B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:508FAE65-0963-4DF7-9CCD-11FAFAEDDD84"/>
    <pav:createdOn>2014-03-31 08:58:47 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:BE588D93-C0EC-4E98-AC83-D151CAD07967"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:44E81086-BA17-4D23-BE19-3D545D7F1B9D"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:2D7FD036-EB64-4C5A-B838-B9A9C1CF132B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:E56B19ED-CC69-40EB-B68A-25F7DB5534A9</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lastSavedOn>2014-03-31 09:06:26 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3CFAD10E-67D2-46B9-9730-9136B4ADF59A">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59E6E4F8-DCB3-4875-86B2-D5885FD80EF7">
    <ao:body rdf:resource="urn:linkedspls:uuid:86366FDE-6665-48F6-BFB3-E95DBF8A1B2A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C8A8CA34-A4B7-4562-9D58-56B6AB8DA2C1"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:F60E7B3E-BED2-415D-AAA3-254E37102FF3</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:47E42AB9-D62B-4972-88FA-874C49292C39"/>
    <pav:lastSavedOn>2014-06-30 11:03:19 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:726A2BFA-10F1-41C0-86B0-38F74B394C11"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7851F628-A8CC-4FA9-A06C-032AC7CF9470"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E6148AE9-D3FF-43CD-B26E-1DDB165D61DD</pav:lineageUri>
    <pav:createdOn>2014-04-21 13:19:11 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:C2A76A18-A463-4D7B-9A00-33BEFE84F768"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:38B0D49A-8B7C-4D71-B2CE-0388425D3B66"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8E97872D-A5EA-4365-A1DA-DD1AFEB4FCE0</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8542DCD4-98AF-4508-A038-FFFE27F30205">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8BEEBA62-C519-4421-9038-113DCDFC9B2C">
    <ao:prefix> </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction.</ao:exact>
    <pav:createdOn>2014-03-22 22:09:39 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8BEEBA62-C519-4421-9038-113DCDFC9B2C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and shoul</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0ED7B264-E15A-44A2-9037-2D21B5180CD2">
    <ao:exact>If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of ZIAGEN.</ao:exact>
    <domeo:uuid>0ED7B264-E15A-44A2-9037-2D21B5180CD2</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>tivity reaction, and if reinitiation of ZIAGEN or any other abacavir-containing product is under consideration, carefully evaluate the reason for discontinuation of ZIAGEN to ensure that the patient did not have symptoms of a hypersensitivity reaction.  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0ED7B264-E15A-44A2-9037-2D21B5180CD2"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-06-23 14:38:12 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D56FB9CC-BBC3-4126-B302-EEAE31038A57">
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1A89E704-ECDB-4495-8848-DB89566FFC2E">
    <ao:suffix>(5.1</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:exact>\nRisk of death in ultra-rapid metabolizers: Conversion of codeine into its active metabolite, morphine, may occur more rapidly and completely resulting in higher than expected morphine levels and respiratory depression or death. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1A89E704-ECDB-4495-8848-DB89566FFC2E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>•</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>1A89E704-ECDB-4495-8848-DB89566FFC2E</domeo:uuid>
    <pav:createdOn>2014-06-30 11:45:41 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0AB99582-A22B-403F-9604-C35A9897CE91">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>0AB99582-A22B-403F-9604-C35A9897CE91</domeo:uuid>
    <ao:prefix>CLINICAL PHARMACOLOGY and PRECAUTIONS ). </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-30 13:23:21 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0AB99582-A22B-403F-9604-C35A9897CE91"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose. Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:56D95EC4-D0D7-4BD6-B13C-E145F6A4E568">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FB1D64ED-6852-4F82-BF48-6711B335904D">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E335D7C-51C5-4E67-AC27-CE657E471F60">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F60046CD-7564-4322-876C-5299CB62C633">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D5D3473-95BD-41AF-81E6-ED19E81798E9">
    <ao:body rdf:resource="urn:linkedspls:uuid:EC203AB9-CA2F-419B-BE90-A6A446A9CFDB"/>
    <pav:lastSavedOn>2014-06-23 14:23:27 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:ACFB40D4-2EF4-455C-A6CF-EF07C399FC84"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC70D092-5124-4A5C-87C3-EA34E4868C05"/>
    <pav:createdOn>2014-04-14 13:44:33 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:6E7BEB44-17B2-4A01-8866-7DAFBEA17CC6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">33</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:17653AA9-221B-4AF9-AED7-70A7913F95CD"/>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:C81648BE-BB1C-4670-B054-AE1D1A22A750</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:0BD57EF4-2E6F-48B7-8271-71B10D257BF0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5CC24F40-EC89-4944-ACB6-F5BE5D10EFDB"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E551C77D-FE61-44B9-BE13-7035B99454EF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A1A913E5-A4E1-43F0-947A-234CE74877D4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:396CB021-3C85-4E20-B020-3714CE558E2D">
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:21696431-95DF-4AEB-A7A1-D4F7E7AE1525">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2EDDDF15-34C4-4321-9EF6-7ACDEBEFD237">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:C6702551-6F18-47F3-B973-CEA4BD6F762E"/>
    <pav:lastSavedOn>2014-06-23 14:35:28 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:055AAAC1-3544-4B8E-BF06-C99328A12B6E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8223C7A7-BA49-4A69-9875-2C592713916E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <pav:createdOn>2014-04-14 14:23:14 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:50D99A83-E2FD-49AC-B6AB-60C0E1E0DF6B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DD3DEA1B-6E10-43EF-A6FE-6549093794BB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EEFA4748-7743-472C-B1E4-21C215670F07"/>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">38</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:5E658F22-7747-4F77-81BF-1746670B4B64</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:A1118944-CD8D-492D-A34A-6893C7DD7CF4"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0496C268-8D3F-4D44-95D9-8D7250579EBE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72D8F9E8-4B4D-4FC2-81A2-A19C5BF05098">
    <pav:createdOn>2014-06-30 12:03:44 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:72D8F9E8-4B4D-4FC2-81A2-A19C5BF05098"/>
    <domeo:uuid>72D8F9E8-4B4D-4FC2-81A2-A19C5BF05098</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:exact>Patients with intermediate TPMT activity may be at increased risk of myelotoxicity if receiving conventional doses of azathioprine tablets.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F8624524-9CEA-4109-AD60-7041876D4E8C">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4C6A2A40-EB7B-43F7-8E2F-DA2AEAFB7030">
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:38CB7B79-EA55-443D-8F52-A694D541E5E3">
    <ao:exact>NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status</ao:exact>
    <ao:prefix>ZIAGEN is contraindicated in patients with previously demonstrated hypersensitivity to abacavir or any other component of the products.  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:38CB7B79-EA55-443D-8F52-A694D541E5E3"/>
    <domeo:uuid>38CB7B79-EA55-443D-8F52-A694D541E5E3</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-23 14:32:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FE990D63-4739-43A5-B062-7A946346B2AF">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:657DCC6E-580E-4775-A090-F145328680B3">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34092-7 CLINICAL STUDIES SECTION</poc:productLabelSection>
    <sio:SIO_000111>34092-7 CLINICAL STUDIES SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9837A225-376D-44A6-959D-05A7DCB03CCE">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:186E793B-79FA-44FB-8629-C2A8C0087C7C">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34071-1 WARNINGS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34071-1 WARNINGS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DEBF47D7-AFD5-41BE-B3B0-C7BACDF7D8A7">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B030FC79-83F8-4FDB-B7CC-7AA176B54243">
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5AB14F2B-DF42-42DD-A33F-63DB4F3769D1">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F9269665-A463-462D-91AE-C30A34300D28">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D2A8C2D7-9A3E-4307-BC2B-4EA4FC30E8A5">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F9A528AF-AAD1-4EF0-A22A-22A6A4B9650C">
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:81FC4ABF-FFA6-4A93-A74E-A025DFD17C00">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:866BF777-5920-4698-B1A9-093E0CE2D75A">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#extensive-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>extensive-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E8E29A4A-3D14-4F45-BCE2-FE6490057A38">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>respiratory depression, extreme sleepiness, confusion, shallow breathing, tonsillectomy, adenoidectomy, obstructive sleep apnea, death</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14099187-A7EA-4F77-905D-B1B942FF80D7">
    <ao:suffix> Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this oc</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-03-22 22:01:09 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:14099187-A7EA-4F77-905D-B1B942FF80D7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:99AB6350-6929-4C24-B144-7B97EBF09B3F">
    <ao:context rdf:resource="urn:domeoclient:uuid:6347DAEC-6E58-45D7-9A9D-16BE602F4930"/>
    <pav:lastSavedOn>2014-06-23 14:35:28 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3AAC0EBB-C224-465A-B843-D37FD8017876"/>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:3D225325-6881-4075-B90F-BA7C163EF10B"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-04-14 14:20:44 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:5E658F22-7747-4F77-81BF-1746670B4B64</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:4CED47B0-38B1-4BA9-872C-2F35C0387D71"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6A7BDA4E-7AB8-4FE1-9B04-B1133604AD33"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:18FBB200-8A2C-4513-9ACB-0E279C528A07"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:F927F2EB-CF06-484F-BF67-71173603066C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E31DDBE1-AD48-4EBD-918C-656A862E759A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F270E3B3-9983-425D-98FB-66F62E36340F"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">38</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:87B38612-F6A1-489D-A3E7-570F6B558C2E">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1042FEEA-5AF3-4E50-B2A1-053451F2236C">
    <ao:body rdf:resource="urn:linkedspls:uuid:F742088C-CD87-493E-B7A6-530F13F928D9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9CD7BCA7-7CF1-485D-B3B8-FD33BDCEFC1E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:84AD1BC2-1109-4576-B08B-E7498F17C3FE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">24</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:681E31E7-86DA-4658-959F-D62DF4BED37D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <pav:createdOn>2014-04-28 15:26:56 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F0330EA2-4FF0-4F48-B85F-51C143A089A8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:61B14255-647D-4AA2-83E5-B81256BF7A50"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2CCDC094-75F1-4A14-8D04-0867D3AF24F4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:32A9DB60-B29A-4DDE-9C14-7F018F0728CA"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:E4117315-0729-44F2-9C60-6A4046880608"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4E001AB1-2305-4837-8AF8-180376395180</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:D5C1D543-12A2-4AD2-973F-CFDA436726C9"/>
    <pav:lastSavedOn>2014-06-30 11:33:55 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3A3DC545-AC9E-4758-9E22-3FFE71F505E6">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:653A3DFC-DFC7-42ED-8D6E-BC5AE5F3E730">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:867AF76D-D05F-409E-BE4E-FAF00531D85B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34067-9 INDICATIONS AND USAGE SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34067-9 INDICATIONS AND USAGE SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D92166A3-0B32-4545-B4CA-719FEDAF410D">
    <ao:exact>Tests are available to determine a patient’s CYP2C19 genotype.</ao:exact>
    <ao:suffix>  </ao:suffix>
    <domeo:uuid>D92166A3-0B32-4545-B4CA-719FEDAF410D</domeo:uuid>
    <pav:createdOn>2014-06-30 11:36:39 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D92166A3-0B32-4545-B4CA-719FEDAF410D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D96A1388-0825-4599-962A-23D155BF20E1">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9C843591-806D-42E0-88A9-58DC59076B3D">
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A95A5108-B963-46F5-8C52-A24452946316">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>66106-6 PHARMACOGENOMICS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#66106-6 PHARMACOGENOMICS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17F4FC04-A894-4AE5-B819-04A114687F45">
    <poc:Comment>add to drop down; alleles necessary?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:48A1E6BD-969F-4E11-B89E-72FDEF815354">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34092-7 CLINICAL STUDIES SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34092-7 CLINICAL STUDIES SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:61549475-56A3-499A-8BDC-5B228AB88444">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7FE72C92-E6F3-4CFF-BC00-E77CE4051FA1">
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:61CB1288-5910-49B6-BD6B-6D9969B20C6B">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7FDE7EC5-68D1-4D11-A164-0B2DA9D73292">
    <pav:lastSavedOn>2014-06-30 12:49:25 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:481D46BB-D4FB-4587-B147-C2FC166A7A51"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:194FD718-B3CA-4D25-B3D2-56D36C1ECB60"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:867BDD21-2583-4787-AEF1-32C615BE5AE1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B230E58-95D9-46A9-A29D-9E6B4FC1F375"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:25C49718-6AE6-438C-9388-8CDE7669E406"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:239C53D0-DD62-4205-BB17-26E9C873641F"/>
    <pav:createdOn>2014-06-30 12:49:25 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D4B543B9-2CFB-4DD5-866F-75375A4F94EA">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D4015F92-6E92-4747-8C53-576B05F5F8DD">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2B18C74E-C402-4DA6-A980-C0CD8AB6866C">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:74942373-FA09-4BCE-8D7C-94D0B41F258F">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Increase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B24A699D-7127-47C1-BFAE-C1ABB6819E2F">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA417E62-D7D9-4F45-8359-10CCF8D13F90">
    <pav:createdOn>2014-06-30 13:09:12 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:EBA440A2-4EF9-40CD-89BF-56AB858385E6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1783DA94-68FD-4EE8-A616-0C6EFC8BF4AB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9748F74E-EF35-4AA4-817B-07FED6D50359"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C90E4AC5-84C6-4CF0-8B91-76FB986FF69B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:5F8131DC-9505-49D1-BF90-FE6E3DEDF87C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-30 13:09:12 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3551AA94-D2DA-4524-BEF2-972A5666C00A"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:513B504A-3874-479B-A6D5-DF0C6411DEDD</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:2446A882-2020-42F8-AD24-FE3B4F839958"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9FEAD25C-8497-4E5F-AC0F-D9B37282619E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0C61F885-2CC4-4FD5-8D20-539146E86B02"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D4F7410C-1DFB-4286-B219-984A8005A9DA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E1161E82-9339-49AD-AAC4-F58471BF51EA">
    <rdfs:label>Do not restart</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4048B9B2-554D-4559-93F6-672B118A87D0">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1BF7FF6-707B-4750-BA47-274111148F96">
    <ao:body rdf:resource="urn:linkedspls:uuid:D513D738-4472-4743-A187-3200479661B2"/>
    <pav:lastSavedOn>2014-03-22 22:15:15 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:BCCF3F22-38AE-4F01-87D0-22C1B07EC947"/>
    <pav:createdOn>2014-03-22 22:14:34 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:009DEEE9-9289-445E-8C79-81457BE96692"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:8542DCD4-98AF-4508-A038-FFFE27F30205"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:7F54C376-30A1-41D7-8621-445FDA308DB9"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4157B9C9-C9C5-4812-8433-5DE9EDAC7F15</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:55B89580-2E0A-4A7D-B09D-AFAF8BF0A3CC"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:207BA609-3844-44A9-98B4-E6695EA86595"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FB9019FF-0075-4223-97CD-9869E977448D">
    <rdfs:label>VKORC1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:47E42AB9-D62B-4972-88FA-874C49292C39">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A1F7627F-2636-46AA-A344-F9978C2AA71C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Inherited resistance to activated protein C has been described in many patients with venous thromboembolic disorders but has not yet been evaluated as a risk factor for tissue necrosis. The risk associated with these conditions, both for recurrent throm</ao:suffix>
    <pav:createdOn>2014-06-30 13:15:04 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. Not all patients with these conditions develop necrosis, and tissue necrosis occurs in patients without these deficiencies.</ao:exact>
    <domeo:uuid>A1F7627F-2636-46AA-A344-F9978C2AA71C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A1F7627F-2636-46AA-A344-F9978C2AA71C"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5BF25FD8-2729-4DCC-801E-315EEA82F89B">
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9D056A46-E560-4D06-B8BC-6316B8B51BDD">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0BD57EF4-2E6F-48B7-8271-71B10D257BF0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1A38012F-D964-4164-A1A4-4A764255C6EE">
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0B7C43C-792D-49E5-B282-D2303F858889">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:79A9C552-B02F-4A1B-8528-B0341E6E516C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>CYP2D6*1/*1xN, CYP2D6*1/*2xN</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1F456E39-8BAF-49DF-A9BC-B27C097C28A7">
    <sio:SIO_000111>66106-6 PHARMACOGENOMICS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#66106-6 PHARMACOGENOMICS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D1D85749-709E-4FD8-A464-C8E7CD8158BB">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Citalopram</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9CE888B2-376C-4C40-BC8C-90A37F6C59F4">
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E34142C5-1680-4612-AC76-D96D8F82364F">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:D6599990-20BF-48F3-9D6E-1815B4DEFF78"/>
    <pav:createdOn>2014-04-14 13:45:50 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-06-23 14:25:28 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:60CFE292-6834-41FC-8255-B81A3D584EE2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F44C82D4-AD38-4E0B-8A24-64DCDDEF9BBF"/>
    <pav:previousVersion>urn:domeoserver:annotationset:F15A9795-D0CF-4C37-B555-738D3D9E8913</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:4C94607D-BB71-41F7-9180-1A759D259286"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">34</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:402D9368-C611-4289-8004-8EEC1A409CCF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:94034230-6BB4-4506-9F59-AF9B5EB1CBD3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CBE4CA75-F135-4D74-8FE0-D90DC7F9F1C8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:B274FA34-1FDE-4C0F-B804-AA8276573C83"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DEBF47D7-AFD5-41BE-B3B0-C7BACDF7D8A7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ABC34EDB-BF59-4E20-8274-F896596AEA01">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clinical Trial</rdfs:label>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D65CE270-4D80-4B9B-824A-BD5403AE0B20">
    <rdfs:label>Decreased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-decreased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an decreased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EED39F7C-032A-4628-9022-2253559E7FEE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C2B58FFF-334C-4A84-A26C-C674C26B1F42"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:81A89FD0-328F-42B9-9E97-F2ECC3D4D0E9</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:028082D6-59BF-44E8-9117-CC155DA8D008"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DAD6A4A1-3C31-49E3-8C6D-C1CA02D6FDC5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7347D856-B9EA-455B-AFC8-9047DC8B5198"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:96ECABED-2877-4D78-8B9B-5349CE5119C0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:169DB9DD-C966-431C-85FE-C3AC1F8E31D3"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-04-14 14:54:36 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F6C33C97-9A50-4F20-ADA2-11BED29A4BA6"/>
    <pav:lastSavedOn>2014-06-23 14:40:56 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E358C12A-EA54-4BBC-B289-833D4ED09D04"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">44</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:AB84AE09-1714-467B-BBDC-93DAA3B339A9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:037A2873-CACE-474F-B3EB-1EF6E0A58FCF">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>sitivity reaction, and if reinitiation of ZIAGEN or any other abacavir-containing product is under consideration, carefully evaluate the reason for discontinuation of ZIAGEN to ensure that the patient did not have symptoms of a hypersensitivity reaction.</ao:prefix>
    <ao:exact> If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of ZIAGEN.</ao:exact>
    <pav:createdOn>2014-03-22 22:18:30 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:037A2873-CACE-474F-B3EB-1EF6E0A58FCF"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A572B29E-DA06-4D69-9DBD-1D5AA92BBB2C">
    <rdfs:label>Recommend</rdfs:label>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E719DBCC-60BF-47C9-A2A6-B5AD564ED472">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Letrozole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:356045E2-590C-4AD5-BBE5-F7B03197C94A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:931F0B8F-C8A6-44A1-8713-51ECF3BB19BB">
    <dct:description>Referred to Prodrug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0EA10D1-D8AA-4606-8CBC-23FA4F5245B5">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>blood transfusions, abnormal CBC results</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F7D9EE5F-E5C0-4296-9825-534C2F768855">
    <domeo:uuid>F7D9EE5F-E5C0-4296-9825-534C2F768855</domeo:uuid>
    <ao:suffix>Two large randomized, controll</ao:suffix>
    <ao:exact>Letrozole tablets was initially studied at doses of 0.1 mg to 5.0 mg daily in six non-comparative Phase I/II trials in 181 postmenopausal estrogen/progesterone receptor positive or unknown advanced breast cancer patients previously treated with at least antiestrogen therapy. Patients had received other hormonal therapies and also may have received cytotoxic therapy. Eight (20%) of forty patients treated with letrozole tablets 2.5 mg daily in Phase I/II trials achieved an objective tumor response (complete or partial response).</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-30 12:02:38 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F7D9EE5F-E5C0-4296-9825-534C2F768855"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:36230084-C9BE-4A01-BF7F-72D2DA64F5FB">
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7FD03E69-B442-41B6-B8EB-38BD572E8F45">
    <domeo:uuid>7FD03E69-B442-41B6-B8EB-38BD572E8F45</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:exact>Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents). These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women.</ao:exact>
    <ao:prefix>The growth of some cancers of the breast is stimulated or maintained by estrogens. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7FD03E69-B442-41B6-B8EB-38BD572E8F45"/>
    <pav:createdOn>2014-06-30 12:00:01 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4663B6D5-B11D-4039-8F32-F7E3BFC2537E">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:53541A7F-ACF6-4030-A4B7-7BA865CDF82F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:732B9DAF-16BA-4DEF-9F6F-33E30E2CCDA7">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0C960F76-C1CF-449E-B404-68D80C32B1A2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E1199968-6650-4D2A-A5E4-EDFBFE7733AE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E1199968-6650-4D2A-A5E4-EDFBFE7733AE"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>The citalopram dose should be limited in certain populations.  </ao:prefix>
    <ao:exact>The maximum dose should be limited to 20 mg/day in patients who are CYP2C19 poor metabolizers or those patients who may be taking concomitant cimetidine or another CYP2C19 inhibitor, since higher citalopram exposures would be expected.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <pav:createdOn>2014-04-28 15:59:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8B7D130A-7127-4E83-93AB-ADD452D00721">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <rdfs:label>Recommend</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:305F92E4-6574-40E6-BDF9-5915C8679BEC">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>death, respiratory depression</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F5898051-49D9-42F0-B014-0C533E59B4F5">
    <ncit:Alleles>HLA-B*1502</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:08EFF9B8-EA16-426F-A773-9FEFAFB0A603">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:990602A6-FB67-4288-B32D-B85635AF420D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D03D6753-24D2-4897-9947-4D727F406A9D">
    <ao:body rdf:resource="urn:linkedspls:uuid:A9F54207-3103-439F-9F37-B7A36B3C8C5F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D1D64E45-3C4F-4484-9A47-A5554CCC4E2A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:A24FCBC0-9830-43DC-87D5-5716D3136B02"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C5943A15-287C-444E-B6F0-5168F9BAB235</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:lastSavedOn>2014-06-23 14:47:30 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6C38BB4D-F315-43B1-BEEC-BB7AC4B12887"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C376A26E-0D2F-4BC1-8979-87D6DC5338C7"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:8164B1B9-99ED-45DC-992E-89D704D2A080"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:BA799867-B4C2-44C3-B530-1E580BE0F7D7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2D733131-6044-41CF-8DEA-55AB5AE7B320"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A9583DF5-41B4-494B-AC27-08CD5AED477B"/>
    <pav:lineageUri>urn:domeoserver:annotation:1A5FE820-1D2D-4217-8498-E6CA3F9DE39C</pav:lineageUri>
    <pav:createdOn>2014-04-14 15:33:19 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B00F626B-2496-40FE-8B44-A026746EF9DB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B83FE4F6-90A7-4140-A2C5-F71A9351F2D0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3FF3DEC0-759E-46A4-AB19-7748B16272DC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3138E2AE-09EE-42FC-A600-DCCFD1E806E3">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:35C5BE0D-1E7D-4AB9-85A8-DE7D27EDC887">
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF427FC6-54B8-4CA4-9C51-233E64726500">
    <pav:createdOn>2014-06-30 12:22:01 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AF427FC6-54B8-4CA4-9C51-233E64726500"/>
    <ao:suffix> Please refer to </ao:suffix>
    <ao:exact>An anastrozole adjuvant trial was conducted in 9,366 postmenopausal women with operable breast cancer who were randomized to receive adjuvant treatment with either anastrozole 1 mg daily, tamoxifen 20 mg daily, or a combination of these two treatments for 5 years or until recurrence of the disease. At a median follow-up of 33 months, the combination of anastrozole and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen therapy alone in all patients as well as in the hormone receptor positive subpopulation. This treatment arm was discontinued from the trial.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>AF427FC6-54B8-4CA4-9C51-233E64726500</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C9CADF5C-CD94-4A8C-B6CF-12220ED65397">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F0C0BB8-3C88-4F5F-888A-993628CE819E">
    <poc:MedicalCondition>respiratory depression, death, obstructive sleep apnea, tonsillectomy, adenoidectomy</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE5D6919-6972-4689-B658-C5432A02F905">
    <ao:body rdf:resource="urn:linkedspls:uuid:A903F38F-38D4-4052-A673-7FF19407E3DB"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:FFDCD61D-7861-4B4F-AE17-4A15CD51BFA2"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:910F9AE9-8398-400D-8505-D971512A67C6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:C553B1B6-192B-4B2C-A32D-72E7FBC6CC65"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:07CDF067-72A2-4DA6-AFEB-7D7F2DCB57DD</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-22 22:00:21 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:4E3D25B8-C473-4C01-A52F-0E6E3FDDBEFD"/>
    <pav:lastSavedOn>2014-03-31 13:47:03 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:FDB20A03-F525-4339-8EEA-2CFD60F6E2CD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:58EFF7E3-78B6-4587-A089-7F58793F2EBF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:C5943A15-287C-444E-B6F0-5168F9BAB235">
    <pav:previousVersion>urn:domeoserver:annotationset:2B99F3B5-C69D-412C-9D44-C62A467E5BCE</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:D03D6753-24D2-4897-9947-4D727F406A9D"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="Nb2ef83ec5d1241b398d27b99f06e79b2"/>
    <dct:description></dct:description>
    <rdfs:label>New set 0</rdfs:label>
    <pav:lastSavedOn>2014-06-23 14:47:29 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:6FE77A90-E5EC-4328-A3D2-DC061F509A03</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143044e90f26014518a19cf70063"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-04-14 15:24:36 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:57DEF5AD-FC2E-4EB0-AED9-CA33AAAF117D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>postmenopausal, advanced breast cancer, early breast cancer</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:51CDF79D-8F09-44DB-AE3B-91C93D13095C">
    <ao:body rdf:resource="urn:linkedspls:uuid:DDEE7195-B373-41DA-9360-816DBE73CFFB"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:BA184D35-B996-4FF0-922B-6B732D552E7C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B0FFCDB3-7874-48E5-99F9-2E81E91B47AF"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:51C4FEDD-5F25-4F57-92BC-5456BC2E4846"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:6E08C847-80F4-4998-AA08-71AE4C51F44B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-31 09:10:25 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-31 09:09:18 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:7BC21EEB-9DB7-4481-AB5F-CDF2B8C45D96"/>
    <pav:lineageUri>urn:domeoserver:annotation:4792249C-8AEE-47E7-BDDB-5D43DC4DB5E4</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C8824A36-9C96-4389-B215-2638B48B5437">
    <ao:exact>Among women with ER positive or unknown breast cancer and positive nodes who received about 5 years of treatment, overall survival at 10 years was 61.4% for tamoxifen vs. 50.5% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 59.7% for tamoxifen vs. 44.5% for control (logrank 2p &lt; 0.00001). Among women with ER positive or unknown breast cancer and negative nodes who received about 5 years of treatment, overall survival at 10 years was 78.9% for tamoxifen vs. 73.3% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 79.2% for tamoxifen vs. 64.3% for control (logrank 2p &lt; 0.00001).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>Among these patients, 54% had node-positive disease and 46% had node-negative disease. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C8824A36-9C96-4389-B215-2638B48B5437"/>
    <pav:createdOn>2014-06-30 12:16:47 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <domeo:uuid>C8824A36-9C96-4389-B215-2638B48B5437</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:720BFDB8-45DA-4138-A91C-A97DEA535F6A">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:53154C36-3543-4DB8-9FA2-B2B42F144C1F">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52601F35-C2AB-4602-BD13-6B9999A0266A">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8D91E7D5-B379-4649-9834-0D01A948DFF8">
    <ao:body rdf:resource="urn:linkedspls:uuid:790612C4-9930-4507-A202-C3A323979033"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6F41EB64-7E4B-4DAA-86FE-348F6836D46E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E62019E-3BAC-4750-881C-C4BCBD5FAB71"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:38963F49-DA9B-4119-8270-79A2613AA599"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3B713685-9EC6-4CDC-A319-C8182DAF4210"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:968D281B-12B7-4913-8E9E-AB28B7A5515C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D76FC3C7-7CFD-4970-AA16-E0B4142CEA6A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">19</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:A8A0399E-FEFC-4AFE-AE32-4D1FD846E003</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:6E5E175F-14BE-4D3D-B53D-AFBEAC6D049F"/>
    <pav:lastSavedOn>2014-06-30 11:51:20 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:49473EAE-FFE9-49C4-8E8F-674168905020"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:FEF94E24-725D-433B-8F55-9E75E14CECB9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0A52235-7692-496A-9DE2-B919FD0C2AC7</domeo:belongsToSet>
    <pav:createdOn>2014-06-02 14:22:39 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:E319F066-2C3E-4B8B-904F-5B682C614A92</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AD99D105-745D-4452-A054-674F93273D57">
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3C70DFC4-2BEA-46AE-A49C-D4BE3E7466B8">
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:A866D2C0-CF5C-4F12-AE01-8E04BC77D311"/>
    <pav:previousVersion>urn:domeoserver:annotationset:F8403FA3-1909-450C-BEF3-1DCE497A37CC</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:69C71795-6ED9-4F74-80C5-653AF2ECE5E2"/>
    <pav:createdOn>2014-04-14 14:29:31 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">40</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0C960F76-C1CF-449E-B404-68D80C32B1A2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:5F727C30-AB90-4303-A365-864EDED053D8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:32360D7F-BE1A-479B-87F3-006E3D28E13F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6118FDF6-9FBD-4FBB-BC8E-583BED7322E8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E17574BF-3BA6-48DA-B0DA-6E8DF716A03D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B495D868-5058-49BA-B2FC-551A76D36CA2"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:1FCB6C74-C406-41C1-8A44-C9D033D5834C"/>
    <pav:lastSavedOn>2014-06-23 14:36:56 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:486E531D-C68D-4F07-8042-A14E58A2143E">
    <rdfs:label>Variant Frequency</rdfs:label>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8E738FB7-477C-4524-B024-29343F2936EA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-30 13:01:21 -0400</pav:createdOn>
    <domeo:uuid>8E738FB7-477C-4524-B024-29343F2936EA</domeo:uuid>
    <ao:suffix> Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele. For patients carrying at least one copy of the CYP2C9*3 allele, t</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8E738FB7-477C-4524-B024-29343F2936EA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>A meta-analysis of 9 qualified studies including 2775 patients (99% Caucasian) was performed to examine the clinical outcomes associated with CYP2C9 gene variants in warfarin-treated patients.3 In this meta-analysis, 3 studies assessed bleeding risks and 8 studies assessed daily dose requirements. The analysis suggested an increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 alleles.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:327B5301-12DD-4333-AF75-3141D1F104B9">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1DAAEA11-218C-4430-A00D-10DF6F5EE0E7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B6570F9A-45F9-4786-BDA7-9D6B899F45DB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-06-23 14:25:28 -0400</pav:createdOn>
    <domeo:uuid>B6570F9A-45F9-4786-BDA7-9D6B899F45DB</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B6570F9A-45F9-4786-BDA7-9D6B899F45DB"/>
    <ao:exact>Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.</ao:exact>
    <ao:prefix>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D0072C9A-B3D9-4846-8E25-33DCAD62CC03">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER_receptor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4EEB4B8C-B4AE-42C6-9E9C-805907F3A548">
    <ao:prefix>What is the most important information I should know about clopidogrel tablets? 1.  </ao:prefix>
    <ao:exact>Clopidogrel tablets may not work as well in people who:\\r\n\\r\n    have certain genetic factors that affect how the body breaks down clopidogrel tablets.</ao:exact>
    <pav:createdOn>2014-06-30 11:42:30 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>4EEB4B8C-B4AE-42C6-9E9C-805907F3A548</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4EEB4B8C-B4AE-42C6-9E9C-805907F3A548"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DAA571EF-10A2-47CA-9E75-9034B0F262F5">
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:54683688-CA47-4069-A6B9-19C2DD2B7A5D">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FB17C9EA-111C-4784-80AC-30417D974CE8">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:3C468A81-A5CF-46BA-999E-C6DB057A8718"/>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:977D4B66-41C2-4CEA-9997-9226A41529E1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E4623FBF-0C69-42E7-912E-1494A9BF4EE2"/>
    <pav:createdOn>2014-04-21 12:30:00 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:1FAA2AB1-96D9-4225-A9E1-763F045EE2CD"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6962260B-200C-48AC-ADF0-CDC5F4A2148B</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B6D3900-DB2F-43B3-910E-08797EA1F227"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E0CD575E-3B67-4030-A5F3-832FE1AC8395"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:720F1FAF-C317-4375-8323-04DFEE0FAAFE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:69F2525A-EF9A-4F04-A361-B7633D964121"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:56454B1C-0054-4957-B706-156C1ECA5394"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9604B86D-1F49-48A3-B079-3CD84C89B0DE">
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:910F9AE9-8398-400D-8505-D971512A67C6">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:suffix> Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:910F9AE9-8398-400D-8505-D971512A67C6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-31 13:47:02 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F7684C08-2D03-4CFE-B6ED-3598D9C30C18">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <rdfs:label>Use specific</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE521BAD-75B0-418A-A885-F72D473E4567">
    <ao:body rdf:resource="urn:linkedspls:uuid:217EA911-9B76-4BEC-8E97-92486BF67C31"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F0B7C43C-792D-49E5-B282-D2303F858889"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-30 13:25:26 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:87B38612-F6A1-489D-A3E7-570F6B558C2E"/>
    <pav:createdOn>2014-06-30 13:25:13 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:A9E04695-935E-489D-B1CC-1339AC7774C6"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:A705C426-39E4-4654-86CD-B5DE3C78D583"/>
    <pav:lineageUri>urn:domeoserver:annotation:D2353C5C-D731-4714-A25A-F28164D531D8</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:B6B4A58C-16B0-408F-A838-47FC8649B72D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E2A31DB2-6CF9-4A0C-9708-109CC7FFA7B5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3AD8ABEC-70ED-4E2B-AB0C-6F8F35433F49">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EF5332EA-A40B-4668-AF2A-6572169A6CFD">
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <rdfs:label>Recommended</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3BB6B488-00C3-4740-9F20-8C6AB5C8FCD5">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E31DDBE1-AD48-4EBD-918C-656A862E759A">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2F4C97C8-3FB9-401C-B323-6300518C3198">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E358C12A-EA54-4BBC-B289-833D4ED09D04">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:291E17EF-EB0A-419A-9930-D6B0402634E2">
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:310AE3DF-6DB4-40D9-809E-0B80BB047A8F">
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:83E53A9A-8702-4167-A12D-1370E2D26E06">
    <ao:body rdf:resource="urn:linkedspls:uuid:C0DE6314-6F80-4149-8B10-CFB417883757"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A20BC568-9BC7-4FA0-9C43-A5A490A74650"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A1739C32-7BA0-4ACD-8448-CDDDAB8D55AE"/>
    <pav:createdOn>2014-04-14 13:58:14 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:36FDCB4E-5E54-4CBA-BC44-04B836C019F0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:79F31203-B89A-4A59-820A-0A830046558E"/>
    <pav:previousVersion>urn:domeoserver:annotationset:F15A9795-D0CF-4C37-B555-738D3D9E8913</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:lastSavedOn>2014-06-23 14:25:28 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B6570F9A-45F9-4786-BDA7-9D6B899F45DB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">34</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:ED352AE7-8ADB-4333-9B07-4FF6A08E047A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:371CCDDE-6701-46A5-B84D-5ECAE73E3523"/>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D62A1217-AE83-41D2-B678-FDCD04344D8B">
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4157B9C9-C9C5-4812-8433-5DE9EDAC7F15</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:043B155D-EEAD-4248-B52C-FA7437F0A139"/>
    <pav:lastSavedOn>2014-03-22 22:15:15 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B30B41E3-5A67-4530-BC81-938E6B016FDF"/>
    <pav:createdOn>2014-03-22 22:13:30 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:EFBCF9E3-E6EB-44EB-9FA9-FA8288501BCA"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7E2CB9FD-6E66-4D71-8B92-4AE2C557E1A3"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:79A46039-020F-4CFF-8F4F-224895ADAB3C"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:0AE4805A-9064-4B43-9C66-7F8E47ECAB77"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:90982EDF-B4D4-45BA-A707-BC09270B9519">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99ADE58D-3F23-4EA1-8830-1F8A6FF82D58">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Not Important</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is not associated with clinically relevant pharmacodynamic effect</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:138F9317-E2D6-4CCC-B563-10CCEEA17309">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4364906C-8414-403A-BB1D-1DDCC5F6A4DA">
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:73C1A497-1E52-406F-A8A2-D5631C088F35"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-22 22:05:18 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-22 22:11:45 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:C11F474C-5FE5-41F1-BF97-71793CD0C79E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F007A3E0-FB60-4CDA-9A07-BC6E3A3F95D1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:933C6C55-0C1F-4A1C-B72F-98683FD68184"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4A5BB36A-D20C-4306-8958-609D3F9A13D0"/>
    <pav:previousVersion>urn:domeoclient:uuid:9372D3E2-2D34-4B3E-9DEE-0B5D2C57BB6B</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:E1161E82-9339-49AD-AAC4-F58471BF51EA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A0C9BAA5-CE9B-433F-BC0C-0552964F164A"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ECF44606-203D-4F28-9A50-FD8FFEEC4CB5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5B205954-23AF-4A0B-B3D4-BF9F14E83942">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:875F6756-255E-43CC-8CA5-19D63561F59A">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-30 12:04:37 -0400</pav:createdOn>
    <ao:exact>The most common non-functional alleles associated with reduced levels of TPMT activity are TPMT*2, TPMT*3A and TPMT*3C. Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity.</ao:exact>
    <ao:prefix>Phenotyping and genotyping methods are commercially available.  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>875F6756-255E-43CC-8CA5-19D63561F59A</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:875F6756-255E-43CC-8CA5-19D63561F59A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DC327A01-6532-49C7-9207-A8BF094FA696">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>VKORC1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CE3D1055-4EAF-4F2F-A2ED-AA9B95C45024">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB14F9C6-5EC7-47CC-A258-035BAAD9EFEC">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:74383823-4D42-47C6-B39E-4DDBA1FB0880">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Decrease from baseline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3D8FCA63-D459-479D-B663-B2AB9028C444">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:10B1EB06-38FD-41C2-A3B7-625B2825B889">
    <ao:suffix> (1.3</ao:suffix>
    <ao:exact>Letrozole tablet is an aromatase inhibitor indicated for: \nAdjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer (1.1)\nExtended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy (1.2)\nFirst and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:10B1EB06-38FD-41C2-A3B7-625B2825B889"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-06-30 11:59:39 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>10B1EB06-38FD-41C2-A3B7-625B2825B889</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8DB42E98-E31C-4559-9876-3E6F208F6AC4">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#66106-6 PHARMACOGENOMICS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>66106-6 PHARMACOGENOMICS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:84AD1BC2-1109-4576-B08B-E7498F17C3FE">
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6B1BA68C-A21B-49F1-8D31-5B808D766739">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:80EF1495-53DE-404E-89C4-746A487232BF">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2EF23CC0-07B7-43BA-8D93-535D7049CF1D">
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE162B39-590D-488C-9A77-88A953329FE5">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F777C391-7D5E-4F49-948B-5B9ACB2587FA">
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:C300EE60-7029-4644-9136-83C2EBF50E3F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:E24DA171-3584-4B17-BCBF-E8BCF31FC65E"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:486E531D-C68D-4F07-8042-A14E58A2143E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6E680A49-5B91-4058-A09E-25A6ED988EFC"/>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB47AA-350E-4E2C-9475-7A7EA7071F31</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:40D06030-B1C8-49C4-B099-49AD079C1CD4"/>
    <pav:previousVersion>urn:domeoserver:annotationset:FA37F879-8CBC-4ABA-B812-53CC76964CFF</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:2C82DE48-F48F-4BCA-A870-57ADDC2FA1FD"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:46A370D2-9D5B-4964-96D7-FECDB2FC0ED4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:BE231C61-B98E-4D13-BF5A-E36767BDAC2A"/>
    <pav:createdOn>2014-04-21 12:22:51 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:2CE370A4-8DC5-44D3-8AAE-0A421EF97BCC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B88B8114-00C9-4EE1-B39D-A1B4B806C203">
    <poc:MedicalCondition>bleeding</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FDB20A03-F525-4339-8EEA-2CFD60F6E2CD">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF8C1810-3B2F-446D-95FB-F6382AEE1DC0">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine tablets.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <domeo:uuid>BF8C1810-3B2F-446D-95FB-F6382AEE1DC0</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BF8C1810-3B2F-446D-95FB-F6382AEE1DC0"/>
    <pav:createdOn>2014-06-30 12:03:53 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Patients with intermediate TPMT activity may be at increased risk of myelotoxicity if receiving conventional doses of azathioprine tablets.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99B84487-54C4-4044-B319-C00A3689F0FA">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0496C268-8D3F-4D44-95D9-8D7250579EBE">
    <domeo:uuid>0496C268-8D3F-4D44-95D9-8D7250579EBE</domeo:uuid>
    <ao:prefix>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0496C268-8D3F-4D44-95D9-8D7250579EBE"/>
    <ao:exact>Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-23 14:35:26 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9DE5C0EE-8425-41E9-90F5-C6819D71FBF1">
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Do not start</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8D30CB12-D87B-444B-A8CC-EE3BA6929B2D">
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B6AFF4AE-81DD-438A-B7C9-68B8467AFB41">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>death, myocardial infarction, stent thrombosis</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:256E17DA-EE2D-43DC-B2E0-D1323508DB8D">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:25348450-1CCF-4BEC-84EF-0EA92F67DD3A">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:65CEA66D-37F6-4803-B0EA-C4E278013D5D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:89320F5F-262D-4657-8A52-4432EC0101F8">
    <ao:context rdf:resource="urn:domeoclient:uuid:DBCD24FF-6ABB-4810-A5CA-DF8F85FF2241"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-31 09:06:26 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7361D556-97F9-41F3-98DD-3F6C66FA6CCB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2F140206-4891-4319-B539-857B384767DF"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:createdOn>2014-03-31 09:04:12 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:EF5332EA-A40B-4668-AF2A-6572169A6CFD"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:2CE69763-0812-4DFF-A359-2A8D8FF706AD"/>
    <pav:previousVersion>urn:domeoserver:annotationset:E56B19ED-CC69-40EB-B68A-25F7DB5534A9</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:A54084C7-81C5-4C71-AEA4-AD05D852A4AB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FB39F2CB-5442-4479-A939-6FDB899B3B62"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:158713E6-223A-4BE2-8C4A-663906E57A2A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:39F4E826-731D-452F-BFE9-052B1EC82FC7">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:87A687A4-9001-4015-86E8-43D83AC97EC6">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:240C39EC-A129-42D3-8602-5C743EC412D2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Based on this study, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected hypersensitivity reaction during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:240C39EC-A129-42D3-8602-5C743EC412D2"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> </ao:prefix>
    <pav:createdOn>2014-03-31 08:59:45 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:37547FE1-0C49-4ACD-8764-330C113732EE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:92FA8990-60EF-4140-9F60-C12E57E3B114">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C4B5F9D6-6190-4D39-A50E-B39CD7193832">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A753145C-8800-49A8-BE99-D558A1390DAE">
    <ao:body rdf:resource="urn:linkedspls:uuid:8C6A6A36-98FB-4F99-83BE-23A9EA2D830C"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:B96A8A3C-923B-4EB4-A25D-1DBC5E84F63D</pav:previousVersion>
    <pav:createdOn>2014-04-14 14:56:50 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DB559FE0-80C3-489C-84A4-F9C2EBBDAE8A"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-06-23 14:43:25 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F4F18F4C-715F-4BFC-9F0A-7EDD54559C59"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CE3D1055-4EAF-4F2F-A2ED-AA9B95C45024"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:60EEDE7C-ECAE-4AC4-8E21-0B889A0CACD8"/>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:139C60FE-2FF1-421B-922B-E11FA45DE8F1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:388DE174-1DEA-4AC5-9B06-83813521DCB6"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A0D2E40-7A85-40CB-AD6E-D192CF8CF693"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">26</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:4743B32B-A374-4701-B3BA-DD766AB522F6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C9D34B80-736E-4124-B99A-5ADD357C4F8B">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>POLG</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:9179</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91FC426C-470A-4F05-8189-438F1BBADDAA">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A0D2E40-7A85-40CB-AD6E-D192CF8CF693">
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:02541206-0D89-4418-A8FF-FA3E161C64DD">
    <sio:SIO_000111>34071-1 WARNINGS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34071-1 WARNINGS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF6CAECE-87B0-44D5-8E9B-5D977FD17B16">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42232-9 PRECAUTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>42232-9 PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:22C583C8-0AC3-4E1C-A595-4E5CCD32A0F9">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE6A11BA-9F40-4FCC-AD6B-A61A5202A894">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2C82DE48-F48F-4BCA-A870-57ADDC2FA1FD">
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:302DE593-A3EE-4718-A421-A02E84C0A956">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B28D214B-5512-4B58-A714-CC034E8D06A9">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE8AF84A-98F2-4EED-8B54-4312A50FBA31">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2014-03-22 22:11:45 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:9372D3E2-2D34-4B3E-9DEE-0B5D2C57BB6B</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA844F00-D043-44E7-BDA4-C852FD04CEA0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2423954D-96B2-404E-8B04-9609825C795A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6A8CCA59-FFB8-48B8-8E0F-797519671DF1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D50CE73F-31C8-4AAD-BF2E-EEDBE1F40F42"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:990A861C-8128-4BEB-B3B9-1F189E42FDD0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:DA126820-256D-4C0A-BAEB-B5A5EC5C0F33"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D66A54D7-BD47-4E22-B2F3-09A5D190955A"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdOn>2014-03-22 22:11:34 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F48C3C33-678B-486C-B677-C6FFA206E24A">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1077B919-51EA-47FD-823A-B432EA4D1829">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C24DFA02-2096-4634-974B-1866183BFD0B">
    <ao:context rdf:resource="urn:domeoclient:uuid:98FB995B-3B3B-4C86-ACA3-EE4F9F310F41"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:855BF4FE-7082-466C-AEC2-BA37C5A2F93C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DC327A01-6532-49C7-9207-A8BF094FA696"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-06-30 13:22:29 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6E09256C-E565-492C-8E37-D44BE4F2A39C"/>
    <pav:lastSavedOn>2014-06-30 13:22:32 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:5B0C74E7-D5E1-4750-A159-40BCA7DDA80D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:A3776D92-8930-4618-9CD5-65A783FA0E71</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:79122512-81D6-47F4-B441-ACD1ADFE6704"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D1D64E45-3C4F-4484-9A47-A5554CCC4E2A">
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0DA8F1F1-00FB-4612-86F5-7F3B3E521995">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA5A93F5-5D2A-44BF-8951-9EF6DFE12F1B">
    <pav:lineageUri>urn:domeoserver:annotationset:EA11DA11-0A03-469A-97E9-855E1FA24490</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2014-04-28 15:59:53 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8BDFDC96-47AF-489E-8F96-DF9B26C6ECBE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E86AE4A1-3150-4C61-A54E-57E3099D70B7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C3F6629B-C646-4E20-9EDB-BD57E82CEDE7"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E1199968-6650-4D2A-A5E4-EDFBFE7733AE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:9D0B809B-F963-4695-8DC7-7F047A774E4F</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:B64EB4D6-84C3-4D10-8AFE-B0CD4E578749"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FC60AC74-EBDA-41D4-B52D-99E6A4F8DB21"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B730B18-8380-46F1-B12C-A7D99D832F96"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5C3FAD25-158A-40FD-BB28-96D11E1A9866"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-04-28 15:01:50 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B5C424F-CAD0-4CE2-BA6C-0AEC6ADA9CAE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:89DFC8E1-C29C-4F16-87D9-1CDEF3CF49FD"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:C8120387-918C-49C5-B2B6-0065FE5054D8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DD2106EC-5F5D-4D09-997E-D0A744AA1320"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:44A37F21-E420-40D5-A9E0-5CEDEFAEF40B">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86C39220-E4FB-4181-9F12-D824F141371B">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:19CB40E5-55B0-4DB4-96AF-609585C45AB3">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6D20A91A-BAD7-4E87-930B-A5394D2732C8">
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6E4DC2F2-83E8-4160-B6D5-B1C311A3EB1E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Add new test result.</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:90F5E54E-2D3A-46B8-B647-746B526D8CC8">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3C468A81-A5CF-46BA-999E-C6DB057A8718">
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B0DD1950-EC36-4509-9941-3B4DA4A38494">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D37999E-F183-41DD-8FEF-19696FD23D30">
    <ao:context rdf:resource="urn:domeoclient:uuid:9A074D82-152F-415F-84A1-93EDCC8179B1"/>
    <pav:lastSavedOn>2014-06-30 11:33:55 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE32B2ED-6147-4876-A62A-CDB5CD4E16C3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">24</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:4E001AB1-2305-4837-8AF8-180376395180</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:A2121F35-BD9F-4B1B-84CA-327F0300B590"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:FED638A3-F491-4246-B5EC-651C306CF76E"/>
    <pav:createdOn>2014-04-28 15:27:38 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E98CB2FA-DA8B-4C38-A381-051FEDE4E5CF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F1F0B2C7-CD6B-47A1-8A2E-0C58AFF1C1AA"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:A7038FFD-EE29-47F3-9179-0A75D09E614A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7302A873-FD71-484E-8E7A-C3C5EE43F4ED">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34084-4 ADVERSE REACTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34084-4 ADVERSE REACTIONS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E1E45497-D882-456B-B573-7A640A307AFB">
    <ao:body rdf:resource="urn:linkedspls:uuid:964EBF55-DC67-43A9-93E2-DBC843BB8D2A"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:00BB6023-1D83-4393-9606-7F0021BEA3B9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:836504CE-5B97-4336-874A-48D2BD7B6107"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7D50A614-4F2B-42C6-A175-0BF3C158B5DA"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:F5009394-6930-445F-90B3-92BC6075D38B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:FBC84091-3201-409B-AEED-D0D661E79218</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">25</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:4DB91673-D6C5-4FAD-B0B5-4B4CB81D8EF8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E7EADDD-1940-4793-A432-894BFB8A0F2A"/>
    <pav:lastSavedOn>2014-06-30 11:34:30 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <pav:createdOn>2014-04-28 15:34:27 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:539AAC42-2631-4B4E-946F-3A27B885004B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8BA5860F-EC3D-4A39-A59F-2C87A9414AC5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B4BFDF8-85C4-40F2-A42F-23B4B1176095">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:850F3B60-ADC8-42A5-8E7E-B50B1E9D39BE">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:96C7AAF0-4163-4CE9-A1C9-9C9DA05E8866">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C2B58FFF-334C-4A84-A26C-C674C26B1F42">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C8A8CA34-A4B7-4562-9D58-56B6AB8DA2C1">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED2F98CA-60F0-4D49-9803-FED968AA3114">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:A1AAAE07-F302-4333-81C8-E2017D3BEC00"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:7D1472F3-6F6E-4A37-82F5-074CC3DD8C8F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1BBDD4B3-A192-494F-BBFC-1B30A3CB35C3"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:9288BB3B-CCF6-4586-B1B8-E53980AABA7F</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:391E5A08-84AA-4F04-BF93-C7505FEF9363"/>
    <pav:lineageUri>urn:domeoserver:annotationset:EA11DA11-0A03-469A-97E9-855E1FA24490</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:D61EF3CA-BC6E-4D40-9A14-5EF6B2C2E6EF"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4B5C424F-CAD0-4CE2-BA6C-0AEC6ADA9CAE</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:08308CA2-E50D-41DB-873B-E57372B5FBDB"/>
    <pav:createdOn>2014-04-28 14:53:37 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:82F247F1-5E0B-472B-8C42-4074C2A25CD0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:913C60A2-43CE-4C57-A674-6B283C08A75E"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-30 11:22:26 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D32E2B19-3891-4F8B-98F3-B65344B0F6A8">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <domeo:uuid>D32E2B19-3891-4F8B-98F3-B65344B0F6A8</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D32E2B19-3891-4F8B-98F3-B65344B0F6A8"/>
    <ao:prefix>) and long duration of warfarin therapy.</ao:prefix>
    <ao:suffix>(see CLINICAL PHARMACOLOGY:</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact> Identification of risk factors for bleeding and certain genetic variations in CYP2C9 and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses </ao:exact>
    <pav:createdOn>2014-06-30 13:19:32 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7DB7DA55-3D41-44AC-9585-F841B07B2CBD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B752346E-6167-497D-B585-83983FA71DA2">
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:50A04DD0-6066-4535-9705-BDCF80948C12"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:52CB1ACE-5349-4E7A-A0E1-84BC726E8B27"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AC497212-D269-4238-AA69-CFE2271A33C3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D22D3EE5-70D2-4E6B-98C6-A6D895D3172C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2014-03-22 22:11:45 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:9372D3E2-2D34-4B3E-9DEE-0B5D2C57BB6B</pav:previousVersion>
    <pav:createdOn>2014-03-22 22:07:26 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:21B282F1-F0CA-488A-B703-88611F099D16"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B79BAC9C-6B3B-4FF1-9F24-2BD40CE200BF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EBB55D0F-81EB-491D-87E0-80476C5A79F6">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>PATIENT COUNSELING SECTION still not listed.  How do we code advise patients?</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A8F70682-D5CB-4276-AB4B-8856ECC0EE29">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacodynamicImpact>
    <rdfs:label>Not Important</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is not associated with clinically relevant pharmacodynamic effect</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA0F2FE0-000F-4D17-9DBE-D18CEFAF648E">
    <poc:MedicalCondition>tissue necrosis</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:32360D7F-BE1A-479B-87F3-006E3D28E13F">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4CB3EFD1-0AC6-4124-967C-F5439301F1C1">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Decrease from baseline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1035F78D-B81D-4CA7-9A11-4648026B2B7A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>SJS, TEN, Chinese ancestry</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1706E63C-45AC-467E-80FD-06108C69A93D">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:930446CC-16E7-4398-8215-BD74669EBB25">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5946A3F9-5969-4A42-95D2-AFE3E8251A48">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B0497B5-2A21-46A2-983F-7992EF169EE9">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55709DA6-0396-4327-B704-FE38E5F01C43">
    <ao:prefix>have a liver that does not function properly. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:exact>Before starting ZIAGEN, tell your doctor about all of your medical conditions, including if you:\nhave been tested and know whether or not you have a particular gene variation called HLA-B*5701.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:55709DA6-0396-4327-B704-FE38E5F01C43"/>
    <pav:createdOn>2014-06-23 14:42:59 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>55709DA6-0396-4327-B704-FE38E5F01C43</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:67FDD5CA-F0B9-408A-BF01-D48590C5451A">
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9BBDBAC7-FADB-4DF5-9066-F29FDFAE5D8A">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>CYP2C9*2, CYP2C9*3</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DBC5988C-D720-43A9-9D01-8713355AB4AB">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>42231-1 SPL MEDGUIDE SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42231-1 SPL MEDGUIDE SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E76B18A1-DB9E-4F80-9F85-F68457DA227D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:12074DF7-B46D-47A9-8527-792E360269FF">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:42129E3A-F6BF-4351-B780-2CCB2B2CA39E">
    <sio:SIO_000111>34075-2 LABORATORY TESTS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34075-2 LABORATORY TESTS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:54942D51-2FE7-4151-873B-B7D21EF96C08">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6578AA5-3295-46D7-B3F2-55CD3CFB5B0F">
    <ao:body rdf:resource="urn:linkedspls:uuid:BA2F9D10-3477-4544-BF32-2176E0DB7BE0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-03-22 22:20:08 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B8FAA54-48A6-4B88-A9A5-5D1373EB3B83"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8063FB58-0C19-4F4D-87DC-7AFA705FCE00"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:073BA57C-2916-4E35-9AF3-AA99E504958C"/>
    <pav:lineageUri>urn:domeoserver:annotation:421C505C-D5B7-4F6A-BA3F-FDEB87152F0A</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:7673EC96-E39E-4D34-A8B6-A31AD2825C94"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:D2A8C2D7-9A3E-4307-BC2B-4EA4FC30E8A5"/>
    <pav:lastSavedOn>2014-03-22 22:22:32 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:AEBF040F-C6A6-48A1-B676-CAAE042125E9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:407F8565-3B9C-4CF8-B785-C8286BCD86A2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D22D3EE5-70D2-4E6B-98C6-A6D895D3172C">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ECE9E8AD-BAEE-4FC0-A880-67D03D8D2EED">
    <pav:createdOn>2014-03-31 08:55:42 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir. </ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>(5.1)</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ECE9E8AD-BAEE-4FC0-A880-67D03D8D2EED"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:90768224-544A-41CF-9969-E08884F1434D">
    <ao:body rdf:resource="urn:linkedspls:uuid:D08A0D01-F380-4BA4-9FDB-5EED31E83429"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9604B86D-1F49-48A3-B079-3CD84C89B0DE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">29</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:B6AFF4AE-81DD-438A-B7C9-68B8467AFB41"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:91F8713E-28D7-41EE-928D-64E365CB5CE4</pav:previousVersion>
    <pav:createdOn>2014-04-28 15:51:09 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:F1D12488-2CA1-4EAD-9A8A-C92106847342"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3BD37A0B-C18E-4E10-8B84-CD80F2C52B8F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B077986-2A80-4158-9CAE-260BB4A5C061"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6EA9FCCB-EF84-4E0D-874F-C372EAFEDA19"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-06-30 11:41:08 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D96A1388-0825-4599-962A-23D155BF20E1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E67801C-8D8E-4822-9211-BFA28585585E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:22B1EFFD-5404-4C26-A535-417D70D5FBA8"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:73528957-0BB4-4A36-9188-2651756AFFD5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94F5EFA2-DEF5-444E-B4C2-7268B36AF650">
    <pav:createdOn>2014-06-30 11:15:40 -0400</pav:createdOn>
    <ao:prefix>Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN. Consideration should be given to avoiding use of other drugs associated with SJS/TEN in HLA-B* 1502 positive  patients, when alternative therapies are otherwise equally acceptable. </ao:prefix>
    <domeo:uuid>94F5EFA2-DEF5-444E-B4C2-7268B36AF650</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Application of HLA-B*1502 genotyping as a screening tool has important limitations and must never substitute for appropriate clinical vigilance and patient management. Many HLA-B*1502-positive Asian patients treated with carbamazepine will not develop SJS/TEN, and these reactions can still occur infrequently in HLA-B*1502-negative patients of any ethnicity.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:94F5EFA2-DEF5-444E-B4C2-7268B36AF650"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:108444AC-C8D7-42EE-A011-BE98A3F592F0">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1CF08EE8-3F2A-4FE9-A883-E2FB099710F3">
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6E08C847-80F4-4998-AA08-71AE4C51F44B">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4BCBEECE-3BEC-4460-9E86-B8C4CFA6608F">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:36D17D73-1169-4131-94F5-24AFD369088A">
    <domeo:belongsToSet>urn:domeoserver:annotationset:E58AE6C8-9E12-4594-8AD3-14D4A9CF5106</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B204F8D-D877-4A83-AC45-1321ACDCBBFF"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:F5BE400E-F969-4FC0-BFAD-18D496F3A285"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:9A5666BB-F43D-45F3-A856-0BDB0E745589"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:7C09E14E-622D-45EA-BE2E-4389BDBB08B3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8D90C751-90B5-4F05-AB1A-DDCFCF0A7849"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D875AEA0-EDFF-45B6-AF0C-AB1DC31DA25C"/>
    <pav:createdOn>2014-04-21 13:08:32 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-06-30 12:05:04 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE02E5FF-3781-4108-A8E8-B28AA4D2E19F"/>
    <pav:lineageUri>urn:domeoserver:annotation:7D847E70-F655-4728-8016-8BEA3CD737EE</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:D291A986-DE92-4F74-9F59-948621826357"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:41D2E64F-6C03-4744-A4FC-79ED77085E81"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C4C83D93-3CF5-4EFD-87AB-DBB3F529A08C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A9583DF5-41B4-494B-AC27-08CD5AED477B">
    <rdfs:label>poor-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2F20CE66-F8C3-45F5-997D-6DA3618A2E36">
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A0C444A-69BB-4499-A9B4-71AB565DFA0F">
    <rdfs:label>Not Important</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is not associated with clinically relevant pharmacodynamic effect</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A5C6F1FB-AC9B-4B8C-A170-5BBAFC3A938E">
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <rdfs:label>ER_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5F64639D-C8D4-4F49-9DA5-D0F85949DC0D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AE8364C5-84D3-4210-94AB-392D28082812">
    <rdfs:label>Clinical Trial</rdfs:label>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47718F61-F7FA-4A83-BB17-C13189D5E884">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:B0D15111-C445-4596-9C63-C7EFADEB3394"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FE990D63-4739-43A5-B062-7A946346B2AF"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-31 08:56:07 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:0C36300D-CA3C-4C26-A406-FC14CBBC2C74</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:1694EBD6-F324-4F34-BF46-96811165F624"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:17885E5A-0B08-4791-8E05-BD3606CC3AC3"/>
    <pav:createdOn>2014-03-31 08:55:42 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B44F6619-C144-4D12-B575-BA96FED0BC7B"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:ECE9E8AD-BAEE-4FC0-A880-67D03D8D2EED"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2BEFD527-0C92-4B61-A2B9-12F931EDC707">
    <ao:exact>The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional. CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese.</ao:exact>
    <domeo:uuid>2BEFD527-0C92-4B61-A2B9-12F931EDC707</domeo:uuid>
    <ao:prefix>Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel’s active metabolite.  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2BEFD527-0C92-4B61-A2B9-12F931EDC707"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-30 11:36:17 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F10FC0DB-5D49-46E9-A2C2-3CFFC5FBF692">
    <ao:body rdf:resource="urn:linkedspls:uuid:D43C334C-4869-4108-9C67-E96EA2063195"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DAA571EF-10A2-47CA-9E75-9034B0F262F5"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:74EB8F8A-FCEA-41C8-BAB2-B4DFA1190D34"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:67AF0D11-13BE-4E8C-A78E-337527148480"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F0F7787E-5F9C-47A4-86B2-D64F1B7602B6"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:8CC36B67-27C2-4FD8-935B-A2A6264F7849"/>
    <pav:createdOn>2014-06-30 13:02:40 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:E779EFBF-EC27-464D-8896-1987AD0C64DB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-06-30 13:03:17 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:BF375829-3538-4BFD-A5B6-4A2CE209BD07</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:54683688-CA47-4069-A6B9-19C2DD2B7A5D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:01669DF8-5D8B-4A00-A56B-B761EDE23526"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:27F9E2A8-C54A-4F87-A02D-4F8EFF5D382F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0B5E6C3-0B65-414A-9318-F39AEE9C75E4">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA4519DC-727B-4A71-AFAE-85DE63C6BE8D">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1739C32-7BA0-4ACD-8448-CDDDAB8D55AE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:413F51D3-4F13-471E-85D1-A227CEDBF377">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F1F72593-1500-4B06-AE14-AE29B3EAE9B1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F1F72593-1500-4B06-AE14-AE29B3EAE9B1"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:exact>Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>F1F72593-1500-4B06-AE14-AE29B3EAE9B1</domeo:uuid>
    <pav:createdOn>2014-06-30 11:33:50 -0400</pav:createdOn>
    <ao:prefix>Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy.  (12.5) </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F4EE660C-81BD-481C-87C1-B5548B4F1A11">
    <rdfs:label>ESR1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:216A1896-63FD-45FE-ACBB-80F82EB9ACE5">
    <domeo:uuid>216A1896-63FD-45FE-ACBB-80F82EB9ACE5</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-04-14 14:04:16 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:216A1896-63FD-45FE-ACBB-80F82EB9ACE5"/>
    <ao:exact>HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</ao:exact>
    <ao:prefix>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:33C9F7CE-B041-40EE-8E53-5C94B51B626C">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1769615F-FAC0-4900-9DC6-5021630F8524">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:29A5252E-79CA-41F6-BF34-26789C947F8D">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17111230-1211-460A-B383-3D65082506CF">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DCAE5D15-64ED-4B98-9356-0513BD12B1E0">
    <rdfs:label>Prodrug</rdfs:label>
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC60A959-7F51-4A07-AC53-377513C87002">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdfs:label>Increased Efficacy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E24DA171-3584-4B17-BCBF-E8BCF31FC65E">
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2D0B9A22-6129-4786-B0A4-7384B3324DF0">
    <pav:createdOn>2014-06-30 11:33:21 -0400</pav:createdOn>
    <ao:prefix>[see Clinical Pharmacology (12.5)].   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>2D0B9A22-6129-4786-B0A4-7384B3324DF0</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2D0B9A22-6129-4786-B0A4-7384B3324DF0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:D0A52235-7692-496A-9DE2-B919FD0C2AC7">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">23</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:8D91E7D5-B379-4649-9834-0D01A948DFF8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:91050818-2692-4B82-B3D8-A52A364F00D7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8F4ED235-6F4A-4BDD-A23F-6F2D9FC7A396"/>
    <pav:createdOn>2014-06-02 13:27:05 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:8B036858-70F5-4077-8333-F34F19A042EC"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E319F066-2C3E-4B8B-904F-5B682C614A92</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:6A2E1BD4-3863-4A37-AD9D-6B54F3CF3E54"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143044e90f26014518a19cf70063"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4F5C1D0C-9AFC-4B3A-83EC-AC9CB72FB0C9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3665D7A9-FCD1-4278-8B7F-5EA5B3CC19D3"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:7B209F2D-47BE-4267-B895-92D67A47AE61"/>
    <permissions:permissions rdf:nodeID="N6f00d5a003e2474fa91492ba5593f3d0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE483709-CD8C-4493-A2B7-8E589B98BF31"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F880CCED-A2A0-4330-B02F-070F7BF5AF00"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2014-06-30 11:55:13 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:B2B947EB-71A4-4702-909D-5AE6FE30D592</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:E7B4486A-24AB-4642-ADB0-B78FF5AF0E42"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C89E80EC-0820-406B-99C8-D495EC5F054E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4DA6E07F-7E36-48E4-A071-62F94AA47FB9">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:44D99766-DFE5-4574-AF0D-48B1878395B0">
    <rdfs:label>ESR1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A7038FFD-EE29-47F3-9179-0A75D09E614A">
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2F140206-4891-4319-B539-857B384767DF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:04422703-DCDE-4204-A942-3FEC91CA56D0">
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8CC36B67-27C2-4FD8-935B-A2A6264F7849">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17583134-0072-4B0F-AE5B-F068E67A4CF1">
    <rdfs:label>Variant Frequency</rdfs:label>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B6DAC59D-AF4D-4014-BA7D-4E214B9102CD">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42232-9 PRECAUTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>42232-9 PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7C09E14E-622D-45EA-BE2E-4389BDBB08B3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4BCB8722-D18D-4573-863A-0106417F0E4B">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:507AAF39-F42E-4A74-860F-425386B82BED">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34092-7 CLINICAL STUDIES SECTION</poc:productLabelSection>
    <sio:SIO_000111>34092-7 CLINICAL STUDIES SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:564FEFB4-6F3C-4EC5-83C4-F2B923D57CFC">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C904A0A3-252D-4872-B966-44B63E18E430">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:878D746A-3252-462C-AA1E-A857E2FC63AF">
    <domeo:uuid>878D746A-3252-462C-AA1E-A857E2FC63AF</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:878D746A-3252-462C-AA1E-A857E2FC63AF"/>
    <ao:prefix>Leukopenia and/or thrombocytopenia are dose-dependent and may occur late in the course of therapy with azathioprine tablets. Dose reduction or temporary withdrawal may result in reversal of these toxicities. Infection may occur as a secondary manifestation of bone marrow suppression or leukopenia, but the incidence of infection in renal homotransplantation is 30 to 60 times that in rheumatoid arthritis. Anemias, including macrocytic anemia and/or bleeding have been reported. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-30 12:04:50 -0400</pav:createdOn>
    <ao:exact>TPMT genotyping or phenotyping can help identify patients with low or absent TPMT activity (homozygous for non-functional alleles) who are at increased risk for severe, life-threatening myelosuppression from azathioprine tablets (see CLINICAL PHARMACOLOGY, WARNINGSand PRECAUTIONS: Laboratory Tests). Death associated with pancytopenia has been reported in patients with absent TPMT activity receiving azathioprine.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2DE7C82E-87D5-4A30-8DC1-75927DA0FF1E">
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:54722E3B-3E2D-4588-9273-0CAEB7A40EDB">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1C81595D-9448-4ED4-9731-68138AAA5864">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0BD5D97A-48FE-4639-AFFA-348BA4F27E1E">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AC3CA09A-7F4D-4251-92E9-089254257BF3">
    <rdfs:label>ESR1, PGR</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9202A289-75A4-4A41-ADFA-9449DA718D24">
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A35BACC-77B7-4822-A677-4D72A3B91942">
    <domeo:uuid>8A35BACC-77B7-4822-A677-4D72A3B91942</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Respiratory depression and death have occurred in children with obstructive sleep apnea who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). These children may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8A35BACC-77B7-4822-A677-4D72A3B91942"/>
    <ao:suffix> Codeine is contraindicated for post-operative pain management in all pediatric patients undergoing tonsillectomy and/or adenoidectomy </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <pav:createdOn>2014-06-30 11:52:19 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5F22FE69-5D03-4E0A-95BF-D779C67A2FCF">
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4F233EAC-B92F-417C-9A99-AE8B63C98A45">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdfs:label>Prodrug</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0A551B4E-FB8F-4083-BD23-A1C1B7F4ABCA">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C6988919-6455-4291-92FF-E4F63DF9F9BF">
    <domeo:uuid>C6988919-6455-4291-92FF-E4F63DF9F9BF</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C6988919-6455-4291-92FF-E4F63DF9F9BF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Some published studies suggest that intermediate metabolizers have decreased active metabolite exposure and diminished antiplatelet effects.\\r\n\\r\nThe relationship between CYP2C19 genotype and clopidogrel bisulfate treatment outcome was evaluated in retrospective analyses of clopidogrel bisulfate-treated subjects in CHARISMA (n=2428) and TRITON-TIMI 38 (n=1477), and in several published cohort studies. In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolizers. In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers.</ao:exact>
    <pav:createdOn>2014-06-30 11:41:06 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>† Vasodilator-stimulated phosphoprotein – platelet reactivity index; smaller value indicates greater platelet inhibition </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:54AD3A78-A7C9-4CD4-B715-3E91C92E64A6">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8431F83B-801B-499C-A34F-25B983A4B198">
    <ao:suffix> The planned duration of treat</ao:suffix>
    <ao:exact>A double-blind, randomized, placebo-controlled trial of letrozole tablets was performed in over 5,100 postmenopausal women with receptor-positive or unknown primary breast cancer who were disease free after 5 years of adjuvant treatment with tamoxifen.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8431F83B-801B-499C-A34F-25B983A4B198"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <domeo:uuid>8431F83B-801B-499C-A34F-25B983A4B198</domeo:uuid>
    <pav:createdOn>2014-06-30 12:00:36 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:58563954-332F-464C-8460-68E5B2018068">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>66106-6 PHARMACOGENOMICS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#66106-6 PHARMACOGENOMICS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:371E9234-A9B7-442E-859C-76A157371805">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F35196A-9B27-4982-ACB1-82F6E1AEE305">
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4C94607D-BB71-41F7-9180-1A759D259286">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F45C51D-C093-4FEB-A57B-7D59EB1E01DA">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:009DEEE9-9289-445E-8C79-81457BE96692">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:009DEEE9-9289-445E-8C79-81457BE96692"/>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-22 22:14:34 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:194FD718-B3CA-4D25-B3D2-56D36C1ECB60">
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:58A5256A-166D-4E36-9513-8392BC71360E">
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Recommend</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9C6627CE-F5DF-4F72-AA63-7AC2438EFB56">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE02E5FF-3781-4108-A8E8-B28AA4D2E19F">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CBE4CA75-F135-4D74-8FE0-D90DC7F9F1C8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:402D9368-C611-4289-8004-8EEC1A409CCF">
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C736103C-9AA0-48C1-8314-B13D1585FA1C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Add drug selection recommendation of "indicated for"</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E525054-D8AA-41ED-B402-1724F218F644">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Increase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:592CCB10-6744-415A-9E3D-BA1CA292DC87">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34071-1 WARNINGS SECTION</poc:productLabelSection>
    <sio:SIO_000111>34071-1 WARNINGS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:964EBF55-DC67-43A9-93E2-DBC843BB8D2A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9CA1FBF8-5D9F-4C89-9F89-2BC4E3DB1BF5">
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-04-28 15:07:12 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9CA1FBF8-5D9F-4C89-9F89-2BC4E3DB1BF5"/>
    <ao:exact>20 mg/day is the maximum recommended dose for patients who are greater than 60 years of age, patients with hepatic impairment, and for CYP2C19 poor metabolizers or those patients taking cimetidine or another CYP2C19 inhibitor</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D90283E-E189-4D7A-B2FE-77B0A097DC40">
    <rdfs:label>Variant Frequency</rdfs:label>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EF81C005-29F6-4197-A7F0-73DFD8BCE232">
    <sio:SIO_000111>34080-2 NURSING MOTHERS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34080-2 NURSING MOTHERS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0EF2A15B-07C7-4714-B698-FA75EA02612F">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FBE1CF41-A5EC-4665-B2D5-A9DBD4B43608">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E11F0D6C-95F3-42B2-811F-05032EFF6897">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8223C7A7-BA49-4A69-9875-2C592713916E">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:945EB72E-5C75-41B0-B8FC-637E1EF0AE7D">
    <rdfs:label>Carbamazepine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:361D5826-4D47-4DC3-A6FC-C7D8C1594A3A">
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6F41EB64-7E4B-4DAA-86FE-348F6836D46E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience signs of overdose (such as extreme sleepiness, confusion, or shallow breathing)</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6F41EB64-7E4B-4DAA-86FE-348F6836D46E"/>
    <domeo:uuid>6F41EB64-7E4B-4DAA-86FE-348F6836D46E</domeo:uuid>
    <pav:createdOn>2014-06-30 11:50:46 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F270E3B3-9983-425D-98FB-66F62E36340F">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5FCDB62A-A30F-44C0-8195-0C47BECA767B">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4835A301-3D76-4808-B690-1E812E56166C">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>breast cancer, ovariectomy, adrenalectomy, hypophysectomy</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9739D8D8-F16D-4FF9-BD63-1945B116EEC4">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA5D15E4-F701-4E25-BBA7-93F9828C1D00">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>alleles = multiple copies?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:867BDD21-2583-4787-AEF1-32C615BE5AE1">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>VKORC1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:139701B4-343D-4042-94C9-2491CED57B47">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5CA30A28-B75A-4D14-87B5-8F1D73A58AF0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA13F366-ED95-4FE2-95FF-E471EA29F211">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb2ef83ec5d1241b398d27b99f06e79b2">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:21DAABB4-71ED-4547-9902-CAEFBC1D07BB">
    <rdfs:label>Prodrug</rdfs:label>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:903F27DB-914A-44A2-B01F-A36164AAC4DB">
    <domeo:uuid>903F27DB-914A-44A2-B01F-A36164AAC4DB</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:903F27DB-914A-44A2-B01F-A36164AAC4DB"/>
    <pav:createdOn>2014-06-23 14:35:44 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2903BD03-170B-40A1-A944-4092D506137E">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>less severe adverse cutaneous reactions, anticonvulsant hypersensitivity syndrome, non-serious rash (maculopapular eruption)</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CB74EF29-97D6-47E2-9621-FAF1E3947B17">
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd3d7d7364dd3473bb2176ddc0d0b2c36">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3BD37A0B-C18E-4E10-8B84-CD80F2C52B8F">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A837016-62F3-4B6D-9730-CDAD010A98DE">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>VKORC1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F1D12488-2CA1-4EAD-9A8A-C92106847342">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-30 11:40:00 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <domeo:uuid>F1D12488-2CA1-4EAD-9A8A-C92106847342</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F1D12488-2CA1-4EAD-9A8A-C92106847342"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>The relationship between CYP2C19 genotype and clopidogrel bisulfate treatment outcome was evaluated in retrospective analyses of clopidogrel bisulfate-treated subjects in CHARISMA (n=2428) and TRITON-TIMI 38 (n=1477), and in several published cohort studies. In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolizers. In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers.</ao:exact>
    <ao:prefix>Some published studies suggest that intermediate metabolizers have decreased active metabolite exposure and diminished antiplatelet effects.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1158AAB8-3C05-4AED-8029-D6E9BA759355">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2BB0E9F3-52F1-4631-B37B-DBFB53B3B0C9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Before starting ZIAGEN, tell your doctor about all of your medical conditions, including if you:\nhave been tested and know whether or not you have a particular gene variation called HLA-B*5701.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>2BB0E9F3-52F1-4631-B37B-DBFB53B3B0C9</domeo:uuid>
    <pav:createdOn>2014-06-23 14:42:21 -0400</pav:createdOn>
    <ao:prefix>have a liver that does not function properly. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2BB0E9F3-52F1-4631-B37B-DBFB53B3B0C9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC70D092-5124-4A5C-87C3-EA34E4868C05">
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EEFA4748-7743-472C-B1E4-21C215670F07">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7FA5409D-3EA5-4F92-B738-8577DCEB4D97">
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:7EA25A65-2DD3-4F50-9FBC-7CAEB8962648"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8B7D130A-7127-4E83-93AB-ADD452D00721"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">41</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:0ED7B264-E15A-44A2-9037-2D21B5180CD2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:90F5E54E-2D3A-46B8-B647-746B526D8CC8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:8B7C9D72-5DD1-48AE-928D-A78CCDF396C9</pav:previousVersion>
    <pav:lastSavedOn>2014-06-23 14:38:28 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:4162AC13-E724-4245-A26F-FB7A7E5DE47B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:60854BED-9BA2-4BC9-B21C-3D443607A39C"/>
    <pav:createdOn>2014-04-14 14:34:53 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B11E300-2DF5-4B21-9D43-4D0A02109A59"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C8120387-918C-49C5-B2B6-0065FE5054D8">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC492FDD-E07F-4334-BB62-1224B3D73215">
    <sio:SIO_000111>34080-2 NURSING MOTHERS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34080-2 NURSING MOTHERS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A34F9A47-B7C3-4092-A86D-EE6977A46776">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:30109FCA-AC6F-4DEB-8DA2-400E1EF7BD38">
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FC60AC74-EBDA-41D4-B52D-99E6A4F8DB21">
    <poc:Comment>Again, refers to increased exposure; we infer metabolism.  Said decrease from baseline as added a max dose.</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FDC6F95B-339C-4DB3-AD3D-ED2779DF97AC">
    <poc:Comment>Did not annotate normal separately in this case.</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FFAD21ED-1A91-4964-8805-2A96E687B281">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Recommend</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:529AD6A6-8E8F-489A-ACB4-7A0F257564D4">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#66106-6 PHARMACOGENOMICS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>66106-6 PHARMACOGENOMICS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF0F356A-4BD3-4AB3-80E4-DF7EF3CD5F00">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:prefix>ministered with chemotherapy, there may be a further increase in the incidence of thromboembolic effects. For treatment of breast cancer, the risks and benefits of tamoxifen should be carefully considered in women with a history of thromboembolic events.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CF0F356A-4BD3-4AB3-80E4-DF7EF3CD5F00"/>
    <domeo:uuid>CF0F356A-4BD3-4AB3-80E4-DF7EF3CD5F00</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-30 12:36:03 -0400</pav:createdOn>
    <ao:exact> In a small substudy (N = 81) of the NSABP P-1 trial, there appeared to be no benefit to screening women for Factor V Leiden and Prothrombin mutations G20210A as a means to identify those who may not be appropriate candidates for tamoxifen therapy.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:22D57AAC-94C2-4570-A368-E1EA9EB21860">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:50A04DD0-6066-4535-9705-BDCF80948C12">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:599459E0-8D98-4627-BC38-BA5B6BEC6B33">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F498E725-B59B-4357-806F-4F316B1EAB6C">
    <pav:createdOn>2014-06-30 12:30:35 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:992B34F9-3D0C-4B27-BFF9-A17DF3F9A363"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:FBA8BE44-2409-4673-8D2F-0E2947538FCE"/>
    <pav:lineageUri>urn:domeoserver:annotationset:77B5C0D4-B728-4F8B-B5B3-E3B3BE2E8C85</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3159C026-77DF-48B8-9A7B-19FDC9D6FD34"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:3746E014-4500-4C39-A007-7B912571A900"/>
    <pav:lastSavedOn>2014-06-30 12:36:12 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7FE72C92-E6F3-4CFF-BC00-E77CE4051FA1"/>
    <pav:previousVersion>urn:domeoserver:annotationset:7A99CBE7-D53A-4DB8-9A92-C3D451D28A0B</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:867AF76D-D05F-409E-BE4E-FAF00531D85B"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BCD381EE-901B-423A-AB9C-3DE76C7BF9E1">
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FB39F2CB-5442-4479-A939-6FDB899B3B62">
    <rdfs:label>Do not restart</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:681E31E7-86DA-4658-959F-D62DF4BED37D">
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3AFDF697-A5A4-42EF-BE12-893415E6A1D6">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:772D1C25-7E9B-4E85-ADB4-BF14E6BF7323">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>death, nursing</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5CC24F40-EC89-4944-ACB6-F5BE5D10EFDB">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:545DF6CB-5BC9-413E-A0C5-696FCED7CD6E">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:71E2C57F-182F-4316-8B69-739932B3E614">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9D677F0E-9F2F-436D-A841-1E5038B33935">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5ED3EB82-A209-453F-8EBC-3338CD4BE633">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:84646AA6-8E85-4656-8515-E49CB15EADB4">
    <rdfs:label>Codeine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D79C039C-CEA6-4F1E-BD39-551E5EC30D17">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:055AAAC1-3544-4B8E-BF06-C99328A12B6E">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:399D443C-D2F6-4970-824D-D31A4503C94A">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B79BAC9C-6B3B-4FF1-9F24-2BD40CE200BF">
    <ao:exact>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.</ao:exact>
    <ao:prefix>Serious and sometimes fatal hypersensitivity reactions have been associated with ZIAGEN and other abacavir-containing products. </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients </ao:suffix>
    <pav:createdOn>2014-03-22 22:07:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B79BAC9C-6B3B-4FF1-9F24-2BD40CE200BF"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BA2F9D10-3477-4544-BF32-2176E0DB7BE0">
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DF92C1E1-A223-4737-8028-06DD03B558D2">
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:25F3A5BA-0A71-49F5-A250-1863F45FE3A9"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4157B9C9-C9C5-4812-8433-5DE9EDAC7F15</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-31 14:04:24 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-22 22:15:05 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC17395A-7D36-45CC-BFB3-4271FD68383B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:76AEC8EC-841B-4618-8A97-4D6655CE39F4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:476620C9-1693-43B1-9388-D0A05A007BB0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:108444AC-C8D7-42EE-A011-BE98A3F592F0"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9258FFBC-DCDC-4C6C-A375-9FC03C323B54">
    <rdfs:label>Azathioprine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3616601B-9F53-4ECD-985B-8205444D8F7C">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55B89580-2E0A-4A7D-B09D-AFAF8BF0A3CC">
    <rdfs:label>Do not restart</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55BCCCDC-ED3F-427D-AFFE-0E80E459C63A">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-03-31 09:01:41 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:suffix> Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen i</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:55BCCCDC-ED3F-427D-AFFE-0E80E459C63A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Screening for carriage of the HLA -B*5701 allele is recommended prior to initiating treatment with abacavir. </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5CCA20AA-4D3C-40F4-BAED-C832E665FA35">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:719A5C02-D66E-489E-89AA-07BB27CD191F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DADB08A1-6AB5-4DE3-83DF-A8D4A8A12E2F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:8026784E-DC9A-4F18-963D-495E0532BB97"/>
    <pav:lastSavedOn>2014-06-30 11:33:55 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6633F336-4557-4642-A5C6-1A8E0057B2A9</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A1A364D-4605-4907-84D6-773AB8094C55"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">24</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:1BE9D66D-0F12-4A57-A32C-C93C2329C708"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AFC75336-C9AF-46CD-8D54-9AF03B796A96</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:ABEE5CB7-ED0D-41AF-9E83-A2013E029601"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7DEDF8DC-A385-40F7-A245-769DD46D6F05"/>
    <pav:createdOn>2014-04-28 15:25:28 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5F64639D-C8D4-4F49-9DA5-D0F85949DC0D"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:4E001AB1-2305-4837-8AF8-180376395180</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:A8189564-74C8-463F-9927-917478975C75"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0346E7F6-185E-4FDE-B2EB-671C0576CC75"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:752AF63F-9AC6-4011-8D37-310DB23CFB68">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:32F674E2-70DC-4D21-87DA-B2FC17FC2EF5">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#intermediate-activity</poc:Variant>
    <rdfs:label>intermediate-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:79AEDAF0-0AC0-4A44-9F6D-05B14ECEF74F">
    <ao:context rdf:resource="urn:domeoclient:uuid:E014618E-3373-4F61-BAF6-4ABD45885081"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FFAD21ED-1A91-4964-8805-2A96E687B281"/>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1DAAEA11-218C-4430-A00D-10DF6F5EE0E7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:49BB5EDC-8915-4D4F-8243-415CFB7F13FA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F45C51D-C093-4FEB-A57B-7D59EB1E01DA"/>
    <pav:previousVersion>urn:domeoserver:annotationset:9CD1FA68-606B-432D-868F-5FA9882274FA</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">43</pav:versionNumber>
    <pav:createdOn>2014-04-14 14:52:36 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:12074DF7-B46D-47A9-8527-792E360269FF"/>
    <pav:lastSavedOn>2014-06-23 14:40:12 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:D5500718-FBE6-4836-BA4B-D8CE04084F18"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8112D95B-8CA4-42C2-8097-E42E759FEF68">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:56C616E5-80D0-4A03-8C0B-348E4596BF51">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CBD21A8A-BC49-4B8A-B7A3-E42A5C22F7CB">
    <poc:Comment>Add drug selection recommendation of "indicated for"</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5B264A8F-827F-4546-BEC0-334B51ED1056">
    <poc:Comment>how do we code \\\\\\\"tell your doctor\\\\\\\"</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:482A9B43-D4B0-4890-91BF-CD5DEC8C7BA6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>metastatic breast cancer, postmenopausal</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B64EB4D6-84C3-4D10-8AFE-B0CD4E578749">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#excretion-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Excretion Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in excretion of the drug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:026B6D2A-8163-421F-B9FD-6DD02C0747FE">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:51EA4BF7-D3D9-48AC-8608-E62CCAE8CF75">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>66106-6 PHARMACOGENOMICS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#66106-6 PHARMACOGENOMICS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9DB50485-E87B-495A-97A1-CE8F7916E40D">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D1F73A7B-87F7-4F2B-93BA-E28FF40C75AD">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:977E5F5B-8852-45BE-A6FC-8DEB91191DED">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-06-23 14:40:56 -0400</pav:createdOn>
    <ao:exact>For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk.</ao:exact>
    <domeo:uuid>977E5F5B-8852-45BE-A6FC-8DEB91191DED</domeo:uuid>
    <ao:prefix>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:977E5F5B-8852-45BE-A6FC-8DEB91191DED"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5F8131DC-9505-49D1-BF90-FE6E3DEDF87C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-SNP-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-SNP-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5EE59E00-2977-4F09-A933-867C3E165210">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:62355131-B3CD-4D53-A9E0-B1F52DABD85D</pav:previousVersion>
    <pav:lastSavedOn>2014-06-30 13:20:01 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B9375CD1-7E67-42D6-B380-D95AD08BF64B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D4B543B9-2CFB-4DD5-866F-75375A4F94EA"/>
    <pav:lineageUri>urn:domeoserver:annotationset:68A10F51-6D9E-47A6-8097-DBB3E93CB776</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A47452DD-7832-44E5-BAAD-AA6F9248F971"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:4EF0C28D-12C2-45C0-80E6-19CEDE1069C8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:001C41DA-FFD9-4CBB-BD9F-23AB499D74AA"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:78CB3193-D01C-49AA-B39B-C35887919EED"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B6DAC59D-AF4D-4014-BA7D-4E214B9102CD"/>
    <pav:createdOn>2014-06-30 13:20:01 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1CDD08-AC31-4AA0-9F78-BF28E53FBF90</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:FB9019FF-0075-4223-97CD-9869E977448D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C376A26E-0D2F-4BC1-8979-87D6DC5338C7">
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56ECCD1C-D5DA-4A5F-A470-A96F404E1CB8">
    <pav:lineageUri>urn:domeoserver:annotationset:77B5C0D4-B728-4F8B-B5B3-E3B3BE2E8C85</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:147B38AF-9E51-4D8A-B5CF-D7FAE7375257"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <pav:lastSavedOn>2014-06-30 12:38:17 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdOn>2014-06-30 12:38:14 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3616601B-9F53-4ECD-985B-8205444D8F7C"/>
    <pav:previousVersion>urn:domeoserver:annotationset:0E79262F-3D42-431A-B631-A20D483C3172</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:310AE3DF-6DB4-40D9-809E-0B80BB047A8F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:52237365-23A3-4118-A8F8-316E02FC46D9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC60A959-7F51-4A07-AC53-377513C87002"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A5C6F1FB-AC9B-4B8C-A170-5BBAFC3A938E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:87C8AC12-6BA5-4D3B-A53C-9F5CBB063BCB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F4F18F4C-715F-4BFC-9F0A-7EDD54559C59">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity </poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6DB437A-60FD-4998-97F4-9BA04097046A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:746B1DCC-2D97-4F85-9CB7-22A8D2279302">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:25C49718-6AE6-438C-9388-8CDE7669E406">
    <sio:SIO_000111>43679-0 MECHANISM OF ACTION SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43679-0 MECHANISM OF ACTION SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:54804CDF-87E3-4C5C-9C13-A18143DF3B86">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:161EC61C-3A7E-4CCF-93D6-FA3749DF7BAF">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:78CB3193-D01C-49AA-B39B-C35887919EED">
    <ao:exact>Identification of risk factors for bleeding and certain genetic variations in CYP2C9 and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>78CB3193-D01C-49AA-B39B-C35887919EED</domeo:uuid>
    <pav:createdOn>2014-06-30 13:20:01 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:78CB3193-D01C-49AA-B39B-C35887919EED"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:814CFBFC-9845-4B07-B4DE-628384917722">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA0C425E-2A1E-4059-BAC2-34BD4239836F">
    <ao:exact>In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estrogen- and progesterone-receptor levels less than 10 fmol. In women aged 60 to 70 years, there was a trend toward a beneficial effect of tamoxifen without any clear relationship to estrogen- or progesterone-receptor status.</ao:exact>
    <domeo:uuid>FA0C425E-2A1E-4059-BAC2-34BD4239836F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FA0C425E-2A1E-4059-BAC2-34BD4239836F"/>
    <pav:createdOn>2014-06-30 12:25:05 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix> </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F4A1F36B-587E-4CAB-89F7-D0D9C1FF9786">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16882C5F-4C53-4466-A9CC-FC6BCF5EEE08">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C65A90AC-060B-4128-BBC1-2590A86A3560">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Not Important</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is not associated any clinically relevant pharmacokinetic with respect to the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F96C1A6A-B9D9-48CC-8285-213F65E552C0">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>ESR1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7C3837BB-DAF7-4544-9D2C-A63E2F406BAC">
    <rdfs:label>Codeine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5F4B7893-348F-4B09-866A-BE0644080293">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7418F8FB-E11B-4F6A-946C-8B25C6E6F9DB">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46A370D2-9D5B-4964-96D7-FECDB2FC0ED4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>6-MP undergoes two major inactivation routes (Figure 1). One is thiol methylation, which is catalyzed by the enzyme thiopurine S-methyltransferase (TPMT), to form the inactive metabolite methyl-6-MP (6-MeMP).  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <domeo:uuid>46A370D2-9D5B-4964-96D7-FECDB2FC0ED4</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>TPMT activity is controlled by a genetic polymorphism.1, 2, 3 For Caucasians and African Americans, approximately 10% of the population inherit one non-functional TPMT allele (heterozygous) conferring intermediate TPMT activity, and 0.3% inherit two TPMT non-functional alleles (homozygous) for low or absent TPMT activity. Non-functional alleles are less common in Asians. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:46A370D2-9D5B-4964-96D7-FECDB2FC0ED4"/>
    <pav:createdOn>2014-06-30 12:03:38 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D5500718-FBE6-4836-BA4B-D8CE04084F18">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:027C2589-BFC8-4644-BDD7-59E1118E9A50">
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A8189564-74C8-463F-9927-917478975C75">
    <domeo:uuid>A8189564-74C8-463F-9927-917478975C75</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-06-30 11:33:40 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A8189564-74C8-463F-9927-917478975C75"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:exact>The effectiveness of clopidogrel bisulfate is dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 [see Warnings and Precautions (5.1)]. Clopidogrel bisulfate at recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers</ao:exact>
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE534BB0-3042-44F4-9B63-01291E28FA45">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:50D99A83-E2FD-49AC-B6AB-60C0E1E0DF6B">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8164B1B9-99ED-45DC-992E-89D704D2A080">
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:00AD9037-A37E-4477-9CCF-AF769A47482B">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4CED47B0-38B1-4BA9-872C-2F35C0387D71">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E7BEB44-17B2-4A01-8866-7DAFBEA17CC6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Discontinue ZIAGEN as soon as a hypersensitivity reaction is suspected. Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6E7BEB44-17B2-4A01-8866-7DAFBEA17CC6"/>
    <pav:createdOn>2014-06-23 14:23:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:prefix>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.  (5.1) </ao:prefix>
    <domeo:uuid>6E7BEB44-17B2-4A01-8866-7DAFBEA17CC6</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60CFE292-6834-41FC-8255-B81A3D584EE2">
    <pav:createdOn>2014-06-23 14:23:46 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:60CFE292-6834-41FC-8255-B81A3D584EE2"/>
    <domeo:uuid>60CFE292-6834-41FC-8255-B81A3D584EE2</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Discontinue ZIAGEN as soon as a hypersensitivity reaction is suspected. Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <ao:prefix>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.  (5.1) </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:514D9B63-92BC-45AD-B61F-062FD65D8BF2">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:45B95464-0287-435F-86B4-0253D73E6DA8">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-06-23 14:39:45 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>45B95464-0287-435F-86B4-0253D73E6DA8</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:45B95464-0287-435F-86B4-0253D73E6DA8"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>CNA106030 (PREDICT-1), a randomized, double-blind study, evaluated the clinical utility of prospective HLA-B*5701 screening on the incidence of abacavir hypersensitivity reaction in abacavir-naive HIV-1-infected adults (n = 1,650). In this study, use of pre-therapy screening for the HLA-B*5701 allele and exclusion of subjects with this allele reduced the incidence of clinically suspected abacavir hypersensitivity reactions from 7.8% (66/847) to 3.4% (27/803). Based on this study, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected hypersensitivity reaction during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele.</ao:exact>
    <ao:prefix>Studies have shown that carriage of the HLA-B*5701 allele is associated with a significantly increased risk of a hypersensitivity reaction to abacavir. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8D47DE7C-DABA-41CE-B00C-7DA122057C67">
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F10DDB11-A5F0-4B5E-B3CE-47B1F2145E34">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:suffix> For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outwei</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F10DDB11-A5F0-4B5E-B3CE-47B1F2145E34"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.</ao:exact>
    <pav:createdOn>2014-03-31 09:02:38 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6B4C9D47-E3BF-4D75-A661-0D5A649108C6">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clopidogrel</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D2DE610F-DC5B-42B2-8C18-D03E18FE3264">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D875AEA0-EDFF-45B6-AF0C-AB1DC31DA25C">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:87D81A76-B588-47D8-B1D5-76A8263D6516">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34067-9 INDICATIONS AND USAGE SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34067-9 INDICATIONS AND USAGE SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:82545F4A-39F9-48B3-A816-0B653AEF77CA">
    <poc:Comment>Add test result</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A866D2C0-CF5C-4F12-AE01-8E04BC77D311">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701 </ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7BFF4A61-D45D-4C1F-9599-BD435EF039B8">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7BFF4A61-D45D-4C1F-9599-BD435EF039B8"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:prefix>HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. </ao:prefix>
    <pav:createdOn>2014-06-23 14:26:33 -0400</pav:createdOn>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>7BFF4A61-D45D-4C1F-9599-BD435EF039B8</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5C01B11A-0A96-4782-8474-7B0B0F7074FD">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34075-2 LABORATORY TESTS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34075-2 LABORATORY TESTS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:481D46BB-D4FB-4587-B147-C2FC166A7A51">
    <ao:suffix>Therapeutic doses of warfarin decrease the total amount of the active form of each vitamin K dependent clotting factor made by the liver by approximately 30% to 50%.</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient's VKORC1 genotype. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:481D46BB-D4FB-4587-B147-C2FC166A7A51"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <pav:createdOn>2014-06-30 12:49:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>481D46BB-D4FB-4587-B147-C2FC166A7A51</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C11F474C-5FE5-41F1-BF97-71793CD0C79E">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5662AE7C-04D2-4B36-91D7-EE2DC27AB384">
    <poc:MedicalCondition>breast cancers, mortality</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:83AE278F-105A-4DE5-A541-EDB41878FEE9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C5DDB9F7-C202-4F11-830A-22AC8C32D972">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:49BB5EDC-8915-4D4F-8243-415CFB7F13FA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FED638A3-F491-4246-B5EC-651C306CF76E">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D939C426-7E0B-4A32-80F1-7344D702AA97">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Citalopram</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87D0F0C2-6038-41AA-B84E-85497D292836">
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>NSABP B-14, a prospective, double-blind, randomized study, compared tamoxifen to placebo in women with axillary node-negative, estrogen receptor positive (≥ 10 fmol/mg cytosol protein) breast cancer (as adjuvant therapy, following total mastectomy and axillary dissection, or segmental resection, axillary dissection, and breast radiation). After 5 years of treatment, there was a significant improvement in disease-free survival in women receiving tamoxifen. This benefit was apparent both in women under age 50 and in women at or beyond age 50.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-30 12:27:38 -0400</pav:createdOn>
    <ao:suffix>One additional randomized stud</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:87D0F0C2-6038-41AA-B84E-85497D292836"/>
    <domeo:uuid>87D0F0C2-6038-41AA-B84E-85497D292836</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E91F8D63-309E-4A05-9F9A-6C42F2D86071">
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3919A0FC-9B55-4ED7-9514-90C32737E519">
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:98E9963D-2C0C-454B-A9DC-070814A6B531">
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F422F587-45DC-4DC7-A282-356062E94D7C">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Add test result to drop down</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:21B282F1-F0CA-488A-B703-88611F099D16">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4743B32B-A374-4701-B3BA-DD766AB522F6">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-23 14:41:38 -0400</pav:createdOn>
    <ao:prefix>In any patient treated with abacavir, the clinical diagnosis of hypersensitivity reaction must remain the basis of clinical decision-making.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4743B32B-A374-4701-B3BA-DD766AB522F6"/>
    <domeo:uuid>4743B32B-A374-4701-B3BA-DD766AB522F6</domeo:uuid>
    <ao:exact>Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C940F77D-EACF-4BC4-BF01-761762EDF0C0">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:05220B0B-E773-4262-8FFB-37C20132138B">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C19</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4F3A0EB6-D824-48B6-9824-5CFC954EB8B7">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A47452DD-7832-44E5-BAAD-AA6F9248F971">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>bleeding</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EF8CD2C6-A0E1-4347-BE88-A674C977C78D">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Add drug selection recommendation of "indicated for"</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A2E1BD4-3863-4A37-AD9D-6B54F3CF3E54">
    <ao:body rdf:resource="urn:linkedspls:uuid:CFEC8925-05FE-4B69-A89C-06BBA59517E9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:57C31E76-2CAB-44D8-BF63-BD3A403D8090"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">18</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:9DCD19CE-D636-45D6-B994-A9BDBCA32621"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:74942373-FA09-4BCE-8D7C-94D0B41F258F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:84E1DA52-81E4-4BFA-B539-5B91FB1CCCD7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E95CB72B-266C-4522-BB11-260AD99D20A1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3AE8BFD1-C5F0-405A-AA64-8DF1B1E22071"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2843A3D9-6EFA-4C13-B8B2-56032F725BBD"/>
    <pav:previousVersion>urn:domeoserver:annotationset:605F34B5-3AC2-42FC-B392-282A5716080C</pav:previousVersion>
    <pav:createdOn>2014-06-02 14:21:06 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:813B467D-E573-4F02-B5FD-95E3A0050ADC"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0A52235-7692-496A-9DE2-B919FD0C2AC7</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:79A9C552-B02F-4A1B-8528-B0341E6E516C"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:BCAE5E0C-30F2-4E8B-8D8E-687ADD4CA18B"/>
    <pav:lastSavedOn>2014-06-30 11:50:24 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:E319F066-2C3E-4B8B-904F-5B682C614A92</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E2CB9FD-6E66-4D71-8B92-4AE2C557E1A3">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7E2CB9FD-6E66-4D71-8B92-4AE2C557E1A3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>HLA-B*5701-negative patients may develop a hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</ao:exact>
    <pav:createdOn>2014-03-22 22:14:51 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9B2F43E4-7567-4CE3-A607-E0FC62A2C865">
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Prodrug</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:24265221-E0B1-4F13-A2EB-0E9D9DC6F5D4">
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E2D22DB5-DE0A-472B-A6D0-2BFCA267886E">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3542</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>F5</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CD75F884-0A53-4582-AC31-492E9137F76E">
    <rdfs:label>Metabolism Increase</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B97B97E4-D927-457C-8BC7-8AF594D5FD9F">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>42231-1 SPL MEDGUIDE SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42231-1 SPL MEDGUIDE SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C6B564A1-ECD5-4228-8E37-B298AE35DE9A">
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AB84AE09-1714-467B-BBDC-93DAA3B339A9">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D742086D-FBE4-4E5E-8129-F5C607743253">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4DA93D3D-14FD-4739-A7EC-F5ADCEDB5CB0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D777A328-AEC0-4B48-8600-F84337D718D1">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>42231-1 SPL MEDGUIDE SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42231-1 SPL MEDGUIDE SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B90750B7-FB2D-473A-BDC7-2488F5F05E49">
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:78AFE987-8397-4F6B-BFB1-A215075C2797">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D8B0CCC0-6E93-4175-9490-3B07D43C176E">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1F9B8CBD-BC64-4EF6-A7CE-5ED4242D4C3C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:283D346E-70C4-4BA5-A324-BF69F44C2CDA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7837AD3A-635E-44DB-94FD-C81623976C01">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E04D6C70-2D6F-4D7B-88FD-4E2EF8886CAC">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6D6458DB-4B7A-4047-9A4E-854DB95439BF">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34070-3 CONTRAINDICATIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34070-3 CONTRAINDICATIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B077986-2A80-4158-9CAE-260BB4A5C061">
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0F7495B8-0992-476A-98CC-CD6EF2EC377D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>FIX TABLE</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:97694242-B4F8-4F1C-BB40-15F7AA4313B0">
    <poc:MedicalCondition>post menopausal</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E6EA4868-B541-4A53-9D34-1E6CAD274D8C">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34071-1 WARNINGS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34071-1 WARNINGS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F2185B16-8B27-4708-8E81-3BB0550B3A35">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C149CB6A-CE40-4BB1-914A-78298BDE4A29">
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4C36F11A-E282-4BFB-849D-B93A233A50FB">
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ABC38527-F428-4D89-B349-CF1D993B7031">
    <sio:SIO_000111>34092-7 CLINICAL STUDIES SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34092-7 CLINICAL STUDIES SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0346E7F6-185E-4FDE-B2EB-671C0576CC75">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A397B9B2-FD1E-4F7C-AF2A-E574DDFC476A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6EA9FCCB-EF84-4E0D-874F-C372EAFEDA19">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A4216A9D-F032-421F-A904-D698F0AFF3D1">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:98D18AEE-09C7-40A9-A144-DE02F0A10386">
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9A5666BB-F43D-45F3-A856-0BDB0E745589">
    <domeo:uuid>9A5666BB-F43D-45F3-A856-0BDB0E745589</domeo:uuid>
    <ao:prefix>Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for non-functional alleles) .  </ao:prefix>
    <ao:exact>Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9A5666BB-F43D-45F3-A856-0BDB0E745589"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-30 12:05:03 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:103A8210-5E84-43A2-AE2C-0BDD939E55BE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:797741A1-950B-4AB4-AACC-91449700A96E">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8696D99F-9273-44E6-ABE8-8C347A8CBFE3">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D5483BE2-25AD-4265-9A40-3155983DEB22">
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D6235B22-042E-4C36-A104-B353CF92CEB8">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1918EE39-EC8D-40CD-88DD-7786F622ADD4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DDEE7195-B373-41DA-9360-816DBE73CFFB">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:40C626E6-884D-4EA1-A1CA-C16B5F06A3F0">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-high</poc:TestResult>
    <rdfs:label>biomarker-level-high</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6E09256C-E565-492C-8E37-D44BE4F2A39C">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>VKORC1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2D733131-6044-41CF-8DEA-55AB5AE7B320">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A20BC568-9BC7-4FA0-9C43-A5A490A74650">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:992B34F9-3D0C-4B27-BFF9-A17DF3F9A363">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:07F347BB-54A7-4EBD-96D0-3FEE77788DE0">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DD3DEA1B-6E10-43EF-A6FE-6549093794BB">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:048C3B36-1BEC-46CD-96A0-C39142C44747">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6E5E175F-14BE-4D3D-B53D-AFBEAC6D049F">
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1E6D8BE7-AC23-449A-83E2-9806683F8162">
    <pav:createdOn>2014-04-14 15:01:13 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5F22FE69-5D03-4E0A-95BF-D779C67A2FCF"/>
    <pav:lineageUri>urn:domeoserver:annotationset:58174CF3-E5D8-4BEC-8857-1BD326C312E6</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:5B205954-23AF-4A0B-B3D4-BF9F14E83942"/>
    <pav:previousVersion>urn:domeoserver:annotationset:436736A3-D943-4562-9B1B-725C6DA22266</pav:previousVersion>
    <pav:lastSavedOn>2014-06-23 14:43:25 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:8AFC4AFD-4B5C-4E61-BE29-E2952A9887A0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF7AF633-8B36-41BF-AC4F-0BA548A0DB2F"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:8E64225F-F6B0-40B1-B4DB-69CB3ADCCA82"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:30109FCA-AC6F-4DEB-8DA2-400E1EF7BD38"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A605AB42-068A-40D5-839C-9FE2F1ADA4A6</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:59E1AD64-B70C-45AC-B670-8CA9256F6329"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">27</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC19F85C-8A63-4FF5-AC2E-DB69D0D86182"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E826D255-0A7E-4F3C-A59F-675E8A9B606E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AB7285FA-D26A-4A3E-88F3-722B5A433B2B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0C61F885-2CC4-4FD5-8D20-539146E86B02">
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD33E8D1-8AEF-4E43-9C57-35AB0263305D">
    <domeo:uuid>BD33E8D1-8AEF-4E43-9C57-35AB0263305D</domeo:uuid>
    <pav:createdOn>2014-06-30 12:04:08 -0400</pav:createdOn>
    <ao:exact>Patients with intermediate thiopurine S-methyl transferase (TPMT) activity may be at an increased risk of myelotoxicity if receiving conventional doses of azathioprine.</ao:exact>
    <ao:prefix>Severe leukopenia, thrombocytopenia, anemias including macrocytic anemia, and/or pancytopenia may occur in patients being treated with azathioprine. Severe bone marrow suppression may also occur. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BD33E8D1-8AEF-4E43-9C57-35AB0263305D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C6702551-6F18-47F3-B973-CEA4BD6F762E">
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Recommend</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:43B85AB2-533A-4A3B-932F-7CD7177449ED">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E9858AE-79C0-437B-A7EA-AD326494395F">
    <rdfs:label>Recommend</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D6B65EB6-3BF7-43C0-BEF9-77B5DC9D2601">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>VKORC1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2510C893-9155-453B-922C-CF116136DD88">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4E3D25B8-C473-4C01-A52F-0E6E3FDDBEFD">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A00084F3-6649-4F9C-BDA5-E261BBC74F3B">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34092-7 CLINICAL STUDIES SECTION</poc:productLabelSection>
    <sio:SIO_000111>34092-7 CLINICAL STUDIES SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:617FB23D-D90B-41A9-B13D-112F0724E0EC">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:79122512-81D6-47F4-B441-ACD1ADFE6704">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF67FF75-E560-4D2F-BDE0-15789AF13759">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:968D281B-12B7-4913-8E9E-AB28B7A5515C">
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:375DD3AE-F16E-43E9-BB3E-D521613E10AF">
    <domeo:uuid>375DD3AE-F16E-43E9-BB3E-D521613E10AF</domeo:uuid>
    <ao:suffix> In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estr</ao:suffix>
    <pav:createdOn>2014-06-30 12:24:05 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:375DD3AE-F16E-43E9-BB3E-D521613E10AF"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:exact>In the Hubay study, patients with a positive (more than 3 fmol) estrogen receptor were more likely to benefit.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B18AC1F-0336-4DE3-AE4A-C9C0CE29BE6B">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:25A77C80-E001-4AFE-9AB5-73749FB780F9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0A43F475-9E2C-483D-B6D9-13930E867A59">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3F354582-DE01-47DD-929D-B501E8EB5B46">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16C3120F-E19F-453E-9222-0C4CAA7503EB">
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A2BBBDE3-D2ED-4260-A2C1-CD5432736CE7">
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:558B5390-D54F-492E-8261-0744746B91C7">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>Doesn't really say decreased metabolism for PK outcome, it says increased levels or exposure, but not a choice.</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:933C6C55-0C1F-4A1C-B72F-98683FD68184">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3AAC0EBB-C224-465A-B843-D37FD8017876">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ACECDF46-D28E-49E8-B2DF-97FC16B093EA">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>Added test results (or categorize as poor?)</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2293D62E-8DFE-4093-89D0-CE5AFE62A5D7">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60EEDE7C-ECAE-4AC4-8E21-0B889A0CACD8">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9A365B9B-3FE9-4C17-AFDC-838F7A683714">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4777BC06-68FA-4171-A52D-68668AD25547">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:30201CA6-94D8-4A83-9451-AF1497A97E75">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>HLA-B*5701-negative patients may develop a hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</ao:exact>
    <pav:createdOn>2014-06-23 14:35:56 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:30201CA6-94D8-4A83-9451-AF1497A97E75"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>30201CA6-94D8-4A83-9451-AF1497A97E75</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:prefix>For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FBEDA24D-50C7-407C-9337-9A08D9456999">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC47136B-865E-48AE-AD43-B4C2E038387D">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7E8BE7BD-6706-41DA-8A1D-0B7370BBB62B">
    <rdfs:label>Required</rdfs:label>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:MonitoringRecommendation>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A required monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E7A7C80F-C900-4A84-AB0D-3F983C8ED120">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1698D07A-FEE7-4646-9922-CE7AE1E284C6">
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F2C1F1F7-17ED-4AE1-91F9-3A2EE9802A65">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>WARNING: DEATH RELATED TO ULTRA-RAPID METABOLISM OF CODEINE TO MORPHINE\nRespiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism.</ao:exact>
    <pav:createdOn>2014-06-30 11:48:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>F2C1F1F7-17ED-4AE1-91F9-3A2EE9802A65</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F2C1F1F7-17ED-4AE1-91F9-3A2EE9802A65"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0F7B1E31-9D8A-45AA-8F34-A942EE6FBB80">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0479EB37-CD5B-497D-AB68-C261585B92A1">
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <rdfs:label>Recommended</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B17B8190-D4C0-47BD-93D4-59EF1FB8A973">
    <poc:Comment>Add drug selection recommendation of "indicated for"</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F01C02F-0F0D-49BE-8BFD-675A75F2FC42">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34092-7 CLINICAL STUDIES SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34092-7 CLINICAL STUDIES SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2843A3D9-6EFA-4C13-B8B2-56032F725BBD">
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:58DF4FFA-C471-49E6-B1E7-F9AD44FF292D">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>No gene symbol for protein C (PROC) and protein S.  Add a not there for the future.</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D64C9075-1FB5-47EA-9312-70A065865D71">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B39F957-E88F-427C-AC41-F1B9DC711A02">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Citalopram</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E67801C-8D8E-4822-9211-BFA28585585E">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:95001B32-BCDE-46A6-A31C-19D445F40585">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na713f4159fa74743bdad29a749ba7fee">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:33DF4147-AF32-4C0A-BC7E-F80CCCE6834F">
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4162AC13-E724-4245-A26F-FB7A7E5DE47B">
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:26F33332-4430-4B1C-AEDE-DC532B427FC2">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34070-3 CONTRAINDICATIONS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34070-3 CONTRAINDICATIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F54C376-30A1-41D7-8621-445FDA308DB9">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F4B6BFE-FDCE-4584-B309-F2FE0FFE0892">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E88FDC54-C499-48EE-BE43-B919760B2AB6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>Drug selection refers to other drugs not drug of interest.  ?  Add Drug selection recommendation or not?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:905B00B5-CD9F-4F5A-BDCD-2E0771AC9B73">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A26C991-50B7-4DDC-BF64-F11EE048F98A">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:787BD215-4E21-4960-A53D-22791987879E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F5009394-6930-445F-90B3-92BC6075D38B">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:97A00FDB-1B7E-4BA6-B531-7DA063BAC30B">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:25F3A5BA-0A71-49F5-A250-1863F45FE3A9">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99D32DEA-1DC0-471A-B15D-40992DFDA3E1">
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3D225325-6881-4075-B90F-BA7C163EF10B">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:549211CB-8AFF-415A-B1BD-09BC38B52755">
    <poc:MedicalCondition>Abacavir naive</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:27ECD580-6FBD-4860-AF7C-6D918CCAA65F">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2185EE39-FD81-4C83-ABDF-E5D59B789F96">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91373757-CDC9-41DF-834E-F17713AEE49F">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6C85B913-2858-4D1D-9AAF-E971C083B56E">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2271B33C-B8BE-45D2-BE91-FC49EEC7F4DA">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2423954D-96B2-404E-8B04-9609825C795A">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:07F4F9C7-1286-482C-9AD5-B17158B8DE17">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA3DC068-1206-46E2-9872-6AA4128F9AA9">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D181BF33-A971-4C1A-8908-20D2F9B0EA61">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A9263118-2AF9-4363-A044-80F842A46F75">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:37614B56-7E7C-420A-959A-82B4155B865F">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5666EA61-2604-4EA0-923E-C3F3965ED1CA">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F45F585A-05C5-49B5-BABB-73BFBE9E9753">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BAF9B034-78F8-482A-9158-845E6B793A4E">
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:09AF0419-C474-466C-9CFA-513366CFB1B2">
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2EF12CE2-C7B6-43E9-8273-1A86AC282CD6">
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Concomitant medication concern</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7780497E-7FA1-4043-A85C-7AD8535B86EB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F3229B1-9DC9-47C2-BAA8-1B7679F38B10">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77594AF7-4C1F-4FAA-8FC3-84489C84CB17">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D3EDFFC9-9EE3-45DD-B147-801DAB72DF3D">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Citalopram</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7673EC96-E39E-4D34-A8B6-A31AD2825C94">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>If hypersensitivity cannot be ruled out, DO NOT reintroduce ZIAGEN or any other abacavir-containing product.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-03-22 22:20:08 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:exact> Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7673EC96-E39E-4D34-A8B6-A31AD2825C94"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8C44EE5A-5A11-4743-B389-617115FC82BB">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ED434685-C34B-43FB-AA23-F008E3AF787A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A54084C7-81C5-4C71-AEA4-AD05D852A4AB">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F927F2EB-CF06-484F-BF67-71173603066C">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:38963F49-DA9B-4119-8270-79A2613AA599">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>respiratory depression, overdose, extreme sleepiness, confusion, shallow breathing.</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E2D2D450-639D-4D10-B6B5-D0735D582167">
    <rdfs:label>Recommend</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F9A68240-FAD6-4604-8DEE-1B0E4AF9BD21">
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4D27D69B-2F63-4940-AD74-710454AA1E6A">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E2118E19-85E9-439B-A2BE-5001150AB7C2">
    <rdfs:label>Recommend</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:63302B4D-3943-432F-9962-94FC88216BF3">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34092-7 CLINICAL STUDIES SECTION</poc:productLabelSection>
    <sio:SIO_000111>34092-7 CLINICAL STUDIES SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3728C2D2-73B4-4F3A-A648-FD42247BA4EE">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60854BED-9BA2-4BC9-B21C-3D443607A39C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D4DBC7AE-A1A8-401A-9345-BB0D2918876C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>previously tolerated abacavir</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E86A2192-2C3E-4D7F-A0BC-6E287398885C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1532F8ED-1CF3-45D5-8A36-00FA8FD6060D">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ED198F67-8FAC-4F01-B6A5-79EF37E40269">
    <rdfs:label>Recommended</rdfs:label>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D1DA67AC-9434-4681-B83E-62E189DF97CF">
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8648AFA6-90E3-4694-9036-FA71297EDFF7">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#66106-6 PHARMACOGENOMICS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>66106-6 PHARMACOGENOMICS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DC523344-070F-4A21-93A7-EA5583F3D921">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:85E2D258-637C-4BA3-8639-3A9449CB6A79">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>intermediate-activity</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#intermediate-activity</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A4C02E85-B069-4AF9-BE5D-3C781D0C2CC1">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6D228B36-7EE7-4E73-A125-2D77761283AF">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-level-low</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE4DF0AD-E3A1-4585-AD52-A6AA64D0349C">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C19</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1A3E31C8-D293-4C5F-8F69-0259C4EBE393">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9B46003C-0670-415D-A0B8-07A2C1200DF4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>biomarker-level-low</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C2A76A18-A463-4D7B-9A00-33BEFE84F768">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Carbamazepine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:96D64C07-9E27-46D2-BE64-358670990970">
    <ncit:Alleles>CYP2C9*2, CYP2C9*3</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CE76789E-AB5D-4F50-AF22-F3C2D4249992">
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E84521E-DB93-437E-ABDA-390CB71443FA">
    <poc:Comment>Add test result</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DD65D0CA-5F1F-4015-B5EA-5786A91B7E0A">
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1AAAE07-F302-4333-81C8-E2017D3BEC00">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6477100F-B124-46B7-94A1-A46956E0A307">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0F28EBB9-5E26-448C-911F-5DD64A1FA5F7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B86AA3CC-B57F-4BBB-A6C0-F20063F46FFF">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#extensive-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>extensive-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B9375CD1-7E67-42D6-B380-D95AD08BF64B">
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C300EE60-7029-4644-9136-83C2EBF50E3F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B9C6119C-3C0F-46B0-8614-1EBBBA8066D4">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB8F110F-7415-4B13-AB5B-23F1D7A1C6BF">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <domeo:uuid>DB8F110F-7415-4B13-AB5B-23F1D7A1C6BF</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>I</ao:prefix>
    <ao:suffix>4</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DB8F110F-7415-4B13-AB5B-23F1D7A1C6BF"/>
    <pav:createdOn>2014-06-30 13:06:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>n an observational study, the risk of achieving INR &gt;3 during the first 3 weeks of warfarin therapy was determined in 219 Swedish patients retrospectively grouped by CYP2C9 genotype. The relative risk of over anticoagulation as measured by INR &gt;3 during the first 2 weeks of therapy was approximately doubled for those patients classified as *2 or *3 compared to patients who were homozygous for the *1 allele.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BDDA7498-9665-4B25-9958-F37E05C7F491">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2CE370A4-8DC5-44D3-8AAE-0A421EF97BCC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:75C4424E-2C9D-40D9-82CF-7E02CFDCA301">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FBA969DE-1978-4391-A338-E793E7F5F06C">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D43C334C-4869-4108-9C67-E96EA2063195">
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52F46F4F-994A-471F-88EF-A2701E9008A7">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A54E0819-D1CA-4418-838F-FA1698E5AB14">
    <dct:description>Referred to Prodrug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:19F33D58-FE1E-46C1-B076-70725190FF1F">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:790612C4-9930-4507-A202-C3A323979033">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:00B62E1D-9BFE-498E-82E3-A23E5F356480">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:677AE6BB-D9DD-44B7-90F8-559967319E56">
    <ncit:Alleles>multiple copies of the gene for cytochrome P450 isoenzyme 2D6</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:028082D6-59BF-44E8-9117-CC155DA8D008">
    <ao:prefix>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:028082D6-59BF-44E8-9117-CC155DA8D008"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-23 14:40:32 -0400</pav:createdOn>
    <ao:exact>For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk.</ao:exact>
    <domeo:uuid>028082D6-59BF-44E8-9117-CC155DA8D008</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4DD12842-1372-434A-AAAC-CF806F82DBB8">
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:20E1A485-18B3-4C4F-82DA-B81AB694ED2D">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9816DE92-75B8-4F98-BAC5-A337C56E26C8">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0D634683-D28C-42DC-9911-DFD0C9EB289D">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ED9FC62F-6F5A-4AEC-B2EB-900F4C21E312">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Carbamazepine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B3F5BE7C-7508-4D94-B8EE-CF1506541167">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CD7BE61C-D111-48EB-A232-1241D41AB8BC">
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C3F6629B-C646-4E20-9EDB-BD57E82CEDE7">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2277FF0A-7DF0-46CD-A37F-9F346456C2BE">
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7BC21EEB-9DB7-4481-AB5F-CDF2B8C45D96">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7BC21EEB-9DB7-4481-AB5F-CDF2B8C45D96"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>).</ao:prefix>
    <pav:createdOn>2014-03-31 09:09:18 -0400</pav:createdOn>
    <ao:suffix>Your doctor can determine with a blood test if you have this gene variation. If you get a symptom from 2 or more of the following groups while taking ZIAGEN, call your doctor right away to determine if you should stop taking this medicine</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact> Patients taking ZIAGEN may have a serious allergic reaction (hypersensitivity reaction) that can cause death. Your risk of this allergic reaction is much higher if you have a gene variation called HLA-B*5701 than if you do not. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FFDCD61D-7861-4B4F-AE17-4A15CD51BFA2">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3F04058D-E19C-45A2-8FED-97E877DAD6A9">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:05A8BCC3-6277-4F17-A060-416AD1F106CE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B0FFCDB3-7874-48E5-99F9-2E81E91B47AF">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1564A1CD-1DE3-44A9-B41C-23910512D5FC">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:28576E2D-4BF3-4504-9083-578A2CB1EB0A">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BCAE5E0C-30F2-4E8B-8D8E-687ADD4CA18B">
    <ao:exact>Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (gene duplications denoted as *1/*1xN or *1/*2xN). The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. </ao:exact>
    <pav:createdOn>2014-06-30 11:50:23 -0400</pav:createdOn>
    <domeo:uuid>BCAE5E0C-30F2-4E8B-8D8E-687ADD4CA18B</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience signs of overdose (such as extreme sleepiness, confusion, or shallow breathing) </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BCAE5E0C-30F2-4E8B-8D8E-687ADD4CA18B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:08B881EF-DF79-4F2E-8989-15AFC669C759">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>bleeding</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D50A614-4F2B-42C6-A175-0BF3C158B5DA">
    <ao:exact>Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is achieved through an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by genetic variations in CYP2C19 [see Boxed Warning] and by concomitant medications that interfere with CYP2C19.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7D50A614-4F2B-42C6-A175-0BF3C158B5DA"/>
    <pav:createdOn>2014-06-30 11:34:01 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <domeo:uuid>7D50A614-4F2B-42C6-A175-0BF3C158B5DA</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>Proton Pump Inhibitors Avoid c</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:69C71795-6ED9-4F74-80C5-653AF2ECE5E2">
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99FA827B-1348-4AAF-B462-A763B372625B">
    <sio:SIO_000111>34075-2 LABORATORY TESTS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34075-2 LABORATORY TESTS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AC497212-D269-4238-AA69-CFE2271A33C3">
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A66A7AB1-C314-421A-9CD3-AF23ABF28E51">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6F731CE1-E6B4-41AA-98C6-30C94B771E61">
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Codeine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9EE83BC1-292A-4DC6-92A2-6BDA81A04501">
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:65137868-B001-4C93-B966-A8E06E33B0E9">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FBE92D3D-0364-42A8-82BB-F97A84F672A1">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3535</dailymed:HGNCGeneSymbol>
    <rdfs:label>F2</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CFEC8925-05FE-4B69-A89C-06BBA59517E9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:73C1A497-1E52-406F-A8A2-D5631C088F35">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:016B445E-4C36-4A69-A68F-8C8A0A19611C">
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D66FA8C3-8BAB-4A6F-8234-6DD134876578">
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EF919E4C-C0B0-4D8B-A273-2F4A806A828D">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Letrozole</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9BCAF415-84AF-4907-8BCF-E79F35898B2C">
    <dct:description>Referred to clinical trial</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:25FCDBC8-E43E-4F5F-AE2A-A12D1E6FB7A5">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D87AC20-773F-4241-AA52-57BF86A4A93A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N960164cae5824bc2910206e9a39196f7">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:31432C21-1CC7-4786-94EE-581440200D4B">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5DBD6868-2A73-4E0E-944E-4DCB9B33336C">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:42FA1C17-B780-423F-B993-EAF8D8DF0329">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6DC3D6BC-081A-4B0D-B1DE-234266603363">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5239657F-5948-4803-B690-76D953D60764">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9748F74E-EF35-4AA4-817B-07FED6D50359">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Decrease from baseline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A74CD0BB-2B56-45FC-B50D-C7952B9C9AE4">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A74CD0BB-2B56-45FC-B50D-C7952B9C9AE4"/>
    <ao:prefix>Patients with intermediate thiopurine S-methyl transferase (TPMT) activity may be at an increased risk of myelotoxicity if receiving conventional doses of azathioprine.  </ao:prefix>
    <ao:exact>Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>A74CD0BB-2B56-45FC-B50D-C7952B9C9AE4</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <pav:createdOn>2014-06-30 12:04:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:37A6082B-5282-4E60-83ED-F39B3618B569">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>toxicity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A48D46C7-8F7E-4426-8C3D-CCA08F946DB0">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Codeine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14BA7077-8D33-42DD-A380-DD27F50087AD">
    <ao:exact>The effect of the scheduled duration of tamoxifen may be described as follows. In women with ER positive or unknown breast cancer receiving 1 year or less, 2 years or about 5 years of tamoxifen, the proportional reductions in mortality were 12%, 17% and 26%, respectively (trend significant at 2p &lt; 0.003). The corresponding reductions in breast cancer recurrence were 21%, 29% and 47% (trend significant at 2p &lt; 0.00001).</ao:exact>
    <ao:prefix> nodes who received about 5 years of treatment, overall survival at 10 years was 78.9% for tamoxifen vs. 73.3% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 79.2% for tamoxifen vs. 64.3% for control (logrank 2p &lt; 0.00001). </ao:prefix>
    <domeo:uuid>14BA7077-8D33-42DD-A380-DD27F50087AD</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-30 12:18:51 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:14BA7077-8D33-42DD-A380-DD27F50087AD"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DADB08A1-6AB5-4DE3-83DF-A8D4A8A12E2F">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BAF3588C-CD18-4C25-B486-8956069332AC">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:25781413-3765-4C00-AB09-CF920462A870">
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C751B6F1-6EDE-4C87-A5FE-1A6E0D3D4C92">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60208860-79EE-4EFA-BB03-9218CBD7E12F">
    <ncit:Alleles>HLA-B*1502</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2F3B0124-31A3-451B-BA81-5652303A452C">
    <ao:prefix>HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid>2F3B0124-31A3-451B-BA81-5652303A452C</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <pav:createdOn>2014-06-23 14:25:44 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2F3B0124-31A3-451B-BA81-5652303A452C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5AC5462B-2AAA-42B0-BA6D-B0EFB4BC80C9">
    <rdfs:label>ER_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8EE67176-9F55-46AB-91C9-4F10951C11A4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C37B19E6-A2FE-4CF4-9914-61A4EF8E7827">
    <ao:body rdf:resource="urn:linkedspls:uuid:FBA969DE-1978-4391-A338-E793E7F5F06C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:96D6F8F1-F51A-4EBC-BFF7-C799690B4401"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:55819029-EACE-49D3-9A09-5DA751DA0CDE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F211EFB-8429-4BE7-8E97-2DC2313E9DBE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-04-14 14:04:16 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:C7CB636F-0374-4648-9C14-E151AB0B6507"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:B9C6119C-3C0F-46B0-8614-1EBBBA8066D4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:34FE8B53-03E6-4D06-9371-F1EA1CC5BEDD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <pav:lastSavedOn>2014-04-14 14:04:17 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:216A1896-63FD-45FE-ACBB-80F82EB9ACE5"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:801BC1FA-BBDA-4DB4-8D6A-73A41CF0C375</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9692B313-0E4E-4D52-9D7C-456D2EE68F54">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17653AA9-221B-4AF9-AED7-70A7913F95CD">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:512081E4-B6CF-4E36-B991-10F09074D3A4">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:15CFACDA-93A0-4CF4-81F6-D807D5C1DDD5">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F211EFB-8429-4BE7-8E97-2DC2313E9DBE">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AB653C40-C16E-4E15-AF0A-01467E32868A">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60E169BB-ADA3-4069-A5AD-09029A8F4F19">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5229A912-1F9A-40AD-9994-79886D701F6C">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:EF161740-C79C-4D2A-9002-4B0A139BF81E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E2D22DB5-DE0A-472B-A6D0-2BFCA267886E"/>
    <pav:createdBy>urn:person:uuid:080e143044e90f26014518a19cf70063</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:850F3B60-ADC8-42A5-8E7E-B50B1E9D39BE"/>
    <pav:createdOn>2014-06-30 12:35:15 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:77B5C0D4-B728-4F8B-B5B3-E3B3BE2E8C85</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:7A99CBE7-D53A-4DB8-9A92-C3D451D28A0B</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:91E145AE-4A66-4F7C-885F-39E651D5592A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0FC7785B-7A6A-40CF-AC44-767C8675DFAA"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5D4A2EE-013A-42C1-B47D-8A1723DD6E13</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-30 12:36:12 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E8B220AF-2EA7-4429-BC11-4C7ECC9BFBE4">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99C027B2-936F-4C6B-AF41-38394AEC4210">
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Concomitant medication concern</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FC766D1F-0C5B-4C57-8386-30CC6B3408B5">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Carbamazepine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1BFA2B92-6713-4B9F-90AE-FCFD6ED07058">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>TPMT*2, TPMT*3A, TPMT*3C</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FBD3A076-17BF-416E-9EEC-89C39FD558A3">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA00EA65-56B8-400A-BD7B-CBC28C8835D4">
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8E902352-92DC-4687-80A3-2CE0B7F85201">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:977D4B66-41C2-4CEA-9997-9226A41529E1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>blood transfusions</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:571A40A9-6C8A-4451-8D48-850DB2D15DDD">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34075-2 LABORATORY TESTS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34075-2 LABORATORY TESTS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5542691E-3FD7-4CD4-B22C-7D237B921E99">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>abacavir naiive</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:726A2BFA-10F1-41C0-86B0-38F74B394C11">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <rdfs:label>Do not start</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CF3C9EDB-86A3-43C4-8D5B-0E221AA24650">
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F5BE400E-F969-4FC0-BFAD-18D496F3A285">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ABF85151-DB4C-4069-9F3D-A22A295FE2B7">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*1502</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3C75F25B-730C-424C-8A4A-C55F0D242716">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact> Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3C75F25B-730C-424C-8A4A-C55F0D242716"/>
    <pav:createdOn>2014-03-22 22:16:15 -0400</pav:createdOn>
    <ao:prefix>HLA-B*5701-negative patients may develop a hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55F59962-81BB-4F69-B3DD-6B65B3526228">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>55F59962-81BB-4F69-B3DD-6B65B3526228</domeo:uuid>
    <ao:prefix>Known or suspected deficiency in protein C mediated anticoagulant response </ao:prefix>
    <pav:createdOn>2014-06-30 13:16:49 -0400</pav:createdOn>
    <ao:exact>Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. Not all patients with these conditions develop necrosis, and tissue necrosis occurs in patients without these deficiencies.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:55F59962-81BB-4F69-B3DD-6B65B3526228"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CBEBA97D-4F36-4510-91B7-69B7D35D5F14">
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9A0675C5-A6BA-4582-A77B-1E90DB7B1E3A">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3A01499B-5164-40C0-A088-804F0AEC5A43">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5B23BB9C-106E-465B-95E4-A09741FC6B9E">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34067-9 INDICATIONS AND USAGE SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34067-9 INDICATIONS AND USAGE SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EEF1E888-1159-48A3-9DAF-879DB61D6326">
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:445C56FC-3F37-4EDE-AD86-0E5B03A0BAF8">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B989DC55-96AA-4A58-B072-99CFCD1CAFEB">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>add test result to drop down; check search of location using magnifying glass to make sure it comes up correct. It should be the same as the next one with and additional sentence for intermediate metabolizer.</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C0DE6314-6F80-4149-8B10-CFB417883757">
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdfs:label>Recommend</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D43D74B1-E88C-4FBE-8716-B5F76BDE8FF1">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:40D06030-B1C8-49C4-B099-49AD079C1CD4">
    <sio:SIO_000111>34090-1 CLINICAL PHARMACOLOGY SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34090-1 CLINICAL PHARMACOLOGY SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2A14FC31-E82E-4B10-A2F4-D8F098563B2A">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B8FB07F0-0211-45FC-B75C-FC0ED5802AAD">
    <rdfs:label>Do not restart</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:123F2BE5-B94B-4FB6-AEA8-29625DCA77E5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B70DD975-4D1D-4F7B-A6D2-55287EFC95A9">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34090-1 CLINICAL PHARMACOLOGY SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34090-1 CLINICAL PHARMACOLOGY SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9396C455-7DD2-4BF6-B3E0-EB48C239E903">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-level-low</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1A0A0DFA-90BF-45A5-941C-4C791EE30F18">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:37D8A15F-B81C-4D02-ACB8-420691E1AE81">
    <rdfs:label>Prodrug</rdfs:label>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7851F628-A8CC-4FA9-A06C-032AC7CF9470">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C5775E84-0546-4E6E-B45D-FFA024B1972E">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9953D1B9-8B96-4EC4-AEF7-D059402BDC26">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D7469020-1B15-4E1B-884C-C23AB75DB446">
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F5C240E5-0680-4CDA-ACC9-4DB8C5A0984B">
    <ao:body rdf:resource="urn:linkedspls:uuid:91373757-CDC9-41DF-834E-F17713AEE49F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:65137868-B001-4C93-B966-A8E06E33B0E9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:53541A7F-ACF6-4030-A4B7-7BA865CDF82F"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdOn>2014-03-22 22:01:43 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:14CAC4B1-07A5-489D-887D-9893ED5002CD</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-22 22:03:57 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6DEB1090-C8F8-4229-9532-5B3125B903CE</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF75BAC3-9B1E-4E6C-9666-F407F87B964F"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E2D2D450-639D-4D10-B6B5-D0735D582167"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:BC59C368-6171-459A-BA88-9B57AAC67FD8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5B4047A9-42A5-46E5-9848-74F5005C2F7D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B52DDA70-3E7C-4358-8558-ADAC22E0B522"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:643D5630-A314-4EB0-86E3-0C32AA09CD16">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A640EA70-3185-419A-8CAB-67E0D6F126F2">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BA184D35-B996-4FF0-922B-6B732D552E7C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>Hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:69C92FEB-FB69-48D0-8F98-B667A717D1A0">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15924106-592A-47E7-A01C-764A16E257DC">
    <ao:prefix>Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>15924106-592A-47E7-A01C-764A16E257DC</domeo:uuid>
    <ao:exact>The estrogen- and progesterone-receptor values may help to predict whether adjuvant tamoxifen citrate tablet therapy is likely to be beneficial.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:15924106-592A-47E7-A01C-764A16E257DC"/>
    <pav:createdOn>2014-06-30 12:31:59 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:04E39F17-24C2-48B2-87A1-2648282F8A03">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:82F247F1-5E0B-472B-8C42-4074C2A25CD0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>82F247F1-5E0B-472B-8C42-4074C2A25CD0</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:82F247F1-5E0B-472B-8C42-4074C2A25CD0"/>
    <ao:exact>Citalopram steady state levels were not significantly different in poor metabolizers and extensive metabolizers of CYP2D6.</ao:exact>
    <pav:createdOn>2014-06-30 11:22:25 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6535077F-E961-482C-8B57-F786CEC0E8B6">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:93023233-0D8E-497C-BBF0-DE5DD31AF15E">
    <poc:MedicalCondition>Asian</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E063046-0F94-45F2-80FD-A860D5215EB0">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34071-1 WARNINGS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34071-1 WARNINGS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:071CEC58-02E9-4DA2-8259-93E87A6EFD3B">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Codeine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:83CA0C0D-6F7B-4FD7-94F8-FAB3FE827447">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9BF54AC2-D58D-4056-A806-0296CD55AF18">
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6E4FAE9A-BCAB-43D2-99CA-20C3101D8DD0">
    <ncit:Alleles>HLA-B*1502</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0FD58238-87B6-456F-8854-AE23F15B6EF1">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34075-2 LABORATORY TESTS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34075-2 LABORATORY TESTS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A696E3C2-ABF6-4D74-8862-D11D03E8A317">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43679-0 MECHANISM OF ACTION SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>43679-0 MECHANISM OF ACTION SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0F7787E-5F9C-47A4-86B2-D64F1B7602B6">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FE1B382B-9F39-4CAA-8A59-17376ED6F061">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3C6E27C-CBBA-4B36-810C-D42C3FA4AB93">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F3C6E27C-CBBA-4B36-810C-D42C3FA4AB93"/>
    <pav:createdOn>2014-06-30 12:04:40 -0400</pav:createdOn>
    <domeo:uuid>F3C6E27C-CBBA-4B36-810C-D42C3FA4AB93</domeo:uuid>
    <ao:exact>Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. TPMT testing may also be considered in patients with abnormal CBC results that do not respond to dose reduction. Early drug discontinuation in these patients is advisable. TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:231FB605-C0BA-4076-A03F-F60FA03C8005">
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <rdfs:label>Recommend</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C8BA2048-FAC6-4C0F-B145-427A17AD3E63">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F349B074-7921-49F7-81EB-C8633E266F1E">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>PATIENT COUNSELING SECTION still not listed.  How do we code advise patients?</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D70BC1ED-3697-423C-8725-02DBC445E312">
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:07E8EBFA-A60A-44A6-B4FF-E40C91C5BB4C">
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C7E5E18B-7DAC-440F-A4AE-4F3F0BE85F12">
    <poc:Comment>MErge with above annoation due to \"rates provided above\"?</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:49F3189A-5919-4644-A23D-E7DDE2686F73">
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D040FB4D-6347-4C25-B523-64D3BCE93BA1">
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F8166271-C1E5-46A1-9876-DA65BA73DCD9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>severe life-threatening myelosuppression, pancytopenia, death</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:001C41DA-FFD9-4CBB-BD9F-23AB499D74AA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>VKORC1</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7AE1124F-F104-4EB3-9415-257F81B2E3CE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE32B2ED-6147-4876-A62A-CDB5CD4E16C3">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FDF4DC15-174B-44D2-8BB3-1ED10ED1ED83">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9ADC7DB1-8D79-4494-96BB-4A7FA41490E8">
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F2190B2B-E2DC-45AB-AB25-CB7DD9192C64">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>severe life-threatening myelotoxicity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:87C8AC12-6BA5-4D3B-A53C-9F5CBB063BCB">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42232-9 PRECAUTIONS SECTION</poc:productLabelSection>
    <sio:SIO_000111>42232-9 PRECAUTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:62E969AE-74E5-408D-9A40-653A02F406B1">
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F3FDFBC5-B694-42BC-8B00-F60FE7BE0B9E">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34092-7 CLINICAL STUDIES SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34092-7 CLINICAL STUDIES SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2AC31440-393B-42C4-BEF9-164B6631EF5B">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>42231-1 SPL MEDGUIDE SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42231-1 SPL MEDGUIDE SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A2BB972A-BB8A-4A43-9864-7D082638383E">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:239D0F43-DA9B-4ED8-A683-6BF29DB82241">
    <pav:createdOn>2014-06-23 14:34:14 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:239D0F43-DA9B-4ED8-A683-6BF29DB82241"/>
    <ao:prefix>ZIAGEN is contraindicated in patients with previously demonstrated hypersensitivity to abacavir or any other component of the products. </ao:prefix>
    <domeo:uuid>239D0F43-DA9B-4ED8-A683-6BF29DB82241</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:59E1AD64-B70C-45AC-B670-8CA9256F6329">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:93F6979E-271D-482A-A141-5F0AD6C66E22">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1474E26E-D19C-4FDC-9AB0-792A82BB0A07">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:29951346-424F-4492-B79A-EF5022CB7F05">
    <domeo:uuid>29951346-424F-4492-B79A-EF5022CB7F05</domeo:uuid>
    <ao:prefix>6-MP undergoes two major inactivation routes (Figure 1). One is thiol methylation, which is catalyzed by the enzyme thiopurine S-methyltransferase (TPMT), to form the inactive metabolite methyl-6-MP (6-MeMP).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>TPMT activity is controlled by a genetic polymorphism.1, 2, 3 For Caucasians and African Americans, approximately 10% of the population inherit one non-functional TPMT allele (heterozygous) conferring intermediate TPMT activity, and 0.3% inherit two TPMT non-functional alleles (homozygous) for low or absent TPMT activity. Non-functional alleles are less common in Asians. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:29951346-424F-4492-B79A-EF5022CB7F05"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-30 12:03:33 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3689FD7C-4B03-41A9-A867-74E8C7C0FC0E">
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E95F30F-36EE-40C4-991B-275A3AB9E17C">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A74A9220-EE01-45C5-B563-AB9F4F6F5D7A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6FC50BDC-78A6-4D50-8D6E-7FEB6DAFF0E2">
    <pav:createdOn>2014-06-30 11:51:19 -0400</pav:createdOn>
    <ao:suffix> </ao:suffix>
    <domeo:uuid>6FC50BDC-78A6-4D50-8D6E-7FEB6DAFF0E2</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6FC50BDC-78A6-4D50-8D6E-7FEB6DAFF0E2"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:prefix>Codeine is secreted into human milk.</ao:prefix>
    <ao:exact> In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine’s active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:867AB118-200E-4AFC-9BFB-E39692D1406F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>TPMT*2, TPMT*3A, TPMT*3C</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:68B37481-F382-41B9-AEF5-DB241FA9325F">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F5AE3B3E-B864-4A19-B48C-DC1343C799A3">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Clopidogrel</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:539AAC42-2631-4B4E-946F-3A27B885004B">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:90D83A05-A7E7-4005-976B-C4210F7CA28D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>THIS ONE IS BROKEN, LOCATION OF ANNOTATION IS APPLIED TO IS INCORRECT.</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0627866-7207-4CDB-B718-21756549DDC1">
    <poc:MedicalCondition>severe life-threatening myelotoxicity </poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1A913E5-A4E1-43F0-947A-234CE74877D4">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AEBF040F-C6A6-48A1-B676-CAAE042125E9">
    <poc:MedicalCondition>hla-b*5701 absent, hypersensitivity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4DD1AE8C-CB2C-4887-993E-A8A44B2A06CB">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F007A3E0-FB60-4CDA-9A07-BC6E3A3F95D1">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>CONTRAINDICATIONS (34070-3)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CONTRAINDICATIONS (34070-3)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B11E300-2DF5-4B21-9D43-4D0A02109A59">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:864E5B2D-ED7F-4A2C-8736-D569472536C2">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4CA8EAB9-51E6-4B97-AFD7-E2D4FCC3DC56">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>extreme sleepiness, confusion, shallow breathing, nursing, breastfeeding</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:097ADA1B-6976-4BDE-AFB2-BB3B661FEAA4">
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BA799867-B4C2-44C3-B530-1E580BE0F7D7">
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ED185C6D-0EC4-46D9-9192-DC5925A5D18B">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E62D1169-48C0-4111-A664-6E935B2BE813">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8C6A6A36-98FB-4F99-83BE-23A9EA2D830C">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E759252F-F886-4AB1-9DDB-9C5EC3A84DCE">
    <poc:MedicalCondition>QT prolongation</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2cdf0219d90a45d089123ff1e5a8bd8c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:961381E3-666C-448A-8F5E-E67933E35872">
    <poc:Comment>how do we code \\\\\\\"tell your doctor\\\\\\\"</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6133C378-02D8-4301-B20A-9D2595AF1A04">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>myelotoxicity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B510E06B-24AA-42F4-885F-7A183BFBB2EB">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:763ABA1D-A316-42DE-AA02-A7123411CD6C">
    <rdfs:label>Letrozole</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:47C06731-44B6-43B1-A393-9B723D8C46B5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8734D580-771F-422E-B2C2-CD625AC13731">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9843AD8C-F6A5-4324-81DE-9E7505C0CCAF">
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F997305F-4F06-4D67-9354-EE0AE3BED65C">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4983978B-E3A3-4BE0-AB51-21C8B49B0EDA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1BBDD4B3-A192-494F-BBFC-1B30A3CB35C3">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1C112F5C-A77D-466F-942A-A407FE0CF126">
    <poc:MedicalCondition>Asian, SJS, TEN</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FD773F35-854D-4F87-A80F-4F4782F991EC">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:237CBF43-3113-4746-AC7C-0EEE2CD7D926">
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:exact>CNA106030 (PREDICT-1), a randomized, double-blind study, evaluated the clinical utility of prospective HLA-B*5701 screening on the incidence of abacavir hypersensitivity reaction in abacavir-naive HIV-1-infected adults (n = 1,650). In this study, use of pre-therapy screening for the HLA-B*5701 allele and exclusion of subjects with this allele reduced the incidence of clinically suspected abacavir hypersensitivity reactions from 7.8% (66/847) to 3.4% (27/803).</ao:exact>
    <pav:createdOn>2014-03-31 08:58:47 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:237CBF43-3113-4746-AC7C-0EEE2CD7D926"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Based on this study, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected hypersensitivity reaction during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E4117315-0729-44F2-9C60-6A4046880608">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:817AD388-46C0-4445-8DB6-0F338A24872D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>multiple copies of the gene for cytochrome P450 isoenzyme 2D6 [CYP2D6] </ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA191114-E5D7-495A-9C11-23DD267847E1">
    <ncit:Alleles>CYP2C9*3</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4C6F6544-9DB6-404F-BD19-22E1463B3B1D">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:362F640C-AB81-40B0-8D31-9BB314901AFB">
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER_receptor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8D90C751-90B5-4F05-AB1A-DDCFCF0A7849">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>one non-functional allele (heterozygous)</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:22B1EFFD-5404-4C26-A535-417D70D5FBA8">
    <sio:SIO_000111>66106-6 PHARMACOGENOMICS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#66106-6 PHARMACOGENOMICS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C4C83D93-3CF5-4EFD-87AB-DBB3F529A08C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>to generic for allele vs leaving phenotype on its own?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0FDD7BA5-D168-490F-94C1-35D9C071D955">
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA3B0B94-7858-4E6B-B828-AB6A8867E1D3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdfs:label>Prodrug</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B274FA34-1FDE-4C0F-B804-AA8276573C83">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D0869B07-1155-430B-8AD6-B3D91EA533C0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Use specific</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:75D988CE-7527-421D-AAA6-0C9C0D4B30DF">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E98CB2FA-DA8B-4C38-A381-051FEDE4E5CF">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DA126820-256D-4C0A-BAEB-B5A5EC5C0F33">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D7C73AD-5779-4EBD-A3A2-517775A82AEB">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7144B0C9-3D2F-4940-885E-C5510A56AB67">
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Increase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2CD7E6EE-8F43-4B03-92B9-825A2FD231CF">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:87B8F5B0-8381-4CA7-AE0B-30C481D164B4">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Clopidogrel</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE2B43A2-F01E-499B-B632-58EB54437102">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B170901-0396-4A6F-B879-394F3EF91EDB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1EE19009-F28A-47FD-8E3D-A8E9B82B8708">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is not associated with clinically relevant pharmacodynamic effect</dct:description>
    <rdfs:label>Not Important</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EF161740-C79C-4D2A-9002-4B0A139BF81E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-30 12:35:15 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In a small substudy (N = 81) of the NSABP P-1 trial, there appeared to be no benefit to screening women for Factor V Leiden and Prothrombin mutations G20210A as a means to identify those who may not be appropriate candidates for tamoxifen therapy.</ao:exact>
    <ao:prefix>inistered with chemotherapy, there may be a further increase in the incidence of thromboembolic effects. For treatment of breast cancer, the risks and benefits of tamoxifen should be carefully considered in women with a history of thromboembolic events. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EF161740-C79C-4D2A-9002-4B0A139BF81E"/>
    <domeo:uuid>EF161740-C79C-4D2A-9002-4B0A139BF81E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:76924EA6-1981-4B77-ADA6-C632565C6480">
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdfs:label>Prodrug</rdfs:label>
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1523E385-B7C2-4B6B-B365-918336BC31D4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:558D142F-DBE9-4EB9-9F46-4244D63F2FAF">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C553B1B6-192B-4B2C-A32D-72E7FBC6CC65">
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77D310FC-B5EB-4AEB-AE29-1746D651FEB3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA8116F7-E363-4BB1-9815-7EC432A940C1">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:410722E1-1877-490D-944A-22265E55A048">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9C3F4619-C266-4C03-ACF8-B5180BDF384C">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:119F933E-FFF4-4D53-BC7B-2727B9BFAACE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:208EC5EB-DF9F-4549-835B-D22F46813813">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D26DCABA-C665-4147-A57B-F26195C0188E">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86052180-6BE9-4913-AEF5-69CD8CDFBDBD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E7EADDD-1940-4793-A432-894BFB8A0F2A">
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Concomitant medication concern</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.0alpha-040">
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
    <foafx:version>2.0alpha</foafx:version>
    <foafx:build>040</foafx:build>
    <foafx:homepage></foafx:homepage>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4683D5EB-6628-4644-AF10-7D65325E3A8C">
    <rdfs:label>Recommend</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7FD85CE9-994B-4E84-9DA8-1C07BDEC44AF">
    <poc:MedicalCondition>respiratory depression, death, tonsillectomy, adenoidectomy</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1F1294AA-1E74-402F-9AED-0611A4B739AB">
    <poc:MedicalCondition>hypersensitivity, hla-b*5701 negative</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1CAED89B-42E4-493D-B92F-8663CD7F580E">
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2C6B9A5A-8AF2-42AD-BBC3-F6BD0F24F710">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:81525CE9-0714-4D48-9149-6C8B8671E117">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A3C1B92C-CBE0-4BA8-A41C-D3C3CD26FA51">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D90D2F8E-34C7-4183-919B-C6541F45FF51">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A705C426-39E4-4654-86CD-B5DE3C78D583">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <rdfs:label>UGT1A1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2CE69763-0812-4DFF-A359-2A8D8FF706AD">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17885E5A-0B08-4791-8E05-BD3606CC3AC3">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A6669B83-B750-4BCE-A012-641844F7058E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1564200f8e48460a8d0a85c3c1c411b6">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DBCD24FF-6ABB-4810-A5CA-DF8F85FF2241">
    <ao:prefix> </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DBCD24FF-6ABB-4810-A5CA-DF8F85FF2241"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:exact>For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk.</ao:exact>
    <pav:createdOn>2014-03-31 09:04:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:04B8D3B4-3A5C-4768-8DA3-C8C5D6222987">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3159C026-77DF-48B8-9A7B-19FDC9D6FD34">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C22FFE05-E6B2-4D81-81D7-BFA7F760B4E4">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E568EFC-3592-49B7-A800-3C6E0D51E918">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA731133-82ED-4CB3-BCB9-8BD9BD290A27">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D727CBF5-9DC7-4B41-88A3-A9F0C7943BAF">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#intermediate-activity</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>intermediate-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:51C4FEDD-5F25-4F57-92BC-5456BC2E4846">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0F470552-D38F-4A4F-9BCF-4088552F5D62">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A85EF876-AF0D-4316-82E4-390553A6DEBD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D291A986-DE92-4F74-9F59-948621826357">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E44DEE5B-4DE2-4DE7-B9F4-2EF2B8ECDB21">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0FC7785B-7A6A-40CF-AC44-767C8675DFAA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Not necessary</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-necessary</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>Testing related to the pharmacogenomic biomarker is not necessary.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C2B100AA-AED8-4D23-A22B-217E6AF13448">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34071-1 WARNINGS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34071-1 WARNINGS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4E6A2736-0750-43A7-A6E9-E7C80E5447ED">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL STUDIES (34092-7)</poc:productLabelSection>
    <sio:SIO_000111>CLINICAL STUDIES (34092-7)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6C38BB4D-F315-43B1-BEEC-BB7AC4B12887">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:720F1FAF-C317-4375-8323-04DFEE0FAAFE">
    <ao:prefix>Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine tablets. 4-9  </ao:prefix>
    <domeo:uuid>720F1FAF-C317-4375-8323-04DFEE0FAAFE</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:720F1FAF-C317-4375-8323-04DFEE0FAAFE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-30 12:04:10 -0400</pav:createdOn>
    <ao:exact>TPMT genotyping or phenotyping (red blood cell TPMT activity) can help identify patients who are at an increased risk for developing azathioprine tablets toxicity.2, 3, 7, 8, 9 Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B0DB01D5-CBF4-4F69-ACE4-596319DE386B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:37985B75-E006-4646-954C-8237811DD0CA">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C6BE7951-1E6B-4301-BC65-53D6F750C89B">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34090-1 CLINICAL PHARMACOLOGY SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34090-1 CLINICAL PHARMACOLOGY SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:651C23D1-8C94-475A-999B-C44BD04331B9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34090-1 CLINICAL PHARMACOLOGY SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34090-1 CLINICAL PHARMACOLOGY SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1AD9A29D-96AB-4840-AF6E-CB07A28360A4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>HLA-B*5701 </ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8C4CA7C1-4757-4722-A8E7-A90189672AF3">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>ESR1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DB559FE0-80C3-489C-84A4-F9C2EBBDAE8A">
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E18535D1-97BE-45EA-89C5-7DFF12A67C62">
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdfs:label>Recommended</rdfs:label>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DAF687CB-C150-4457-815A-875B9BBE8525">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C7CB636F-0374-4648-9C14-E151AB0B6507">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6B9F2EDD-8EC9-441C-9B9C-6DE4ED079F50">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Azathioprine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:398416DB-3813-458C-AEAD-1E703244DEC7">
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>398416DB-3813-458C-AEAD-1E703244DEC7</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:398416DB-3813-458C-AEAD-1E703244DEC7"/>
    <ao:exact>Lipid Study: In a phase 3 safety trial in 262 post menopausal women with resected receptor positive early breast cancer at 24 months comparing the effects on lipid profiles of adjuvant letrozole to tamoxifen, 12% of patients on letrozole had at least one total cholesterol value of a higher CTCAE grade than at baseline compared with 4% of patients on tamoxifen.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-30 12:02:02 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:139C60FE-2FF1-421B-922B-E11FA45DE8F1">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7705072C-9052-4674-921A-6BE7E5A1BAFD">
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34F7A071-6983-40CD-B22D-108DA2488667">
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:26120AB9-1EF9-4541-82FA-D6061CD6EB77">
    <poc:MedicalCondition>breast cancer, mortality</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8AE2E772-5C7A-49D5-AD43-70DA1C97F946">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:05DBF40D-ECCF-4BC6-9077-742EBADF41F9">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Letrozole</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1CE911D3-8E07-4217-B9EF-F20B81C6B51F">
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D08A0D01-F380-4BA4-9FDB-5EED31E83429">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:96D6F8F1-F51A-4EBC-BFF7-C799690B4401">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B0D15111-C445-4596-9C63-C7EFADEB3394">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:40AC27D0-6D44-444E-A3B8-CE5689AD915D">
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Recommend</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:66084BA8-1CB4-456E-817A-27E19B84E73C">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C19</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9600B75E-4610-4889-BDFC-ECAB5CB72410">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>death, nursing</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:28F5248D-2360-4A65-9C87-F31FB5E058FC">
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:75E5EB7F-648F-4EF9-8C33-D00C2D013D0D">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E6B02E4B-FDE8-473A-A978-02F98D0FE07D">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Letrozole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:51D383C3-FE6E-4B78-9094-946EA250AE63">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Did not say provided specific dose recommendations.</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2578ED0F-1456-4115-ABD2-3303381991FB">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D07A471E-9AE7-4A93-BF39-B8A753C23859">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B0D6C928-74B2-4DA1-BBF4-124615410D84">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:45EDCED8-9B43-464F-AC7F-898A9009649D">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6DEFAE04-80DB-4944-B89A-89A36B339F01">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:31115D88-2436-4D8C-B5E2-A7636A9DA498">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B973C15-149D-4D98-90E2-4A06A2F30ABD">
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0195CB09-02AC-47BF-A708-470D85342CEE">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>death, respiratory depression, tonsillectomy, adenoidectomy</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D6599990-20BF-48F3-9D6E-1815B4DEFF78">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F6F47A9-4B77-44DC-9EC2-E73867EC5231">
    <poc:MedicalCondition>acute coronary syndrome (ACS), percutaneous coronary intervention (PCI) </poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BCD590DE-4767-42DB-A1CC-95099463B7D0">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8CC7CC7E-B852-4CC8-8722-89DA67CDACC1">
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:89CFECFF-FA62-4DDF-8491-A92805B332EC">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>over anticoagulation</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:79F31203-B89A-4A59-820A-0A830046558E">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:80201FA1-C475-48D5-9DD6-975B4F8DD33A">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B30B41E3-5A67-4530-BC81-938E6B016FDF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N51b89368f82b49578d5920d8464f68a3">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:599C562C-AF77-481A-9522-37F7FE7D35CE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3F9C95E5-3E51-4181-8B39-0EF6D0D28957">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:98FB995B-3B3B-4C86-ACA3-EE4F9F310F41">
    <pav:createdOn>2014-06-30 13:22:29 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>An INR of greater than 4.0 appears to provide no additional therapeutic benefit in most patients and is associated with a higher risk of bleeding. Initial Dosage </ao:prefix>
    <ao:exact>The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by:\n●\n     Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\n●\n     Genetic factors (CYP2C9 and VKORC1 genotypes).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>98FB995B-3B3B-4C86-ACA3-EE4F9F310F41</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:98FB995B-3B3B-4C86-ACA3-EE4F9F310F41"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9949892E-EB19-49D8-A737-FAF19F57740B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:18FBB200-8A2C-4513-9ACB-0E279C528A07">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701 </ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6C46DA96-FEC2-4B95-8625-1684409FF5E6">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8B9A8142-A3D9-411C-BFE7-DD2A2C9E4588">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B3109958-C49A-4EC9-AC70-C869B50D7E19">
    <ncit:Alleles>homozygous for non-functional alleles</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4079A418-64B5-4D13-BEAA-79C2F16D8E58">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Need an option for discontinue</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:508FAE65-0963-4DF7-9CCD-11FAFAEDDD84">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FEF94E24-725D-433B-8F55-9E75E14CECB9">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:94034230-6BB4-4506-9F59-AF9B5EB1CBD3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:01669DF8-5D8B-4A00-A56B-B761EDE23526">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>CYP2C9*2 </ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E551C77D-FE61-44B9-BE13-7035B99454EF">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3958ACA5-AE43-4D05-8DDA-C14850163ED9">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7361D556-97F9-41F3-98DD-3F6C66FA6CCB">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F742088C-CD87-493E-B7A6-530F13F928D9">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF74DA0E-580E-47E3-831F-DB38FFA1DAF4">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:78A1719D-0994-4541-ACAD-575FC841174F">
    <rdfs:label>Do not restart</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B58710C3-10FA-4324-B774-6BB2FF164982">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8175988B-12BF-411F-A136-BAFE3294C9B0">
    <rdfs:label>Required</rdfs:label>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:MonitoringRecommendation>
    <dct:description>A required monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A66F219-499B-4560-AA94-F96598D0B126">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA844F00-D043-44E7-BDA4-C852FD04CEA0">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:94569D13-A994-40FA-BDCF-C0391FE365FD">
    <poc:MedicalCondition>unknown hla-b*5701 status</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7B1D893F-6D49-4E8E-84CD-1AF31A949F9D">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0E61C616-830C-42EA-A5CA-1C03C20ABEE9">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:844BE367-B458-4768-AECE-7675D4FBC121">
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17461CFF-684F-4CC1-9811-4C5C13C44A01">
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4DB91673-D6C5-4FAD-B0B5-4B4CB81D8EF8">
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:27FF0571-815C-48EE-8217-44C7CA977578">
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3EB27716-2423-4BFA-B0F0-C5B6D824F956">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:043B155D-EEAD-4248-B52C-FA7437F0A139">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:74DD167E-84A5-4F2E-9B72-BEF1FCA1F812">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12014</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EEEC10EA-111A-47B5-A583-70C4B3F28C0D">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6F2EA2D8-F158-41C8-A138-52E47C92AF0B">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4EF0C28D-12C2-45C0-80E6-19CEDE1069C8">
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-monitoring-strategy</poc:MonitoringRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Change monitoring strategy</rdfs:label>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <dct:description>A strategy changed monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BFA2E65F-3DF8-4BF4-80DE-791E469C1461">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>include test results in dropdown</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:836504CE-5B97-4336-874A-48D2BD7B6107">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdfs:label>Prodrug</rdfs:label>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BE231C61-B98E-4D13-BF5A-E36767BDAC2A">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:44E81086-BA17-4D23-BE19-3D545D7F1B9D">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA9DB972-7500-4AC1-B7DF-126C0429537A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdfs:label>Prodrug</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1BE9D66D-0F12-4A57-A32C-C93C2329C708">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4366F716-A9BD-4BB3-A724-CD58B2F64C8C">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity </poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:00BB6023-1D83-4393-9606-7F0021BEA3B9">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D9566645-2367-4127-97ED-FEFEB81B1860">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4EBD3E7B-F7AA-4839-9764-73A89D5C987F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF1F10F0-D061-4FDE-925A-1B1B7243A890">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E4623FBF-0C69-42E7-912E-1494A9BF4EE2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A0C9BAA5-CE9B-433F-BC0C-0552964F164A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AB7285FA-D26A-4A3E-88F3-722B5A433B2B">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0C1275CE-E02A-4CA5-9EC8-0B105F3598C6">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Chinese, SJS, TEN</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34FE8B53-03E6-4D06-9371-F1EA1CC5BEDD">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6f00d5a003e2474fa91492ba5593f3d0">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:89DFC8E1-C29C-4F16-87D9-1CDEF3CF49FD">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AFE902B5-9F02-47A7-B23B-3F49A78A50C8">
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:217EA911-9B76-4BEC-8E97-92486BF67C31">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Use specific</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DFBABE58-5163-486D-9C9E-3EABDEDFE17C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E69519CE-CDB4-4ADE-9142-E9FF4BAFBE3D">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D41F355D-F8FE-4A71-87B6-FCA587AFAA6A">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>CYP2C9*2, CYP2C9*3</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D50CE73F-31C8-4AAD-BF2E-EEDBE1F40F42">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:734B20E0-4BAF-4E5F-A4EE-CABD0B5E152C">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nefc4c1b5764f402ea31b179b328b7394">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F7349E9A-62A7-4DAD-838A-D499FB22C6F7">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8AFC4AFD-4B5C-4E61-BE29-E2952A9887A0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8ECC3E70-0C1E-435D-8ADB-82D27204984F">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34067-9 INDICATIONS AND USAGE SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34067-9 INDICATIONS AND USAGE SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4AB5FE0A-C183-4F94-B914-1228DE7E4196">
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF6CBD3F-A19F-4BC9-93F5-AC24A293075D">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF75BAC3-9B1E-4E6C-9666-F407F87B964F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>previously tolerated abacavir</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FDAA4CB2-811A-4928-8A6A-39B907F9F312">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:61316A76-662A-471A-A970-BFBF8EBB83E7">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34071-1 WARNINGS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34071-1 WARNINGS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4E47853C-E984-40EF-88E5-116C7DE0A76D">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:289239D5-3976-472F-9914-D5F5369EE441">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>Hypersensitivity cannot be ruled out, HLA-B*5701 Negative</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F3B6A4B9-0416-414A-8BF4-C9ACD4D497C3">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:892A695C-E193-428D-AC55-6A2B7CB155C9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>death, myocardial infarction, stent thrombosis</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CCE70AC9-D0A9-404D-A9AB-347491143696">
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <rdfs:label>Recommended</rdfs:label>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7347D856-B9EA-455B-AFC8-9047DC8B5198">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb52f683eb1a644149b9838a5c6972ed8">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A0FDB6D8-3B29-4169-B943-7B9136C0BE5F">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7B074451-BDA1-480C-9A76-1FB4ABA06C50">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52237365-23A3-4118-A8F8-316E02FC46D9">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9CD7BCA7-7CF1-485D-B3B8-FD33BDCEFC1E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>acute coronary syndrome, percutaneous coronary intervention </poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C90E4AC5-84C6-4CF0-8B91-76FB986FF69B">
    <ncit:Alleles>VKORC1-1639G&gt;A</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55819029-EACE-49D3-9A09-5DA751DA0CDE">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-decreased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an decreased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Decreased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:958C79FD-EC3C-4B05-84AC-164A4BF11722">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB08B748-CC53-4FAE-92CF-D91CBEB2C83B">
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BE935BB7-5787-43F4-A8B9-B9FEE59E4B1A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>did not use low or absent phenotype as these terms are not used with this drug.  It's all poor metabolizer for CYPs</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:93494806-AB88-48E2-9119-48F2F284F99F">
    <poc:Comment>how to annotation increased effect with increased duration of therapy (PD?)</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:42E0A5C2-D6F2-4284-9E56-B11A767DB4D0">
    <dct:description>Referred to Prodrug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1DB91157-FBA4-4FE0-BAB1-68BB8A5A145E">
    <ao:exact>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:suffix> For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> </ao:prefix>
    <pav:createdOn>2014-03-22 22:10:26 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1DB91157-FBA4-4FE0-BAB1-68BB8A5A145E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91815DE5-C358-4A60-8E59-4C8D7FAE5784">
    <poc:MedicalCondition>myelotoxicity </poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:480F809C-0DAD-4297-969A-E832E3A5A336">
    <poc:MedicalCondition>death, respiratory depression, tonsillectomy, adenoidectomy </poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
</rdf:RDF>
